
<html lang="en"     class="pb-page"  data-request-id="687e87de-d596-415d-9313-e92da49e337c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-19;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c00149"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Bifunctional and Unusual Amino Acid β- or γ-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB0,+ and Enhanced Metabolic Stability: An Application to Floxuridine" /></meta><meta name="dc.Creator" content="Yongbing  Sun" /></meta><meta name="dc.Creator" content="Yu  Ke" /></meta><meta name="dc.Creator" content="Chunshi  Li" /></meta><meta name="dc.Creator" content="Jian  Wang" /></meta><meta name="dc.Creator" content="Liangxing  Tu" /></meta><meta name="dc.Creator" content="Lvjiang  Hu" /></meta><meta name="dc.Creator" content="Yi  Jin" /></meta><meta name="dc.Creator" content="Hao  Chen" /></meta><meta name="dc.Creator" content="Jianping  Gong" /></meta><meta name="dc.Creator" content="Zhiqiang  Yu" /></meta><meta name="dc.Description" content="Floxuridine (FUdR, 5-fluoro-2-deoxyuridine) was widely used in patients with tumor. But the poor activity and severe side effects have been observed in the clinic, which resulted from increased deg..." /></meta><meta name="Description" content="Floxuridine (FUdR, 5-fluoro-2-deoxyuridine) was widely used in patients with tumor. But the poor activity and severe side effects have been observed in the clinic, which resulted from increased deg..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 3, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00149" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00149" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00149" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00149" /></link>
        
    
    

<title>Bifunctional and Unusual Amino Acid β- or γ-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB0,+ and Enhanced Metabolic Stability: An Application to Floxuridine | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00149" /></meta><meta property="og:title" content="Bifunctional and Unusual Amino Acid β- or γ-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB0,+ and Enhanced Metabolic Stability: An Application to Floxuridine" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0009.jpeg" /></meta><meta property="og:description" content="Floxuridine (FUdR, 5-fluoro-2-deoxyuridine) was widely used in patients with tumor. But the poor activity and severe side effects have been observed in the clinic, which resulted from increased degradation cleavage of FUdR to 5-FU by thymidine phosphorylase and reduced transporter-mediated entry into cells. In this study, we have synthesized a series of l-aspartic acid β-esters and l-glutamic acid γ-esters of FUdR to improve the metabolic stability of FUdR and target FUdR to cancer cells via amino acid transporter ATB0,+ which was exclusively up-regulated in some cancerous tissue. The uptake mechanism, stability, in vitro/in vivo antiproliferation action, pharmacokinetics, and tissue distribution were studied. The combined results showed the unusual 5′-β-l-Asp-FUdR possessed a better tumor inhibition rate and a better metabolic stability than FUdR through a ATB0,+-mediated prodrug approach. The present study provided the first proof-of-concept of exploiting ATB0,+ for tumor-selective delivery of nucleoside analogues in the form of prodrug." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00149"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00149">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00149&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00149&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00149&amp;href=/doi/10.1021/acs.jmedchem.0c00149" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 10816-10828</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02122" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00223" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Bifunctional and Unusual Amino Acid β- or γ-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB<sup>0,+</sup> and Enhanced Metabolic Stability: An Application to Floxuridine</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yongbing Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongbing Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongbing++Sun">Yongbing Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yu Ke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yu Ke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Ke">Yu Ke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chunshi Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chunshi Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chunshi++Li">Chunshi Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Wang">Jian Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9589-4056" title="Orcid link">http://orcid.org/0000-0002-9589-4056</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liangxing Tu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liangxing Tu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liangxing++Tu">Liangxing Tu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lvjiang Hu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lvjiang Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</div></div><span class="conrtib-corresp"><strong>*</strong>L.H.: email, <a href="/cdn-cgi/l/email-protection#5b332e372d31323a353c363a32371b6a6d6875383436"><span class="__cf_email__" data-cfemail="563e233a203c3f3738313b373f3a166760657835393b">[email protected]</span></a>; phone/fax, +86-791-87119623.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lvjiang++Hu">Lvjiang Hu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8170-6459" title="Orcid link">http://orcid.org/0000-0001-8170-6459</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yi Jin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yi Jin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yi++Jin">Yi Jin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</div></div><span class="conrtib-corresp"><strong>*</strong>H.C.: email, <a href="/cdn-cgi/l/email-protection#5f3c373a31373e302b3c32371f6e696c713c3032"><span class="__cf_email__" data-cfemail="54373c313a3c353b2037393c146562677a373b39">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Chen">Hao Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianping Gong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianping Gong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianping++Gong">Jianping Gong</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Zhiqiang Yu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiqiang Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Southern Medical University, No. 1023, Shatai South Road, Guangzhou 510515, China</div></div><span class="conrtib-corresp"><strong>*</strong>Z.Y.: email, <a href="/cdn-cgi/l/email-protection#9fe6eae5eedfecf2eab1fafbeab1fcf1"><span class="__cf_email__" data-cfemail="364f434c4776455b4318535243185558">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiqiang++Yu">Zhiqiang Yu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1688-5558" title="Orcid link">http://orcid.org/0000-0002-1688-5558</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00149&amp;href=/doi/10.1021%2Facs.jmedchem.0c00149" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 10816–10828</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 3, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 January 2020</li><li><span class="item_label"><b>Published</b> online</span>3 September 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 October 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00149" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00149</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10816%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYongbing%2BSun%252C%2BYu%2BKe%252C%2BChunshi%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D19%26contentID%3Dacs.jmedchem.0c00149%26title%3DBifunctional%2Band%2BUnusual%2BAmino%2BAcid%2B%25CE%25B2-%2Bor%2B%25CE%25B3-Ester%2BProdrugs%2Bof%2BNucleoside%2BAnalogues%2Bfor%2BImproved%2BAffinity%2Bto%2BATB0%252C%252B%2Band%2BEnhanced%2BMetabolic%2BStability%253A%2BAn%2BApplication%2Bto%2BFloxuridine%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10828%26publicationDate%3DOctober%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00149"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">749</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00149" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Bifunctional and Unusual Amino Acid β- or γ-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB0,+ and Enhanced Metabolic Stability: An Application to Floxuridine&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yongbing&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Ke&quot;},{&quot;first_name&quot;:&quot;Chunshi&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Liangxing&quot;,&quot;last_name&quot;:&quot;Tu&quot;},{&quot;first_name&quot;:&quot;Lvjiang&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Yi&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jianping&quot;,&quot;last_name&quot;:&quot;Gong&quot;},{&quot;first_name&quot;:&quot;Zhiqiang&quot;,&quot;last_name&quot;:&quot;Yu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;10816-10828&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00149&quot;},&quot;abstract&quot;:&quot;Floxuridine (FUdR, 5-fluoro-2-deoxyuridine) was widely used in patients with tumor. But the poor activity and severe side effects have been observed in the clinic, which resulted from increased degradation cleavage of FUdR to 5-FU by thymidine phosphorylase and reduced transporter-mediated entry into cells. In this study, we have synthesized a series of l-aspartic acid β-esters and l-glutamic acid γ-esters of FUdR to improve the metabolic stability of FUdR and target FUdR to cancer cells via amino acid transporter ATB0,+ which was exclusively up-regulated in some cancerous tissue. The uptake mechanism, stability, in vitro/in vivo antiproliferation action, pharmacokinetics, and tissue distribution were studied. The combined results showed the unusual 5′-β-l-Asp-FUdR possessed a better tumor inhibition rate and a better metabolic stability than FUdR through a ATB0,+-mediated prodrug approach. The present study provided the first proof-of-concept of exploiting ATB0,+ for tumor-selective delivery of nucleoside an&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00149&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00149" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00149&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00149" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00149&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00149" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00149&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00149&amp;href=/doi/10.1021/acs.jmedchem.0c00149" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00149" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00149" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00149%26sid%3Dliteratum%253Aachs%26pmid%3D32882127%26genre%3Darticle%26aulast%3DSun%26date%3D2020%26atitle%3DBifunctional%2Band%2BUnusual%2BAmino%2BAcid%2B%25CE%25B2-%2Bor%2B%25CE%25B3-Ester%2BProdrugs%2Bof%2BNucleoside%2BAnalogues%2Bfor%2BImproved%2BAffinity%2Bto%2BATB0%252C%252B%2Band%2BEnhanced%2BMetabolic%2BStability%253A%2BAn%2BApplication%2Bto%2BFloxuridine%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D19%26spage%3D10816%26epage%3D10828%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/jmcmar.2020.63.issue-19/20201008/jmcmar.2020.63.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Floxuridine (FUdR, 5-fluoro-2-deoxyuridine) was widely used in patients with tumor. But the poor activity and severe side effects have been observed in the clinic, which resulted from increased degradation cleavage of FUdR to 5-FU by thymidine phosphorylase and reduced transporter-mediated entry into cells. In this study, we have synthesized a series of <span class="smallcaps smallerCapital">l</span>-aspartic acid β-esters and <span class="smallcaps smallerCapital">l</span>-glutamic acid γ-esters of FUdR to improve the metabolic stability of FUdR and target FUdR to cancer cells via amino acid transporter ATB<sup>0,+</sup> which was exclusively up-regulated in some cancerous tissue. The uptake mechanism, stability, <i>in vitro</i>/<i>in vivo</i> antiproliferation action, pharmacokinetics, and tissue distribution were studied. The combined results showed the unusual 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR possessed a better tumor inhibition rate and a better metabolic stability than FUdR through a ATB<sup>0,+</sup>-mediated prodrug approach. The present study provided the first proof-of-concept of exploiting ATB<sup>0,+</sup> for tumor-selective delivery of nucleoside analogues in the form of prodrug.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24348" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24348" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nucleoside analogues continue to make a major contribution to the current chemotherapy of cancer.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a><i>In vivo</i> intracellular delivery was the initial and key step for nucleoside analogues to exert their pharmacological activity.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Specialized nucleoside transporters, such as equilibrative nucleoside transporter (ENT) and concentrative nucleoside transporter (CNT), were essential for the cytotoxicity of nucleoside analogues in cancer cells.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> However, the deficiency and the low capacity of ENT vitiated the cellular uptake of nucleoside analogues, thus producing drug resistance and side effects.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Floxuridine (FUdR, 5-fluoro-2-deoxyuridine) was a typical fluorinated pyrimidine analogue and used for the treatment of various solid tumors. Similar to other nucleoside analogues, it was very inefficient for FUdR to transverse cancer cell membranes. Furthermore, FUdR could be rapidly metabolized to 5-fluorouracil (5-FU) <i>in vivo</i> by thymidine phosphorylase (TP). This degradative cleavage of FUdR to 5-FU represented another acquired drug resistance in the clinic because FUdR inhibited the proliferation of cancer cells 10- to 100-fold higher than 5-FU.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> As a consequence, FUdR was often administered to patients via painful hepatic artery infusion (HAI).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Therefore, targeting the delivery of FUdR to cancer cells efficiently and improving the metabolic stability of glycosidic bond were very meaningful and valuable not only for enhancing the therapeutic effect and obviating the systemic toxicity but also for the patient compliance. Numerous prodrug technologies have been attempted to circumvent the limitations associated with FUdR, such as conjugates of chenodeoxycholic acid (CDCA) targeted to Na<sup>+</sup>/taurocholate cotransporting polypeptide (NTCP),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> peptide transporter 1 (PEPT1)-targeted peptidomimetics,<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> phosphoramidate protides,<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> and so on. However, no further information on these prodrugs is reported at present.</div><div class="NLM_p">Rapid proliferation of cancer cell required enhanced supply of nutrients to serve as the building blocks for the synthesis of macromolecules (DNA, RNA, proteins, and lipids) and as the carbon source for generation of metabolic energy inside cancer cells.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> To meet these requirements, some membrane transporters were specifically up-regulated in cancer cells to transport more nutrients, especially neutral and cationic amino acid transporter B<sup>0,+</sup> (ATB<sup>0,+</sup>, gene code SLC6A14).<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> ATB<sup>0,+</sup> can transport all neutral and cationic amino acids as well as many drugs, such as valacyclovir, valganciclovir, and nitric oxide synthase inhibitor using the inward-directed Na<sup>+</sup>/Cl<sup>–</sup> gradient and the inside negative membrane potential as the driving force.<a onclick="showRef(event, 'ref16 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref16 ref19 ref20">(16,19,20)</a> The full understanding of cancer proliferation has prompted a novel transporter-mediated approach to achieve cancer-tissue-targeted drug delivery.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Except for broad substrates specificity and high transport capacity, ATB<sup>0,+</sup> was exclusively up-regulated in some maligant tissues, for example, estrogen receptor (ER)-positive breast cancer, pancreatic cancer, and colon cancer. It has been reported that patients with colorectal cancer showed approximately 20-fold increase in SLC6A14 mRNA levels in tumor tissue over normal tissue.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> These characteristics have conferred ATB<sup>0,+</sup> a very promising and attractive target for anticancer drug design and can avoid undesirable off-target effects.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The ATB<sup>0,+</sup>-targeted drug development strategy is effective for tissue specific delivery using amino acids as the targeting or recognition promoieties.<a onclick="showRef(event, 'ref21 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref23">(21,23)</a> For example, treatment of ATB<sup>0,+</sup>-positive tumors cells with α-methyl-<span class="smallcaps smallerCapital">dl</span>-tryptophan (α-MT), a blocker of ATB<sup>0,+</sup>, led to a significant suppression of the colony-forming ability, whereas ATB<sup>0,+</sup>-negative cell lines were not affected.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Aspartic acid or lysine-decorated docetaxel-loading liposomes developed by Sun et al. could be targeted to ATB<sup>0,+</sup> transporter, and they displayed higher antitumor efficacy and less systemic toxicity.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">Inspired by the above findings, we hypothesized that amino acid-based prodrugs, especially some unusual amino acid β- or γ-ester prodrugs, could increase the binding affinity of nucleoside analogues to ATB<sup>0,+</sup>.<a onclick="showRef(event, 'ref23 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref23 ref26 ref27">(23,26,27)</a> Our assumption is stated as follows: first, because the substrates of ATB<sup>0,+</sup> were very broad, amino acid β- or γ-ester prodrugs could be accommodated by the binding pocket of ATB<sup>0,+</sup>;<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> second, β- or γ-amino acids introduced into the prodrugs would increase the resistance of prodrugs to metabolic degradation in the systemic circulation because the compounds composed of β- or γ-amino acids are completely resistant toward proteolytic and metabolic hydrolysis,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> ensuring that more intact prodrugs can be recognized by ATB<sup>0,+</sup>.</div><div class="NLM_p last">Herein, we put forward an unusual amino acid β- or γ-ester prodrugs strategy to increase the affinity of FUdR to ATB<sup>0,+</sup>. A series of FUdR <span class="smallcaps smallerCapital">l</span>-aspartic acid β-esters and <span class="smallcaps smallerCapital">l</span>-glutamic acid γ-esters have been synthesized in the present study. As a comparison, <span class="smallcaps smallerCapital">l</span>-valine α-esters of FUdR were also synthesized. These prodrugs were screened regarding the affinity to ATB<sup>0,+</sup> and the chemical/metabolic stability. The homology mode of ATB<sup>0,+</sup> was constructed and applied to reveal the interaction between the prodrugs and ATB<sup>0,+</sup> at the molecular level.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> All results demonstrated that the candidate prodrug <span class="smallcaps smallerCapital">l</span>-aspartic acid β-carboxyl ester (5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR) was stable in the systemic circulation and can markedly increase the metabolic stability of FUdR to TP. 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR exhibited a significantly higher inhibition rate for ATB<sup>0,+</sup>-positive tumor in a xenograft mouse model compared with FUdR after intravenous injection. The combined results corroborated the idea that exploiting ATB<sup>0,+</sup> for tumor-selective delivery of nucleoside analogues was feasible in the form of a prodrug.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Synthesis of Prodrugs</h3><div class="NLM_p">Boc-<span class="smallcaps smallerCapital">l</span>-Val, Boc-<span class="smallcaps smallerCapital">l</span>-Asp-O<i>t</i>Bu, and Boc-<span class="smallcaps smallerCapital">l</span>-Glu-O<i>t</i>Bu were used as the starting materials to synthesize α-, β-, and γ-carboxyl esters of FUdR, respectively. The protecting group Boc and <i>t</i>Bu were removed with 95% trifluoroacetic acid (TFA) in water (<i>v/v</i>) within an hour to prevent the formation of the amide product (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), and then the target compounds were precipitated and purified with ice-cold ether. Nine prodrugs were confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and mass spectrometry. The purities were determined by HPLC.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Synthesis of <span class="smallcaps smallerCapital">l</span>-valine α-ester prodrugs of FUdR. (b) Synthesis of <span class="smallcaps smallerCapital">l</span>-aspartic acid β-ester or <span class="smallcaps smallerCapital">l</span>-glutamic acid γ-ester prodrugs of FUdR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Interaction between Prodrugs and ATB<sup>0,+</sup></h3><div class="NLM_p">The inhibition of ATB<sup>0,+</sup>-mediated uptake of glycine, a typical substrate of ATB<sup>0,+</sup>, could be applied to assess the interaction between the substrates and ATB<sup>0,+</sup>. It can be seen from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> that all nine prodrugs could inhibit the uptake of glycine by ATB<sup>0,+</sup>, but the parent drug failed. IC<sub>50</sub> for 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR was 0.82 ± 0.14 mM, and it possessed the highest affinity to ATB<sup>0,+</sup> followed by 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR. Furthermore, enhanced ATB<sup>0,+</sup>-mediated uptake in <i>X. laevi</i>s oocytes-ATB<sup>0,+</sup> was observed with all prodrugs when compared with mock <i>X. laevi</i>s oocytes cells. The enhancement extent in uptake ranged from 2.44- to 9.28-fold, and 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR exhibited the highest improvement. So the process of nine prodrugs into <i>X. laevi</i>s oocytes-ATB<sup>0,+</sup> cells was a ATB<sup>0,+</sup>-mediated process, and they were all substrates of ATB<sup>0,+</sup>. As a comparison, the ability of these prodrugs to inhibit PEPT1-mediated uptake of gly-sar was investigated. It could be seen from <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> that only three <span class="smallcaps smallerCapital">l</span>-valine α-esters displayed significant inhibition of gly-sar uptake; <span class="smallcaps smallerCapital">l</span>-aspartic acid and <span class="smallcaps smallerCapital">l</span>-glutamic acid monosubstituted ester of FUdR showed very weak inhibition as FUdR, and <span class="smallcaps smallerCapital">l</span>-aspartic acid and <span class="smallcaps smallerCapital">l</span>-glutamic acid disubstituted ester could not interact with PEPT1. Furthermore, the enhanced PEPT1-mediated uptake was observed only for 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 3′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, and 3′, 5′-di-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, and there was no significant difference for the <span class="smallcaps smallerCapital">l</span>-aspartic acid β-ester and <span class="smallcaps smallerCapital">l</span>-glutamic acid γ-esters of FUdR between MDCK-PEPT1 cell and MDCK cell. Therefore, <span class="smallcaps smallerCapital">l</span>-aspartic acid β-esters and <span class="smallcaps smallerCapital">l</span>-glutamic acid γ-esters of FUdR were not the substrates of PEPT1. 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR displayed the highest affinity to ATB<sup>0,+</sup> when <span class="smallcaps smallerCapital">l</span>-valine, <span class="smallcaps smallerCapital">l</span>-aspartic acid, and <span class="smallcaps smallerCapital">l</span>-glutamic acid were coupled to the hydroxyl groups of FUdR at the different sites, respectively. Therefore, we focused our further development efforts on these three prodrugs. When the uptake of these three prodrugs in the presence and absence of glycine was studied in <i>X. laevi</i>s oocytes-ATB<sup>0,+</sup> cells, the inhibition of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR uptake by glycine was from 50% to 57% (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), which further indicated that these compounds were substrates of ATB<sup>0,+.</sup></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Uptake and Glycine Uptake Inhibition in <i>X. laevis</i> Oocytes Cells and <i>X. laevis</i> Oocytes-ATB<sup>0,+</sup> <a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">prodrug/drug</th><th class="colsep0 rowsep0" align="center">uptake inhibition, IC<sub>50</sub> (mM)</th><th class="colsep0 rowsep0" align="center">uptake in <i>X. laevis</i> oocytes-ATB<sup>0,+</sup> (nmol/(mg protein·10 min))</th><th class="colsep0 rowsep0" align="center">uptake in <i>X. laevis</i> oocytes (nmol/ (mg protein·10 min))</th><th class="colsep0 rowsep0" align="center">ATB<sup>0,+</sup>/control</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">0.98 ± 0.13</td><td class="colsep0 rowsep0" align="left">2.34 ± 0.23</td><td class="colsep0 rowsep0" align="left">0.31 ± 0.05</td><td class="colsep0 rowsep0" align="left">7.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">1.63 ± 0.22</td><td class="colsep0 rowsep0" align="left">1.56 ± 0.31</td><td class="colsep0 rowsep0" align="left">0.39 ± 0.07</td><td class="colsep0 rowsep0" align="left">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">2.01 ± 0.18</td><td class="colsep0 rowsep0" align="left">1.03 ± 0.16</td><td class="colsep0 rowsep0" align="left">0.37 ± 0.04</td><td class="colsep0 rowsep0" align="left">2.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">0.82 ± 0.14</td><td class="colsep0 rowsep0" align="left">2.97 ± 0.27</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.01</td><td class="colsep0 rowsep0" align="left">9.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">1.57 ± 0.25</td><td class="colsep0 rowsep0" align="left">1.89 ± 0.32</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.02</td><td class="colsep0 rowsep0" align="left">5.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">2.98 ± 0.21</td><td class="colsep0 rowsep0" align="left">1.12 ± 0.21</td><td class="colsep0 rowsep0" align="left">0.34 ± 0.03</td><td class="colsep0 rowsep0" align="left">3.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">1.13 ± 0.16</td><td class="colsep0 rowsep0" align="left">2.12 ± 0.26</td><td class="colsep0 rowsep0" align="left">0.35 ± 0.04</td><td class="colsep0 rowsep0" align="left">6.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">1.84 ± 0.27</td><td class="colsep0 rowsep0" align="left">1.04 ± 0.21</td><td class="colsep0 rowsep0" align="left">0.28 ± 0.05</td><td class="colsep0 rowsep0" align="left">3.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">2.65 ± 0.20</td><td class="colsep0 rowsep0" align="left">0.78 ± 0.23</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.07</td><td class="colsep0 rowsep0" align="left">2.44</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">Mean ± SD, <i>n</i> = 3.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Uptake and gly-sar Uptake Inhibition in MDCK Cells and MDCK-PEPT1<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">prodrug/drug</th><th class="colsep0 rowsep0" align="center">uptake inhibition, IC<sub>50</sub> (mM)</th><th class="colsep0 rowsep0" align="center">uptake in MDCK-PEPT1 (nmol/(mg protein·10 min))</th><th class="colsep0 rowsep0" align="center">uptake in MDCK (nmol/(mg protein·10 min))</th><th class="colsep0 rowsep0" align="center">PEPT1/control</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">12.21 ± 0.45</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">1.12 ± 0.23</td><td class="colsep0 rowsep0" align="left">1.78 ± 0.32</td><td class="colsep0 rowsep0" align="left">0.41 ± 0.02</td><td class="colsep0 rowsep0" align="left">4.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">1.89 ± 0.35</td><td class="colsep0 rowsep0" align="left">1.23 ± 0.27</td><td class="colsep0 rowsep0" align="left">0.43 ± 0.03</td><td class="colsep0 rowsep0" align="left">2.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">2.24 ± 0.25</td><td class="colsep0 rowsep0" align="left">1.11 ± 0.15</td><td class="colsep0 rowsep0" align="left">0.44 ± 0.04</td><td class="colsep0 rowsep0" align="left">2.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">10.23 ± 0.73</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">13.92 ± 0.56</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">11.45 ± 0.47</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">12.98 ± 0.33</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left"><0.04</td><td class="colsep0 rowsep0" align="left">1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">Mean ± SD, <i>n</i> = 3.</p></div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibition of uptake of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (all 0.5 mM, pH 6.0) by <i>X. laevis</i> oocytes-ATB<sup>0,+</sup> was assessed in the presence of glycine (10 mM): *<i>P</i> < 0.05, significantly different from the absence of glycine. Data are presented as the mean ± SD, <i>n</i> = 4–5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Concentration-dependent uptake of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR determined in X. <i>laevis oocytes</i>-ATB<sup>0,+</sup> cells is shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. The uptake process could be fitted by the Michaelis–Menten equations. The kinetics constants (<i>K</i><sub>m</sub>) for 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR were 54.6 ± 9.56 pmol/μL, 35.6 ± 7.58 pmol/μL, and 84.0 ± 15.2 pmol/μL. The <i>V</i><sub>max</sub> values for 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR were 278.4 ± 23.1, 201.4 ± 34.2, and 234.55 ± 19.7 pmol/(mg protein·min), respectively. The <i>K</i><sub>m</sub> of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR was the lowest, and it showed the highest affinity to ATB<sup>0,+</sup>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Concentration-dependent uptake of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR in <i>X. laevis</i> oocytes-ATB<sup>0,+</sup> cells. <i>V</i> is the uptake rate (picomoles per milligram of protein per minute), and <i>S</i> is the prodrug concentration (micromolar).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.3.  Na<sup>+</sup> and Cl<sup>–</sup> Activation Kinetics</h3><div class="NLM_p">ATB<sup>0,+</sup> was a member of the Na<sup>+</sup>/Cl<sup>–</sup>-dependent transporter family that required both Na<sup>+</sup> and Cl<sup>–</sup> for transport to occur. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> showed the increasing concentrations of Na<sup>+</sup> and Cl<sup>–</sup> (from 0 to 120 mM) on the uptake of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR in X. <i>laevis oocytes</i>-ATB<sup>0,+</sup>. Dose–response curves were fitted to the Hill equations. For Na<sup>+</sup>, the Hill coefficients were 2.06 ± 0.13, 2.14 ± 0.11, and 1.90 ± 0.10 for 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR, respectively. The Cl<sup>–</sup> data yielded a Hill coefficient of 0.97 ± 0.07, 1.13 ± 0.11, and 0.99 ± 0.07 for 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR, respectively. A Hill slope close to 2 for Na<sup>+</sup> suggested the transport cycle involves the binding of about two Na<sup>+</sup> ions, and a Hill slope for Cl<sup>–</sup> ion close to 1 suggested the binding of one Cl<sup>–</sup> ion to one substrate. Therefore, during the process of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR into the X. <i>laevis oocytes</i>-ATB<sup>0,+</sup>, a transport stoichiometry of two Na<sup>+</sup>, one Cl<sup>–</sup>, and one substrate was proposed, which was in agreement with the reported energetics of ATB<sup>0,+</sup>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Na<sup>+</sup> and Cl<sup>–</sup> activation kinetics for ATB<sup>0,+</sup>-mediated transport of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (all 1 mM) in the <i>X. laevis</i> oocytes-ATB<sup>0,+</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.4.  Molecular Docking</h3><div class="NLM_p">The refined homology mode of ATB<sup>0,+</sup> was constructed using DAT and PFKA1 as the templates. The docking results of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR, and 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR revealed the interaction with ATB<sup>0,+</sup> at the molecular level. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR formed seven hydrogen bonds with amino acid residues. The carboxyl group formed hydrogen bonds with Asp478 and Tyr131. The amino group formed a hydrogen bond with Asp478. Additionally, the carbonyl groups on the C-2 and C-6 positions of pyrimidinedione formed hydrogen bonds with Trp60, Ser324, and Ser427. The hydroxyl group at the sugar formed an H-bond with Asn58.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode with the chimera ATB<sup>0,+</sup> (with PDB entries <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4M48">4M48</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O8O">3O8O</a> as the template): (A) 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR; (B) 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR; (C) 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR formed six hydrogen bonds with residues (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). The carboxyl group formed hydrogen bonds with Asp478. The amino group formed hydrogen bonds with Tyr321 and Asp478. As 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, the carbonyl groups on the C-2 and C-6 position of pyrimidinedione also formed two hydrogen bonds with Ser324 and Ser427. The hydroxyl group formed hydrogen bonds with Asn58.</div><div class="NLM_p last">5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR formed only two hydrogen bonds with residues (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). The carbonyl group on the C-2 position of pyrimidinedione formed a hydrogen bond with Tyr131. The hydroxyl group formed a H-bond with Tyr132. The skeleton of pyrimidinedione in 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR formed a π–π conjugation with Tyr321.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">2.5.  Stability Study</h3><div class="NLM_p">The half-lives (<i>t</i><sub>1/2</sub>) calculated from linear regression of pseudo-first-order plots of prodrug concentration vs time are listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. It can been seen that the prodrugs in pH 7.4 phosphate buffer were more stable than in plasma, which indicated that the enzyme in plasma may participate in the hydrolysis of the prodrugs <i>in vivo</i>. The <i>t</i><sub>1/2</sub> values of all prodrugs in plasma were 30 min or higher, which indicated a greater probability of the prodrugs being intact for targeted tissue. It can be observed that β- and γ-esters prodrugs possessed a better stability than α-esters in plasma. The hydrolysis of prodrugs in cancer cell homogenates was very rapid, implying a possibly rapid bioactivation of prodrugs in cancer tissue. When FUdR and the prodrugs were incubated in TP buffers, the <i>t</i><sub>1/2</sub> of all prodrugs were more than 230 min, but the <i>t</i><sub>1/2</sub> of FUdR was only 10.2 min. Therefore, the amino acid-based prodrug strategy could render the glycosidic bond more resistant to TP and improve the metabolic stability of FUdR.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Stability of FUdR and All Prodrugs in pH 7.4 Phosphate Buffer, Rat Plasma, Thymidine Phosphorylase, and Cancer Cell Homogenates<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center"><i>t</i><sub>1/2</sub> (min)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">cell homogenate</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">prodrug/drug</th><th class="colsep0 rowsep0" align="center">phosphate buffer (pH 7.4)</th><th class="colsep0 rowsep0" align="center">rat plasma</th><th class="colsep0 rowsep0" align="center">TP</th><th class="colsep0 rowsep0" align="center">ZR-75-1</th><th class="colsep0 rowsep0" align="center">PaCa-2</th><th class="colsep0 rowsep0" align="center">MB231</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">10.2 ± 4</td><td class="colsep0 rowsep0" align="left">13.2 ± 5.3</td><td class="colsep0 rowsep0" align="left">15.6 ± 8.7</td><td class="colsep0 rowsep0" align="left">23.1 ± 5.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">203.4 ± 27.1</td><td class="colsep0 rowsep0" align="left">78.5 ± 13.9</td><td class="colsep0 rowsep0" align="left">408.3 ± 34.8</td><td class="colsep0 rowsep0" align="left">16.4 ± 2.1</td><td class="colsep0 rowsep0" align="left">11.3 ± 2.1</td><td class="colsep0 rowsep0" align="left">15.3 ± 2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">187.1 ± 22.9</td><td class="colsep0 rowsep0" align="left">65.3 ± 12.7</td><td class="colsep0 rowsep0" align="left">367.5 ± 40.1</td><td class="colsep0 rowsep0" align="left">9.2 ± 1.8</td><td class="colsep0 rowsep0" align="left">12.2 ± 1.3</td><td class="colsep0 rowsep0" align="left">14.9 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">105.6 ± 23.1</td><td class="colsep0 rowsep0" align="left">37.8 ± 6.8</td><td class="colsep0 rowsep0" align="left">256.7 ± 43.1</td><td class="colsep0 rowsep0" align="left">6.7 ± 2.9</td><td class="colsep0 rowsep0" align="left">8.4 ± 1.9</td><td class="colsep0 rowsep0" align="left">10.1 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">286.3. ± 25.4</td><td class="colsep0 rowsep0" align="left">149.7 ± 11.3</td><td class="colsep0 rowsep0" align="left">298.7 ± 23.3</td><td class="colsep0 rowsep0" align="left">13.4 ± 3.1</td><td class="colsep0 rowsep0" align="left">16.4 ± 4.2</td><td class="colsep0 rowsep0" align="left">11.1 ± 3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">178.8 ± 32.1</td><td class="colsep0 rowsep0" align="left">123.8 ± 15.4</td><td class="colsep0 rowsep0" align="left">278.3 ± 19.6</td><td class="colsep0 rowsep0" align="left">24.2 ± 3.5</td><td class="colsep0 rowsep0" align="left">32.1 ± 4.8</td><td class="colsep0 rowsep0" align="left">19.3 ± 3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">98.2 ± 23.5</td><td class="colsep0 rowsep0" align="left">56.1 ± 8.7</td><td class="colsep0 rowsep0" align="left">301.1 ± 20.2</td><td class="colsep0 rowsep0" align="left">16.2 ± 4.2</td><td class="colsep0 rowsep0" align="left">11.3 ± 1.1</td><td class="colsep0 rowsep0" align="left">9.3 ± 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">258.2 ± 35.4</td><td class="colsep0 rowsep0" align="left">114.3 ± 11.2</td><td class="colsep0 rowsep0" align="left">256.3 ± 12.5</td><td class="colsep0 rowsep0" align="left">12.3 ± 2.8</td><td class="colsep0 rowsep0" align="left">20.1 ± 3.9</td><td class="colsep0 rowsep0" align="left">17.3 ± 4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">183.2 ± 30.2</td><td class="colsep0 rowsep0" align="left">97.4 ± 13.3</td><td class="colsep0 rowsep0" align="left">289.1 ± 18.7</td><td class="colsep0 rowsep0" align="left">7.9 ± 1.3</td><td class="colsep0 rowsep0" align="left">10.2 ± 2.3</td><td class="colsep0 rowsep0" align="left">8.3 ± 1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">109.4 ± 40.1</td><td class="colsep0 rowsep0" align="left">67.9 ± 11.6</td><td class="colsep0 rowsep0" align="left">234.9 ± 17.5</td><td class="colsep0 rowsep0" align="left">14.3 ± 4.0</td><td class="colsep0 rowsep0" align="left">17.5 ± 5.1</td><td class="colsep0 rowsep0" align="left">21.1 ± 4.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">Mean ± SD, <i>n</i> = 3.</p></div></div></div><div class="NLM_p">When FUdR and the prodrugs were incubated with the solution of TP, the appearance of 5-FU from 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR was much slower than from FUdR. The disappearance of FUdR and the appearance of 5-FU showed an excellent balance at all time points examined when FUdR was incubated with TP (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Thymidine phosphorylase activity against 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (A) and FUdR (B). 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (A) and FUdR (B) were incubated with a solution of thymidine phosphorylase (2 ng/mL) in phosphate buffer (pH 6.4) at 37 °C, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">2.6.  Antiproliferation Study <i>in Vitro</i></h3><div class="NLM_p">GI<sub>50</sub> values for FUdR and all prodrugs were tested in two ATB<sup>0,+</sup>-positive cancer cells ZR-75-1 and PaCa-2 and one ATB<sup>0,+</sup>-negative breast cancer MB231 cells (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). GI<sub>50</sub> values for FUdR in ZR-75-1, PaCa-2, and MB231 cell were 30.1 mM, 27.3 mM, and 35.1 mM, respectively. In ATB<sup>0,+</sup>-positive ZR-75-1 and PaCa-2 cells, GI<sub>50</sub> for FUdR prodrugs was from 1.6 to 4.2 mM, which was about 7- to 8-fold lower than FUdR. However, the GI<sub>50</sub> values of these prodrugs in ZR-75-1 and PaCa-2 cell were not significantly different between each other, and they did not exhibit any discernible correlations with their affinity to ATB<sup>0,+</sup> (IC<sub>50</sub> in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In the ER-negative breast cancer MB231 cells which did not express ATB<sup>0,+</sup>, GI<sub>50</sub> for all prodrugs was from 29.3 to 38.3 mM, which was not significantly different from GI<sub>50</sub> of FUdR (35.1 mM).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferation Activity in ZR-75-1, PaCa-2, and MB231 Cells<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">GI<sub>50</sub> (mM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">prodrug/drug</th><th class="colsep0 rowsep0" align="center">ZR-75-1</th><th class="colsep0 rowsep0" align="center">PaCa-2</th><th class="colsep0 rowsep0" align="center">MB231</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">30.1 ± 4.6</td><td class="colsep0 rowsep0" align="left">27.3 ± 3.9</td><td class="colsep0 rowsep0" align="left">35.1 ± 4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.1</td><td class="colsep0 rowsep0" align="left">4.2 ± 0.2</td><td class="colsep0 rowsep0" align="left">38.1 ± 3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">2.1 ± 0.2</td><td class="colsep0 rowsep0" align="left">2.6 ± 0.2</td><td class="colsep0 rowsep0" align="left">32.4 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR</td><td class="colsep0 rowsep0" align="left">2.8 ± 0.3</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.4</td><td class="colsep0 rowsep0" align="left">31.7 ± 4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">3.9 ± 0.3</td><td class="colsep0 rowsep0" align="left">3.6 ± 0.2</td><td class="colsep0 rowsep0" align="left">29.3 ± 3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">3.1 ± 0.2</td><td class="colsep0 rowsep0" align="left">4.1 ± 0.3</td><td class="colsep0 rowsep0" align="left">37.6 ± 2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">1.9 ± 0.1</td><td class="colsep0 rowsep0" align="left">2.0 ± 0.2</td><td class="colsep0 rowsep0" align="left">33.1 ± 4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.2</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.3</td><td class="colsep0 rowsep0" align="left">38.3 ± 3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.2</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.1</td><td class="colsep0 rowsep0" align="left">34.9 ± 4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3′,5′-di-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR</td><td class="colsep0 rowsep0" align="left">3.1 ± 0.3</td><td class="colsep0 rowsep0" align="left">3.3 ± 0.2</td><td class="colsep0 rowsep0" align="left">37.3 ± 4.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup><sup>a</sup></sup><p class="last">Mean ± SD, <i>n</i> = 3.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">2.7.  Inhibition of Tumor Growth in Mouse Xenografts</h3><div class="NLM_p">To investigate the therapeutic potential of amino acids prodrugs of FUdR targeted to ATB<sup>0,+</sup>, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR was selected as the optimal compound because of the high affinity to ATB<sup>0,+</sup>, the appropriate stability in plasma, and the rapid bioactivation in cancer cell homogenates. After the 20-day continuous intravenous injection (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR had a higher inhibition rate for ZR-75-1 tumor in xenograft mouse than FUdR (58.6% vs 36.1%). The similar enhanced potency was also observed for 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR in PaCa-2 bearing mouse xenograft model than FUdR (62.4% vs 41.3%) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The tumor inhibition rate for MB-231 tumor was not significantly different between 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR and FUdR (33.8% vs 36.9%). After a 20-day course of treatment, body weights displayed no significant difference between dosed groups and the control group, and so treatment of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR did not cause significant toxicity in any of three dosed groups (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <i>In vivo</i> antitumor efficacy of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR and FUdR in tumor-bearing nude mice: (a) ZR-75–1; (b) PaCa-2; (c) MB-231. The control groups were free to the sucrose–water for drinking, and the treatment group was injected with FUdR or 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (90 mg/kg calculated as FUdR) for 20 successive days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Effect of Tumor Growth in Mouse Xenografts after Intravenous Injection of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (90 mg/kg, Calculated as FUdR) or FUdR (90 mg/kg) for 20 Days<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">body weight (g)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">tumor type</th><th class="colsep0 rowsep0" align="center">group</th><th class="colsep0 rowsep0" align="center">pretreatment</th><th class="colsep0 rowsep0" align="center">post-treatment</th><th class="colsep0 rowsep0" align="center">tumor weight (g)</th><th class="colsep0 rowsep0" align="center">inhibition rate (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ZR-75-1 tumor</td><td class="colsep0 rowsep0" align="left">control</td><td class="colsep0 rowsep0" align="left">21.2 ± 1.3</td><td class="colsep0 rowsep0" align="left">29.2 ± 2.5</td><td class="colsep0 rowsep0" align="left">1.21 ± 0.27</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">20.8 ± 1.4</td><td class="colsep0 rowsep0" align="left">26.8 ± 3.3</td><td class="colsep0 rowsep0" align="left">0.50 ± 0.18<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">58.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">21.3 ± 1.0</td><td class="colsep0 rowsep0" align="left">25.8 ± 3.7</td><td class="colsep0 rowsep0" align="left">0.77 ± 0.26<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">36.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PaCa-2 tumor</td><td class="colsep0 rowsep0" align="left">control</td><td class="colsep0 rowsep0" align="left">21.5 ± 1.2</td><td class="colsep0 rowsep0" align="left">28.4 ± 2.1</td><td class="colsep0 rowsep0" align="left">1.25 ± 0.31</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">21.4 ± 0.8</td><td class="colsep0 rowsep0" align="left">26.3 ± 2.9</td><td class="colsep0 rowsep0" align="left">0.43 ± 0.17<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">62.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">21.0 ± 1.3</td><td class="colsep0 rowsep0" align="left">24.7 ± 3.1</td><td class="colsep0 rowsep0" align="left">0.74 ± 0.33<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">41.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MB-231 tumor</td><td class="colsep0 rowsep0" align="left">control</td><td class="colsep0 rowsep0" align="left">20.9 ± 1.4</td><td class="colsep0 rowsep0" align="left">30.1 ± 4.1</td><td class="colsep0 rowsep0" align="left">1.06 ± 0.32</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">21.3 ± 0.9</td><td class="colsep0 rowsep0" align="left">27.6 ± 3.6</td><td class="colsep0 rowsep0" align="left">0.70 ± 0.26<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">33.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">21.2 ± 1.1</td><td class="colsep0 rowsep0" align="left">28.4 ± 3.2</td><td class="colsep0 rowsep0" align="left">0.67 ± 0.27<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">36.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Data shown are the mean ± SD of tumor weights and mouse body weights for each group of mice (<i>n</i> = 10).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last"><i>P</i> < 0.01 verse control group for the same tumor type.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last"><i>P</i> < 0.05 verse FUdR group for the same tumor type.</p></div></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">2.8.  Pharmacokinetics and Tissue Distribution</h3><div class="NLM_p">The pharmacokinetics and tissue distribution of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR were studied in a nude mouse xenograft model with ZR-75-1 cells to delineate the disposition of the prodrug <i>in vivo</i> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The AUC<sub>0–<i>t</i></sub> of FUdR was 1877.1 ± 100.2 and 4600.1 ± 502.8 ng/g·h in the tumor after FUdR (90 mg/kg) and 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (90 mg/kg, calculated as FUdR) were intravenously injected into the mouse, respectively. Conversely, the AUC<sub>0–<i>t</i></sub> of FUdR in plasma was 3419.0 ± 309.2 ng/mL·h and 1172.9 ± 132.1 ng/mL·h after FUdR and 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR were dosed to the mouse, respectively. These results translated to a tumor-targeting index (AUC<sub>(0–<i>t</i>)</sub> FUdR<sub>(tumor)</sub>/AUC<sub>(0–<i>t</i>)</sub> FUdR <sub>(plasma)</sub>) of 3.9 for 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR and 0.55 for FUdR, and the increase in the targeting index for 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR over FUdR was about 7.1 (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Therefore, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR could be effectively targeted to the ATB<sup>0,+</sup>-positive ZR-75-1 cells and then converted to the parent drug FUdR, thus increasing the exposure of the parent drug in target tissue, which can explain why 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR had a higher inhibition rate for ZR-75-1-derived tumor in mouse than FUdR. In addition, the lower levels of the metabolite 5-FU in plasma were observed after dosing of 5′-β-Asp-FUdR than after FUdR (588.2 ± 67.9 (ng/mL)·h vs 4107.2 ± 453.9 (ng/mL)·h). So the amino acid prodrug can increase the metabolic stability of FUdR <i>in vivo</i> and decrease the formation of 5-FU.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetics Parameters of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR and FUdR in Nude Mouse Xenograft Model with ZR-75-1 Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd (dosed)</th><th class="colsep0 rowsep0" align="center">compd (detected)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL or ng/g)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–<i>t</i></sub> ((ng/mL)·h or (ng/g)·h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Plasma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3419.0 ± 309.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5-FU</td><td class="colsep0 rowsep0" align="left">434.1 ± 45.8</td><td class="colsep0 rowsep0" align="left">4107.2 ± 453.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5066 ± 606.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">145.9 ± 34.2</td><td class="colsep0 rowsep0" align="left">1172.9 ± 132.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5-FU</td><td class="colsep0 rowsep0" align="left">67.8 ± 10.3</td><td class="colsep0 rowsep0" align="left">588.2 ± 67.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Tumor</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">374.4 ± 78.7</td><td class="colsep0 rowsep0" align="left">1877.1 ± 100.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR</td><td class="colsep0 rowsep0" align="left">FUdR</td><td class="colsep0 rowsep0" align="left">700.2 ± 98.3</td><td class="colsep0 rowsep0" align="left">4600.1 ± 502.8</td></tr></tbody></table></div></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Mean (±SD) plasma concentration–time profiles of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, FUdR and 5-FU in nude mouse xenograft model established with ZR-75-1 cells after 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (90 mg/kg calculated as FUdR) was intravenously injected. <i>n</i> = 5–6 at every time point: ◇, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR; ■, FUdR; ▲, 5-FU. (B) Mean (±SD) plasma concentration–time profiles of FUdR and 5-FU in nude mouse xenograft model established with ZR-75-1 cells after FUdR (90 mg/kg) was intravenously injected. <i>n</i> = 5–6 at every time point: ◇, FUdR; ■, 5-FU. (C) Mean (±SD) tumor concentration–time profiles of FUdR in nude mouse xenograft model established with ZR-75-1 cells after FUdR (90 mg/kg) and 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (90 mg/kg calculated as FUdR) were injected to the mice, respectively. <i>n</i> = 5–6 at every time point: ◇, dosing of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR; ■, dosing of FUdR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">3.  Discussion and Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61876" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61876" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Recently, the emphasis in cancer drug development has been shifting from cytotoxic and nonspecific chemotherapies to molecularly targeted and rationally designed drugs, promising greater effectiveness and fewer side effects.<a onclick="showRef(event, 'ref22 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref22 ref29 ref30 ref31">(22,29−31)</a> A variety of biological targets, especially some endogenous transporters that are expressed on the membrane of cancer cell, could be utilized to exploit the differences between normal and cancerous tissues.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The common strategy was to develop a conjugated drug that incorporated a tumor targeting group and a cytotoxic drug. Due to the very high expression in cancerous tissue, the broad substrates specificity, high transport capacity, and the cotransport of Na<sup>+</sup> as well as Cl<sup>–</sup> in the same direction,<a onclick="showRef(event, 'ref16 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref18">(16,18)</a> the ATB<sup>0,+</sup>-targeted delivery strategy allowed exposure of SLC6A14-positve tumor cells to chemotherapy with minimal off-target effects.<a onclick="showRef(event, 'ref17 ref31'); return false;" href="javascript:void(0);" class="ref ref17 ref31">(17,31)</a> So ATB<sup>0,+</sup> was a better drug target than other amino acid transporters, such as SLC1A5, SLC6A19, PEPT1, and so on.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">Like many other nucleoside analogues, poor activity and severe side effects of FUdR have been observed in the clinic, and this innate or acquired drug resistance has been ascribed to several parameters, such as increased degradation cleavage of FUdR to 5-FU by TP and reduced transporter-mediated entry of FUdR into cells.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Therefore, there is a need for an efficient delivery system for FUdR that bypasses these resistance phenomena, improves the therapeutic index, and decreases adverse effects.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> It has been reported that some peptidomimetics consisiting of unusual β- or γ-amino acid demonstrate improved stability and are completely resistant to metabolic enzyme-mediated cleavage when compared to the α-amino acid counterpart.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Additionally, β- or γ-amino acid introduced in the prodrugs can decrease the affinity of prodrugs to PEPT1, a membrane transporter widely expressed in the healthy organ.<a onclick="showRef(event, 'ref10 ref27'); return false;" href="javascript:void(0);" class="ref ref10 ref27">(10,27)</a> Hence, amino acid β- or γ-ester prodrugs of FUdR targeted to ATB<sup>0,+</sup> would not be recognized by PEPT1, and the potential toxicity of prodrugs to the PEPT1-overexpressing normal tissues can be avoided.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Therefore, in the present study, the β-carboxyl group of <span class="smallcaps smallerCapital">l</span>-aspartic acid and the γ-carboxyl group of <span class="smallcaps smallerCapital">l</span>-glutamic acid were coupled to the 3′ or 5′-position hydroxyl of FUdR. Meanwhile, <span class="smallcaps smallerCapital">l</span>-valine α-ester of FUdR was also synthesized as a comparison.</div><div class="NLM_p">The uptake inhibition of glycine (a typical substrate of ATB<sup>0,+</sup>) by the prodrugs was routinely carried out to investigate the prodrugs’ ability to interact with ATB<sup>0,+</sup>. From <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, it can be seen that IC<sub>50</sub> for prodrugs was from 0.82 to 2.98 mM. Additionally, all prodrugs showed several-fold higher direct uptake in <i>X. laevis</i> oocytes-ATB<sup>0,+</sup> than mock <i>X. laevis</i> oocytes. But the parent drug FUdR did not interact with ATB<sup>0,+</sup>. Hence, α-, β-, and γ-ester derivatives of FUdR were all substrates of ATB<sup>0,+</sup>. The experiments that followed, such as inhibition of uptake by glycine, concentration-dependent uptake, and Na<sup>+</sup> and Cl<sup>–</sup> activation kinetics, further suggested that 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR were the substrates of ATB<sup>0,+</sup>. Their transport into cancer cells was an ATB<sup>0,+</sup>-mediated active process and could be seriously inhibited by glycine (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The transport process could be fitted by the Michaelis–Menten equations (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) and complied with the energetics of ATB<sup>0,+</sup> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref16 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref18">(16,18)</a> Interestingly, only three <span class="smallcaps smallerCapital">l</span>-valine α-esters of FUdR were the substrates of PEPT1; β- and γ-esters did not interact with PEPT1 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Therefore, all of the above results proved our hypothesis that ATB<sup>0,+</sup> can accept amino acid β- and γ-esters of FUdR as the substrates. In line with these above observation, Ganapathy and his colleagues’ work have reported in 2004 that <span class="smallcaps smallerCapital">l</span>-aspartate β-benzyl ester and <span class="smallcaps smallerCapital">l</span>-aspartate γ-benzyl ester were the substrates of ATB<sup>0,+</sup>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Like valacyclovir and valganciclovir, <span class="smallcaps smallerCapital">l</span>-valine α-ester of FUdR can be recognized by ATB<sup>0,+</sup> as well as PEPT1 due to the overlap of substrates between ATB<sup>0,+</sup> and PEPT1.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> According to Ganapathy’s opinion,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> to avoid the potential side effects of PEPT1-overexpressing normal tissue, <span class="smallcaps smallerCapital">l</span>-valine α-ester of FUdR should be excluded from the candidate drugs.</div><div class="NLM_p">In the present study, the 3D structure of ATB<sup>0,+</sup> was constructed through a homology modeling approach with DAT and PFKA1 as the template.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The molecular docking indicated 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR formed seven and six hydrogen bonds with ATB<sup>0,+</sup>, respectively, and 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR formed only two hydrogen bonds. So 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR displayed the strongest interaction with ATB<sup>0,+</sup>, which was consistent with the lowest IC<sub>50</sub> of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The refined homology modeling can provide a deeper insight into the interaction between ATB<sup>0,+</sup> and the substrates.</div><div class="NLM_p">Except for targeting to a specific transporter or receptor on cancer cell membrane, delivery and stability were other aspects of cancer drug development that have been receiving much attention.<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> The prodrugs should keep stable and be intact in the systemic circulation before they are delivered to cancer cells to ensure they could be recognized by the biological targets expressed in the surface of cancer cells.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The <i>t</i><sub>1/2</sub> of all prodrugs in plasma was more than 30 min, which implied a greater probability of being intact for targeted tissue (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> The prodrugs containing β- and γ-ester bond indicated a better stability than α-ester prodrug in plasma. When FUdR and the prodrugs were incubated in TP buffers, the <i>t</i><sub>1/2</sub> values of all prodrugs were more than 230 min, but the <i>t</i><sub>1/2</sub> of FUdR was only 10.2 min. So the amino acid derivative approach rendered the glycosidic bond more resistant to TP and improved the metabolic stability of FUdR.</div><div class="NLM_p">The antiproliferation study of FUdR and its derivatives <i>in vitro</i> was investigated in two ATB<sup>0,+</sup>-positive cancer cells ZR-75-1 and PaCa-2 and one ATB<sup>0,+</sup>-negative breast cancer MB231 cells (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In ATB<sup>0,+</sup>-positive cancer cells, all prodrugs displayed a significantly higher inhibition rate than FUdR, but the GI<sub>50</sub> was not different between FUdR and the prodrugs in ATB<sup>0,+</sup>-negative breast cancer MB231 cells. Therefore, the ATB<sup>0,+</sup>-mediated transport may be responsible for the better cytotoxicity of the prodrugs in ATB<sup>0,+</sup>-positive cancer cells. However, the GI<sub>50</sub> for prodrugs in ZR-75-1 and PaCa-2 cells did not exhibit any discernible correlations with their affinity to ATB<sup>0,+</sup>(IC<sub>50</sub> in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), and they were not significantly different from each other. It might be difficult to discern a meaningful correlation between GI<sub>50</sub> and prodrug permeability.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The possible explanation may be that ATB<sup>0,+</sup> had enough time to concentrate all intact prodrugs inside the cancer cells for its high transport capacity when cancer cells were incubated with the prodrugs for 3 h. To test the explanation above, we will determine the concentration of FUdR and prodrugs in cancer cells and clarify this phenomenon in a future study.</div><div class="NLM_p">Because of the highest affinity to ATB<sup>0,+</sup>, the appropriate stability in plasma and in TP buffers, and the rapid bioactivation in cancer cell homogenates, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR was selected as the optimal compound for antiproliferation study <i>in vivo.</i> Like α-MT,<a onclick="showRef(event, 'ref21 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref24">(21,24)</a> 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR possessed a higher antitumor activity against ATB<sup>0,+</sup>-positive ZR-75-1 and PaCa-2 tumor in a xenograft mouse model than FUdR (58.6% vs 36.1% for ZR-75–1, 62.4% vs 41.3% for PaCa-2, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). On the contrary, the inhibition rate for MB-231 tumor was not significantly different between 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR and FUdR (33.8% vs 36.9%). The pharmacokinetics and tissue distribution of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR in mouse xenograft can explain the pharmacological result above (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The tumor to plasma distribution (tumor-targeting index) for FUdR was 7.1-fold higher after 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR dosing than after dosing of FUdR, which meant that 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR could achieve tumor-targeted delivery and less systemic exposure. Therefore, combined with the former transport results, the prodrug can alter the transport pattern of FUdR across the cell membrane and accumulate more parent drug in tumor cells with the aid of ATB<sup>0,+</sup>, thus producing a better pharmacological activity. In a future experiment, we will silence SLC6A14 in ZR-75-1 cells and construct a ZR-75-1/SLC6A14-shRNA bearing tumor mouse xenograft to clarify the role of ATB<sup>0,+</sup> in the uptake of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR into tumor cells further. In addition, the lower levels of the metabolite 5-FU in plasma were observed after dosing of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR than after FUdR. Therefore, the amino acid prodrug conferred protection from metabolic degradation <i>in vivo</i> and decreased the formation of 5-FU (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), which was another factor that contributed to the improved pharmacological activity of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR in the xenograft model.</div><div class="NLM_p last">In conclusion, in the present study we have developed amino acid β- and γ-esters of FUdR to increase the binding affinity toward ATB<sup>0,+</sup>, leading to enhanced ATB<sup>0,+</sup>-targeted delivery and improved antiproliferation activity <i>in vivo</i> accompanied by better metabolic stability of FUdR in systemic circulation. The amino acid β- and γ-esters of FUdR displayed more advantages than their α-counterparts. Our findings disclosed that this bifunctional and unusual amino acid β- or γ-ester prodrugs strategy could be adopted to improve the tumor-targeted delivery of nucleoside analogues with severe side effects and metabolic deactivation.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">4.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63885" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63885" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.1.  Materials</h3><div class="NLM_p last">Floxuridine (FUdR) was purchased from Wuhan Hongxinkang Chemical. Co. Ltd. (Wuhan, China). Boc-<span class="smallcaps smallerCapital">l</span>-Val, Boc-<span class="smallcaps smallerCapital">l</span>-Asp-O<i>t</i>Bu, and Boc-<span class="smallcaps smallerCapital">l</span>-Glu-O<i>t</i>Bu were purchased from GL Chemical Ltd. (Shanghai, China). Carbonyldiimidazole (CDI) was purchased from Changzhou Chongkai Chemical Co. Ltd. (Changzhou, China). 4-Dimethylaminopyridine (DMAP) was purchased from Jiangsu B-win Chemicals Co. Ltd. (Wuxi, China). PEPT1-overespressing MDCK cell (MDCK-PEPT1) and ATB<sup>0,+</sup>-overespressing <i>Xenopus laevis</i> oocytes (<i>X. laevi</i>s oocytes-ATB<sup>0,+</sup>) were established by Cellbio Biology Co. Ltd. (Shanghai China). Thymidine phosphorylase, recombinant from <i>Escherichia coli</i>, was purchased from Sigma-Aldrich (USA). All other chemicals used were of the highest grade available.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">4.2.  Prodrug Synthesis</h3><div class="NLM_p">A solution of BOC-protected amino acid (22 mmol), carbonyldiimidazole (CDI, 3.57 g, 22 mmol), and anhydrous tetrahydrofuran (THF, 150 mL) was stirred under argon at 25 °C for 1.5 h and then 40–50 °C for 20 min. This mixture was slowly added to a stirred solution of FUdR (4.98 g, 20 mmol), DMAP (0.25 g, 2 mmol), triethylamine (TEA, 50 mL), and anhydrous <i>N</i>,<i>N</i>-dimethylformamide (DMF, 100 mL) at 80 °C. The reaction mixture continued to stir at this temperature for 1 h (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The reaction mixture was cooled to room temperature, and TEA and THF were removed under vacuum. The remaining DMF solution was then neutralized to pH 7.5 with acetic acid, and DMF was evaporated under reduced pressure. The residue was diluted with ethyl acetate and successively washed with water and brine. The organic layer was condensed and the residue was purified by silica column chromatography (EtOAc/PE = 1:8 to 1:1) to give BOC-protected 3′-monoester, 5′-monoester, and 3′,5′-diesters of FUdR. The protecting groups Boc and <i>t</i>Bu were removed with 95% trifluoroacetic acid in water (v/v) within an hour to prevent the formation of the amide product, and then the target compounds were precipitated and purified with ice-cold ether. Nine prodrugs were confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and mass spectrometry. The purity of all prodrugs was >95% as determined by HPLC.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR (<b>2a</b>)</h4><div class="NLM_p last">Yield, 35.1%; purity 97.4% according to HPLC; mp 212–214 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 8.47 (s, 3H), 8.22 (d, <i>J</i> = 7.1 Hz, 1H), 6.23 (ddd, <i>J</i> = 8.0, 6.2, 2.0 Hz, 1H), 5.37 (dt, <i>J</i> = 5.2, 2.3 Hz, 1H), 4.08 (td, <i>J</i> = 3.4, 1.7 Hz, 1H), 3.96 (d, <i>J</i> = 4.8 Hz, 1H), 3.67 (d, <i>J</i> = 3.3 Hz, 2H), 2.35 (td, <i>J</i> = 8.3, 5.4 Hz, 2H), 2.19 (pd, <i>J</i> = 7.0, 5.0 Hz, 1H), 0.99 (dd, <i>J</i> = 12.9, 6.9 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.65, 157.58, 157.32, 149.52, 141.75, 139.45, 125.08, 124.74, 84.94, 84.89, 77.13, 61.67, 57.79, 37.20, 29.87, 18.70, 18.05. MS (ESI+) <i>m</i>/<i>z</i> 346.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 3′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR (<b>2b</b>)</h4><div class="NLM_p last">Yield, 26.2%; purity 98.9% according to HPLC; mp 209–211 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 11.81 (s, 1H), 8.54 (s, 3H), 7.89 (d, <i>J</i> = 6.9 Hz, 1H), 6.15 (td, <i>J</i> = 6.7, 1.7 Hz, 1H), 4.48–4.15 (m, 3H), 4.04–3.84 (m, 2H), 2.32–2.09 (m, 3H), 1.20 (s, 1H), 0.99–0.91 (m, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 169.23, 159.46, 159.11, 158.76, 157.59, 157.33, 149.45, 141.65, 139.35, 125.47, 125.13, 118.01, 115.09, 85.18, 85.07, 83.87, 70.38, 70.33, 65.69, 57.91, 57.80, 50.37, 38.74, 38.69, 29.84, 28.74, 23.79, 18.44, 18.40, 17.84, 17.75; MS (ESI+) <i>m</i>/<i>z</i> 346.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 3′,5′-Di-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR (<b>2c</b>)</h4><div class="NLM_p last">Yield, 22.1%; purity 99.3% according to HPLC; mp 212–215 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 11.71 (s, 1H), 8.67 (s, 6H), 8.03 (d, <i>J</i> = 7.1 Hz, 1H), 6.22 (ddd, <i>J</i> = 8.1, 6.1, 1.7 Hz, 1H), 5.37 (dt, <i>J</i> = 7.0, 2.7 Hz, 1H), 4.60–4.47 (m, 1H), 4.47–4.36 (m, 1H), 4.29 (dq, <i>J</i> = 6.8, 3.1 Hz, 1H), 4.03–3.90 (m, 2H), 2.70–2.56 (m, 1H), 2.38 (ddd, <i>J</i> = 14.5, 6.3, 2.4 Hz, 1H), 2.19 (dtd, <i>J</i> = 13.9, 7.0, 4.9 Hz, 2H), 1.04–0.98 (m, 6H), 0.98–0.93 (m, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 169.30, 169.21, 168.57, 159.55, 159.23, 158.92, 157.56, 157.30, 149.52, 141.74, 139.44, 125.66, 125.32, 119.02, 116.05, 113.08, 85.31, 80.92, 75.43, 65.28, 57.83, 57.80, 57.69, 35.60, 29.87, 29.84, 28.96, 18.71, 18.69, 18.58, 18.53, 18.02, 17.99, 17.82. MS (ESI+) <i>m</i>/<i>z</i> 445.3 (M + H)<sup>+</sup>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (<b>3a</b>)</h4><div class="NLM_p last">Yield, 35.3%; purity 97.1% according to HPLC; mp 197–199 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 11.88 (s, 1H), 8.44 (s, 3H), 8.24 (d, <i>J</i> = 7.1 Hz, 1H), 6.20 (ddd, <i>J</i> = 8.1, 5.9, 1.8 Hz, 1H), 5.28 (dt, <i>J</i> = 6.2, 1.8 Hz, 1H), 4.27 (t, <i>J</i> = 5.8 Hz, 1H), 4.09 (q, <i>J</i> = 2.7 Hz, 1H), 3.67 (d, <i>J</i> = 3.0 Hz, 2H), 3.39 (q, <i>J</i> = 7.0 Hz, 3H), 3.05–2.90 (m, 2H), 2.42–2.24 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 170.13, 169.31, 159.10, 158.76, 157.59, 157.32, 149.50, 141.72, 139.42, 125.09, 124.75, 118.42, 115.48, 85.18, 84.95, 76.43, 65.35, 61.70, 48.99, 37.16, 34.90, 15.57. MS (ESI+) <i>m</i>/<i>z</i> 362.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 3′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (<b>3b</b>)</h4><div class="NLM_p last">Yield, 29.6%; purity 98.7% according to HPLC; mp 201–203 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 11.77 (d, <i>J</i> = 4.9 Hz, 1H), 8.33 (s, 2H), 7.82 (d, <i>J</i> = 6.9 Hz, 1H), 6.08–6.05 (m, 1H), 4.23–4.15 (m, 4H), 3.85 (dt, <i>J</i> = 5.7, 4.0 Hz, 1H), 3.29 (t, <i>J</i> = 7.0 Hz, 2H), 2.87 (dd, <i>J</i> = 5.8, 2.9 Hz, 2H), 2.18–2.04 (m, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 168.65, 157.58, 157.32, 149.52, 141.75, 139.45, 125.08, 124.74, 84.94, 84.89, 77.13, 61.67, 57.79, 37.20, 29.87, 18.70, 18.05. MS (ESI+) <i>m</i>/<i>z</i> 362.5 (M + H)<sup>+</sup>.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 3′,5′-Di-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (<b>3c</b>)</h4><div class="NLM_p last">Yield, 15.3%; purity 99.3% according to HPLC; mp 213-215 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 11.84 (s, 1H), 8.40 (s, 6H), 7.90 (d, <i>J</i> = 6.9 Hz, 1H), 6.10 (td, <i>J</i> = 6.3, 3.2 Hz, 1H), 5.20–5.17 (m, 1H), 4.32–4.17 (m, 5H), 3.33–3.28 (m, 6H), 2.96–2.84 (m, 4H), 2.46–2.26 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 170.09, 170.06, 169.67, 169.33, 159.27, 158.93, 157.59, 157.32, 149.48, 141.77, 125.38, 125.04, 117.99, 115.08, 85.26, 81.34, 75.21, 65.32, 64.92, 48.99, 48.96, 35.79, 34.85, 34.56, 15.49. MS (ESI+) <i>m</i>/<i>z</i> 477.3 (M + H)<sup>+</sup>.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (<b>4a</b>)</h4><div class="NLM_p last">Yield, 31.6%; purity 97.8% according to HPLC; mp 207–209 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>,, δ ppm) δ 11.79 (s, 1H), 8.28 (s, 2H), 8.14 (d, <i>J</i> = 7.1 Hz, 1H), 6.10–6.06 (m, 1H), 5.17 (td, <i>J</i> = 4.0, 1.8 Hz, 1H), 4.02–3.91 (m, 1H), 3.57 (d, <i>J</i> = 3.1 Hz, 2H), 3.30 (q, <i>J</i> = 7.0 Hz, 4H), 2.64–2.32 (m, 2H), 2.22 (dd, <i>J</i> = 7.6, 4.3 Hz, 2H), 2.10–1.88 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 171.78, 171.04, 159.08, 158.74, 157.58, 157.32, 149.51, 139.42, 125.07, 124.73, 118.19, 115.27, 85.34, 84.91, 75.60, 65.35, 61.72, 51.71, 37.31, 29.70, 25.49, 15.56. MS (ESI+) <i>m</i>/<i>z</i> 376.3 (M + H)<sup>+</sup>.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (<b>4b</b>)</h4><div class="NLM_p last">Yield, 19.0%; purity 98.2% according to HPLC; mp 215–217 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 11.76 (d, <i>J</i> = 4.9 Hz, 1H), 8.30 (s, 3H), 7.81 (d, <i>J</i> = 6.9 Hz, 1H), 6.09 (td, <i>J</i> = 6.7, 1.7 Hz, 1H), 4.20 (d, <i>J</i> = 5.0 Hz, 2H), 3.89 (q, <i>J</i> = 4.6 Hz, 2H), 3.31 (q, <i>J</i> = 7.0 Hz, 4H), 2.61–2.39 (m, 2H), 2.19–1.95 (m, 4H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 170.20, 169.19, 157.43, 157.06, 147.60, 115.59, 83.28, 82.45, 68.67, 63.47, 62.76, 49.91, 48.61, 38.40, 38.19, 37.98, 37.77, 37.56, 37.35, 37.31, 37.14, 27.70, 26.91, 23.74, 21.89, 13.53. MS (ESI+) <i>m</i>/<i>z</i> 376.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 3′,5′-Di-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (<b>4c</b>)</h4><div class="NLM_p last">Yield, 15.4%; purity 98.5% according to HPLC; mp 208–210 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 11.87 (s, 1H), 11.00 (s, 4H), 8.42 (s, 6H), 7.93 (d, <i>J</i> = 7.0 Hz, 1H), 6.13 (t, <i>J</i> = 7.3 Hz, 1H), 5.19 (d, <i>J</i> = 6.5 Hz, 1H), 4.46–4.00 (m, 3H), 3.92 (q, <i>J</i> = 6.8 Hz, 2H), 2.60 (dd, <i>J</i> = 16.9, 8.3 Hz, 2H), 2.51 (s, 1H), 2.45 (dd, <i>J</i> = 14.7, 7.3 Hz, 1H), 2.32 (dd, <i>J</i> = 14.9, 6.9 Hz, 1H), 2.05 (ddq, <i>J</i> = 20.5, 13.4, 7.1 Hz, 4H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, δ ppm) δ 172.02, 171.80, 170.99, 170.97, 159.80, 159.46, 159.12, 157.59, 157.33, 149.44, 141.77, 139.46, 125.22, 124.88, 118.26, 115.34, 112.41, 85.26, 81.69, 74.48, 64.36, 51.70, 36.00, 29.66, 29.59, 29.50, 25.80, 25.55, 25.43. MS (ESI+) <i>m</i>/<i>z</i> 505.1 (M + H)<sup>+</sup>.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">4.3.  Glycine Uptake Inhibition by Prodrugs</h3><div class="NLM_p"><i>X. laevis</i> oocytes cell and MDCK were obtained from American Type Culture Collection (ATTC, Rockville, MD). Cells were grown routinely in Dulbecco’s modified Eagle’s medium (DMEM, 4500 mg/L glucose) containing 10% fetal bovine serum, 1% nonessential amino acids, 1 mmol/L sodium pyruvate, and 1% <span class="smallcaps smallerCapital">l</span>-glutamine as previously described.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p last">To assess the interaction of prodrugs with ATB<sup>0,+</sup>, the inhibition of prodrugs on glycine uptake by ATB<sup>0,+</sup> was studied. For uptake experiments, <i>X. laevi</i>s oocytes-ATB<sup>0,+</sup> samples were seeded onto 24-well plastic cluster trays at about 2.0 × 10<sup>5</sup> cells/cm<sup>2</sup> for 6 days after seeding. The uptake buffer was 25 mM Hepes/Tris containing 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl<sub>2</sub>, 0.8 mM MgSO<sub>4</sub>, and 5 mM <span class="smallcaps smallerCapital">d</span>-glucose. After washing twice with uptake buffer, <i>X. laevi</i>s oocytes-ATB<sup>0,+</sup> samples were incubated with 10 μM glycine along with various concentrations of FUdR prodrugs (0.1–10 mM) at 37 °C for 10 min. After 10 min, the medium was removed, and the cells were rapidly rinsed twice with 1 mL of ice-cold uptake buffer (pH 6.0). The cells were collected and homogenized in 0.25 mL of water. The homogenates were centrifuged at 1500<i>g</i> for 6 min, and glycine in the supernatant was analyzed by HPLC/MS/MS. The protein concentration of each sample was determined by BCA protein assay. As a comparison, the inhibition of FUdR prodrugs on gly-sar (10 μM, a typical substrate of PEPT1) uptake by MDCK-PEPT1 was also performed as previously reported. IC<sub>50</sub> was determined using nonlinear data fitting.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">4.4.  Uptake of Prodrugs by ATB<sup>0,+</sup></h3><div class="NLM_p">The uptake of FUdR prodrugs in <i>X. laevi</i>s oocytes-ATB<sup>0,+</sup> and mock <i>X. laevi</i>s oocytes cells was evaluated to study the role of ATB<sup>0,+</sup>. Two kind of cells were grown as described above. <i>X. laevi</i>s oocytes-ATB<sup>0,+</sup> and <i>X. laevi</i>s oocytes cells were incubated with FUdR and nine derivatives (all 0.5 mM, pH 6.0) at 37 °C for 10 min. As a comparison, the uptake of FUdR prodrugs by MDCK-PEPT1 and mock MDCK was also performed. The samples were analyzed by HPLC.</div><div class="NLM_p last">The inhibition of uptake of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (all 0.5 mM, pH 6.0) by <i>X. laevi</i>s oocytes-ATB<sup>0,+</sup> was assessed in the presence of glycine (10 mM). The concentration of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR inside the cells was analyzed by HPLC.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">4.5.  Concentration-Dependent Uptake of Prodrugs by ATB<sup>0,+</sup></h3><div class="NLM_p last">To further study the interaction between the derivatives of FUdR and ATB<sup>0,+</sup>, the saturation kinetics for the ATB<sup>0,+</sup>-mediated uptake was performed for 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR. <i>X. laevi</i>s oocytes-ATB<sup>0,+</sup> cells at about 2.0 × 10<sup>5</sup> cells/cm<sup>2</sup> were seeded for 6 days. The derivatives (0–0.4 mM) were added at 37 °C for 10 min, respectively. The concentration inside the cells was analyzed by HPLC.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">4.6.  Na<sup>+</sup> and Cl<sup>–</sup> Activation Kinetics</h3><div class="NLM_p last">To investigate Na<sup>+</sup> or Cl<sup>–</sup> on the ATB<sup>0,+</sup>-mediated uptake process, the free Na<sup>+</sup> or Cl<sup>–</sup> medium was applied to assess their inhibitory potential. The Na<sup>+</sup> free medium was prepared by replacing NaCl with <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-glucamine chloride (NMGCl) in uptake buffers. The Cl<sup>–</sup> free medium was prepared by replacing NaCl, KCl, and CaCl<sub>2</sub> with sodium gluconate, potassium gluconate, and calcium gluconate, respectively, at the same concentration. The uptake of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (1 mM) at the different concentrations of Na<sup>+</sup> or Cl<sup>–</sup> (from 0 to 120 mM) was investigated. The process was fitted to the Hill equations, and the Hill coefficient was calculated. The concentration inside the cells was analyzed by HPLC.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">4.7.  Homology Modeling and Molecular Docking<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></h3><div class="NLM_p">The protein sequences of ATB<sup>0,+</sup> (Uniprot ID: <a href="https://Q9UN76" class="ext-link">Q9UN76</a>) was obtained from the Universal Protein Resource (<a href="https://www.uniprot.org/" class="extLink">https://www.uniprot.org/</a>). After a protein–protein BLAST search against the NCBI Protein Data Bank (PDB) (<a href="https://www.rcsb.org/" class="extLink">https://www.rcsb.org/</a>), the crystal structure of the <i>Drosophila melanogaster</i> sodiun-dependent DAT (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4M48">4M48</a>) was set as the main template. Since the crystal structure of DAT lacks the EL2, a second local blast search was set on residues S205-W270 of ATB<sup>0,+</sup>, identifying the crystallographic structure of phosphofructokinase (PFKA1) from <i>Saccharomyces cerevisiae</i> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O8O">3O8O</a>) as an adequate template to fix the EL2 gap. The sequences of potential templates and ATB<sup>0,+</sup> were aligned using ClustalW to compare the amino acid sequences. Finally, on the basis of the alignment results, the model was generated by using the SWISS-MODEL online server (<a href="https://www.swissmodel.expasy.org" class="extLink">https://www.swissmodel.expasy.org</a>), which could build energy minimized protein model automatically with the ProMod3 engine.</div><div class="NLM_p last">The molecular docking procedure was carried out with Schrödinger Glide docking in the “extra precision” (XP) mode in order to evaluate the ability of the tested compounds to bind the ATB<sup>0,+</sup> binding channel, keeping the five top-scoring poses and setting the rigid docking protocol.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">4.8.  Stability Study</h3><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37">4.8.1.  Chemical Stability</h4><div class="NLM_p last">The stability of the prodrugs (200 μM) in phosphate buffer (pH 7.4) was determined to obtain the contribution of the nonenzymatic hydrolysis. Rate constants of hydrolysis were determined with pseudo-first-order kinetic models. The samples was analyzed by HPLC.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38">4.8.2.  Stability in Plasma</h4><div class="NLM_p last">The solution of prodrugs was added to the glass tube, and the solvent was evaporated by N<sub>2</sub>. The mouse plasma was added to the tube and mixed, and the resulting concentration was 200 μM. Aliquot samples were collected at various time points (0, 30, 60, 90, 120 min). The plasma was pretreated with solid-phase extraction, and the concentration was determined by HPLC–MS/MS.</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39">4.8.3.  Stability in Thymidine Phosphorylase</h4><div class="NLM_p last">FUdR and the prodrugs were added to the solution of thymidine phosphorylase (2 ng/mL) in phosphate buffer (pH 6.4) at 37 °C. The resulting concentration of FUdR and prodrugs was 300 μM. The samples were periodically collected at the predetermined time, quenched with cold TFA, and analyzed for prodrug, FUdR, and 5-fluorouracil (5-FU) with HPLC.</div></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">4.9.  Antiproliferation of Cancer Cell <i>in Vitro</i><a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></h3><div class="NLM_p">The stock solutions of FUdR and FUdR prodrugs were prepared with water and then were 2-fold serially diluted with buffer solutions (25 mM HEPES/Tris buffer, pH 6.4, 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl, 0.8 mM MgSO<sub>4</sub>, and 5 mM glucose).</div><div class="NLM_p last">The cancer cell proliferation studies were performed with ER-positive breast cancer ZR-75-1 cells, the pancreatic cancer PaCa-2 cells, and ER-negative breast cancer MB231 cells with no expression of ATB<sup>0,+</sup>. ZR-75-1 cells and PaCa-2 cells have a high expression of ATB<sup>0,+</sup>. These three cells lines were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS), 1% penicillin–streptomycin at 37 °C, 5% CO<sub>2</sub>, and 5% humidity. The cells were seeded onto 96-well plates at 1.0 × 10<sup>5</sup> cells per well. After incubation for 24 h, the medium was removed and washed with buffer solutions. The drug solutions were added to the well, and these cells were incubated for 3 h. After this period, the drug solutions were removed and the cells were washed gently with buffer solutions. Fresh culture medium was then added to the wells, and the cells were allowed to recover and grow for 24 h before evaluating cell viability with addition of MTT. The absorbance was measured with the microplate reader at a wavelength of 570 nm. GI<sub>50</sub> was calculated using nonlinear data fitting.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41">4.10.  Inhibition of Tumor Growth in Mouse Xenografts</h3><div class="NLM_p">All animal experiments in the present study have been approved by the University Committee on Use and Care of Animals, Jiangxi University of Traditional Chinese Medicines. Female NOD SCID nude mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). The age was about 8 weeks, and the weight was about from 19 to 21 g. The nude mice were allowed to acclimate to the environment for 1 week prior to the experiment. To study the <i>in vivo</i> inhibition of tumor growth, the tumor-bearing nude mice were established. ZR-75-1 cells and MB-231 cells were injected subcutaneously close to the lower mammary gland on the right side of nude mice. PaCa-2 cells were injected subcutaneously into the right flank of the mice.</div><div class="NLM_p last">The tumors were allowed to grow to about 100 mm<sup>3</sup>. Then the animals were divided into the control and the treatment groups (about 10 mice per group) wherein the control groups were free to the sucrose–water for drinking and the treatment group was injected with FUdR or 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (90 mg/kg calculated as FUdR) via tail vein for 20 successive days. Tumor size in control and treatment groups was measured every 2 day by caliper, and the volume of the tumor was calculated using the formula (width<sup>2</sup> × length)/2. On day 20, the tumor was removed from the mice, and the tumor weight and the body weight were calculated.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">4.11.  Pharmacokinetics and Tissue Distribution</h3><div class="NLM_p">The pharmacokinetics and tissue distribution were also approved by the University Committee on Use and Care of Animals, Jiangxi University of Traditional Chinese Medicines. The pharmacokinetics and tissue distribution of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR and FUdR were studied in NOD SCID nude mouse xenograft model established with ZR-75-1 cells to delineate the disposition of the prodrug <i>in vivo</i>. The tumors were allowed to grow to about 100 mm<sup>3</sup>. The mouse was injected with FUdR or 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (90 mg/kg calculated as FUdR) via tail vein. Plasma and tumor were collected at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 h. At every sampling time point, 5 to 6 nude mice were anesthetized with ether and blood was collected via cardiac puncture from every mouse. Then, these mice were sacrificed, and all tumors were also collected. After centrifugation, about 100 μL of plasma from every mouse was collected and frozen. The concentrations of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, 5-FU, and FUdR in plasma and tumor were determined by HPLC–MS/MS.</div><div class="NLM_p last">The pharmacokinetic parameters were processed by noncompartmental analysis using the DAS 2.0 software package (Chinese Pharmacological Society). The plasma or tumor concentration at different times was expressed as the mean ± standard deviation (SD), and the mean concentration–time curves were plotted. The maximum plasma or tumor concentration (<i>C</i><sub>max</sub>) and the time to reach it were observed directly from the concentration–time curves. The area under the plasma concentration–time curve from zero to the time of the final measurable sample (AUC<sub>0–<i>t</i></sub>) was calculated using the linear–trapezoidal rule up to the last sampling point with the detectable level (<i>C</i>).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">4.12.  Analytical Method</h3><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44">4.12.1.  HPLC Analysis</h4><div class="NLM_p last">HPLC for the analysis of FUdR and nine prodrugs was performed on a Shimadzu LC-20ATHPLC system consisting of a SPD-M20A DAD, a SIL-20A autosampler, and a LabSolution workstation. The analytes were separated on ODS C<sub>18</sub> (4.6 mm × 250 mm, 5 μm) with a wavelength of 254 nm, and the analytes were eluted by acetonitrile/water/glacial acetic acid (30:70:0.1%, v/v/v) with a flow rate of 1.0 mL/min. The column temperature was set at 25 °C.</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45">4.12.2.  HPLC–MS/MS Method</h4><div class="NLM_p">Shimadzu LCMS-8050 liquid chromatograph mass spectrometer system (HPLC–MS/MS) was used for the determination of the analyte. A Shimadzu LC-VP HPLC system (Kyoto, Japan) consisting of an LC-30AD pump and a SIL-30AC autosampler was used to separate the analyte.</div><div class="NLM_p">For determination of glycine and gly sar in cell homogenates, glycine, gly sar, and the internal standard isoniazid were extracted from the homogenates using a protein precipitation with methanol. A HILIC column (ACQUITY UPLC BEH HILIC, 50 mm × 2.1 mm, 1.7 μm) was used to separate the analytes from the endogenous components. The elution was carried out using a gradient of acetonitrile and water containing 0.1% formic acid. The ESI source was set in positive ionization mode. The MS/MS transitions of 76.1 → 76.1 for glycine, 147.2 → 90.2 for gly sar, and <i>m</i>/<i>z</i> 138.1 → 121.2 for isoniazid were applied for the determination.</div><div class="NLM_p">For determination of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, 5-FU, and FUdR in plasma and tumor, three analytes and the internal standard lamivudine were extracted from rat plasma or tumor homogenates by Waters Oasis HLB cartridges (Waters Corporation; Milford, MA). The retention and separation were performed on a Shim-pack XR-ODSIII column (75 mm × 2.0 mm, 1.6 μm; Kyoto, Japan). The mobile phase was a mixture of 0.1% formic acid in water (v/v) (mobile phase A) and methanol (mobile phase B). The gradient elution program was as follows: 12% B, 0–0.5 min; 12–95% B, 0.5–3.0 min; 95% B, 4.0 min; 12% B, 4.01–5.5 min. The total analysis time per injection was 5.5 min, and the flow rate was set at 0.2 mL/min. The column oven was maintained at 30 °C. The electrospray ionization (ESI) source was performed in positive mode, and the mass spectrometric parameters were optimized at interface temperature 300 °C, desolvation line temperature 250 °C, and heat block temperature 400 °C; spraying gas, nitrogen, 3.0 L/min; nebulizing gas, 10 L/min; heating gas, 10 L/min. The transitions of 362.3 → 131.1 for 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, 247.2 → 131.1 for FUdR, 131.1→ 131.1 for 5-FU, and 230.1 → 112.3 for lamivudine were applied for the determination.</div><div class="NLM_p last">All methods were validated according to the Guidance for Industry, Bioanalytical, Method Validation, U.S. Food and Drug Administration.</div></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46">4.13.  Statistical Analysis</h3><div class="NLM_p last">The statistical differences were tested using a one-tailed Student <i>t</i> test at the <i>p</i> <  0.01 or at the <i>p</i> <  0.05 level.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00149" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05212" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05212" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00149?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00149</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>), and HPLC of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 3′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 3′,5′-di-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, 3′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, 3′,5′-di-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR, 3′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR, and 3′,5′-di-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Coordinates of homology models for ATB<sup>0,+</sup> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_001.pdf">jm0c00149_si_001.pdf (2.21 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_002.csv">jm0c00149_si_002.csv (1.35 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_003.pdb">jm0c00149_si_003.pdb (365.87 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00149" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75346" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75346" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lvjiang Hu</span> - <span class="hlFld-Affiliation affiliation">Division
of Pharmaceutics, Jiangxi University of
Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8170-6459" title="Orcid link">http://orcid.org/0000-0001-8170-6459</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b6dec3dac0dcdfd7d8d1dbd7dfdaf687808598d5d9db"><span class="__cf_email__" data-cfemail="fa928f968c90939b949d979b9396bacbccc9d4999597">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Chen</span> - <span class="hlFld-Affiliation affiliation">Division
of Pharmaceutics, Jiangxi University of
Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#04676c616a6c656b7067696c443532372a676b69"><span class="__cf_email__" data-cfemail="9efdf6fbf0f6fff1eafdf3f6deafa8adb0fdf1f3">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiqiang Yu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Southern Medical
University, No. 1023, Shatai South Road, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1688-5558" title="Orcid link">http://orcid.org/0000-0002-1688-5558</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2b525e515a6b58465e054e4f5e054845"><span class="__cf_email__" data-cfemail="c1b8b4bbb081b2acb4efa4a5b4efa2af">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongbing Sun</span> - <span class="hlFld-Affiliation affiliation">Division
of Pharmaceutics, Jiangxi University of
Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Ke</span> - <span class="hlFld-Affiliation affiliation">Division
of Pharmaceutics, Jiangxi University of
Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunshi Li</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design & Discovery of Ministry
of Education, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Wang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design & Discovery of Ministry
of Education, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang 110016, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9589-4056" title="Orcid link">http://orcid.org/0000-0002-9589-4056</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liangxing Tu</span> - <span class="hlFld-Affiliation affiliation">Division
of Pharmaceutics, Jiangxi University of
Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi Jin</span> - <span class="hlFld-Affiliation affiliation">Division
of Pharmaceutics, Jiangxi University of
Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianping Gong</span> - <span class="hlFld-Affiliation affiliation">Division
of Pharmaceutics, Jiangxi University of
Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (Grants 81860630, 81560577, and 81360485), the Natural Science Foundation of Jiangxi (Grant 20181BAB205087), the Key Project of Jiangxi (Grant 20192ACB70012), and Jiangxi University of Traditional Chinese Medicine 1050 Youth Talent Project.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">PEPT1</td><td class="NLM_def"><p class="first last">peptide transporter 1</p></td></tr><tr><td class="NLM_term">ATB<sup>0,+</sup></td><td class="NLM_def"><p class="first last">neutral and cationic amino acid transporter B<sup>0,+</sup></p></td></tr><tr><td class="NLM_term">FUdR</td><td class="NLM_def"><p class="first last">floxuridine, 5-fluoro-2-deoxyuridine</p></td></tr><tr><td class="NLM_term">5-FU</td><td class="NLM_def"><p class="first last">5-fluorouracil</p></td></tr><tr><td class="NLM_term">TP</td><td class="NLM_def"><p class="first last">thymidine phosphorylase</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">carbonyldiimidazole</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 39 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparreboom, A.</span></span> <span> </span><span class="NLM_article-title">Role of Equilibrative Nucleoside Transporter 1 (ENT1) in the Disposition of Cytarabine in Mice</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e00534</span> <span class="refDoi"> DOI: 10.1002/prp2.534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1002%2Fprp2.534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=31832201" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&author=J.+T.+Andersonauthor=S.+Y.+Huauthor=Q.+Fuauthor=S.+D.+Bakerauthor=A.+Sparreboom&title=Role+of+Equilibrative+Nucleoside+Transporter+1+%28ENT1%29+in+the+Disposition+of+Cytarabine+in+Mice&doi=10.1002%2Fprp2.534"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fprp2.534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.534%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DJ.%2BT.%26aulast%3DHu%26aufirst%3DS.%2BY.%26aulast%3DFu%26aufirst%3DQ.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DSparreboom%26aufirst%3DA.%26atitle%3DRole%2520of%2520Equilibrative%2520Nucleoside%2520Transporter%25201%2520%2528ENT1%2529%2520in%2520the%2520Disposition%2520of%2520Cytarabine%2520in%2520Mice%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2019%26volume%3D7%26doi%3D10.1002%2Fprp2.534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Cancer Nanotechnology: Enhancing Tumor Cell Response to Chemotherapy for Hepatocellular Carcinoma Therapy</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2019.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2019.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=32104485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BB387mslajug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=581-594&author=Y.+B.+Sunauthor=W.+Maauthor=Y.+Y.+Yangauthor=M.+X.+Heauthor=A.+M.+Liauthor=L.+Baiauthor=B.+Yuauthor=Z.+Q.+Yu&title=Cancer+Nanotechnology%3A+Enhancing+Tumor+Cell+Response+to+Chemotherapy+for+Hepatocellular+Carcinoma+Therapy&doi=10.1016%2Fj.ajps.2019.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy</span></div><div class="casAuthors">Sun Yongbing; Ma Wen; Yang Yuanyuan; Yu Zhiqiang; He Mengxue; Li Aimin; Bai Lei; Yu Bin</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">581-594</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity.  In addition to sorafenib and lenvatinib for the treatment of HCC approved by FDA, various strategies including transarterial chemoembolization, radiotherapy, locoregional therapy and chemotherapy have been investigated in clinics.  Recently, cancer nanotechnology has got great attention for the treatment of various cancers including HCC.  Both passive and active targetings are progressing at a steady rate.  Herein, we describe the lessons learned from pathogenesis of HCC and the understanding of targeted and non-targeted nanoparticles used for the delivery of small molecules, monoclonal antibodies, miRNAs and peptides.  Exploring current efficacy is to enhance tumor cell response of chemotherapy.  It highlights the opportunities and challenges faced by nanotechnologies in contemporary hepatocellular carcinoma therapy, where personalized medicine is increasingly becoming the mainstay.  Overall objective of this review is to enhance our understanding in the design and development of nanotechnology for treatment of HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMcAKB7Fa-xrUfW6udTcc2eYlIdx9esWsObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslajug%253D%253D&md5=227a8b50f76971580bf9cea0798b72d6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2019.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2019.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%2BB.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%2BY.%26aulast%3DHe%26aufirst%3DM.%2BX.%26aulast%3DLi%26aufirst%3DA.%2BM.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DZ.%2BQ.%26atitle%3DCancer%2520Nanotechnology%253A%2520Enhancing%2520Tumor%2520Cell%2520Response%2520to%2520Chemotherapy%2520for%2520Hepatocellular%2520Carcinoma%2520Therapy%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D14%26spage%3D581%26epage%3D594%26doi%3D10.1016%2Fj.ajps.2019.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maag, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfredson, T.</span></span> <span> </span><span class="NLM_article-title">Prodrugs of Nucleoside Analogues for Improved Oral Absorption and Tissue Targeting</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1002/jps.21047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1002%2Fjps.21047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=17696166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FovVCgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2008&pages=1109-1133&author=F.+J.+Liauthor=H.+Maagauthor=T.+Alfredson&title=Prodrugs+of+Nucleoside+Analogues+for+Improved+Oral+Absorption+and+Tissue+Targeting&doi=10.1002%2Fjps.21047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting</span></div><div class="casAuthors">Li Fujun; Maag Hans; Alfredson Tom</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1109-34</span>
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    </div><div class="casAbstract">Nucleoside analogues are widely used for the treatment of antiviral infections and anticancer chemotherapy.  However, many nucleoside analogues suffer from poor oral bioavailability due to their high polarity and low intestinal permeability.  In order to improve oral absorption of these polar drugs, prodrugs have been employed to increase lipophilicity by chemical modification of the parent.  Alternatively, prodrugs targeting transporters present in the intestine have been exploited to facilitate the transport of the nucleoside analogues.  Valacyclovir and valganciclovir are two successful valine ester prodrugs transported by the PepT1 transporter.  Recently, research efforts have focused on design of prodrugs for tissue specific delivery to improve efficacy and safety.  This review presents advances of prodrug approaches for improved oral absorption of nucleoside analogues and recent developments in tissue targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-KOBK65zide2qxNLjzXe8fW6udTcc2eYlIdx9esWsObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FovVCgtQ%253D%253D&md5=ed6aeaf75134be8bc9ef23a89b673b80</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fjps.21047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21047%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%2BJ.%26aulast%3DMaag%26aufirst%3DH.%26aulast%3DAlfredson%26aufirst%3DT.%26atitle%3DProdrugs%2520of%2520Nucleoside%2520Analogues%2520for%2520Improved%2520Oral%2520Absorption%2520and%2520Tissue%2520Targeting%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D97%26spage%3D1109%26epage%3D1133%26doi%3D10.1002%2Fjps.21047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinko, P. J.</span></span> <span> </span><span class="NLM_article-title">Involvement of Multiple Transporters in the Oral Absorption of Nucleoside Analogues</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(99)00026-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2FS0169-409X%2899%2900026-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10837774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVOqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1999&pages=183-209&author=P.+V.+Balimaneauthor=P.+J.+Sinko&title=Involvement+of+Multiple+Transporters+in+the+Oral+Absorption+of+Nucleoside+Analogues&doi=10.1016%2FS0169-409X%2899%2900026-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of multiple transporters in the oral absorption of nucleoside analogues</span></div><div class="casAuthors">Balimane, P. V.; Sinko, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">183-209</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 95 refs.  Many nucleoside analogs such as azt, ddI, ddC, d4T, 3TC, acv and vacv are currently being used in the treatment of patients infected with HIV, suffering from AIDS, or AIDS-related opportunistic infections.  The transport of nucleoside analogs across the gastrointestinal tract is mediated by a no. of transporters that fall into three broad categories, i.e., Na+-dependent concentrative transporters, Na+-independent equilibrative transporters and H+/peptide transporters.  The first two transporter classes contain a large no. of subtypes that are based on the substrate specificity.  Recent studies have shown that most of the anti-HIV nucleoside analogs are transported by one or more of the nucleoside transporters.  Furthermore, certain analogs, such as acv, appear to be absorbed by non-carrier-mediated diffusion, whereas vacv is apparently transported by non-nucleoside transporters (e.g., the oligopeptide transporter, PepT1 and possibly others).  Thus, it is desirable to understand the precise nature of the absorption mechanism of these drugs to improve bioavailability and reduce the variability that is commonly obsd. in vivo in human patients.  A complete understanding of the complex interactions of nucleoside analogs with the various transporters will help in designing better delivery systems and strategies to improve efficacy.  In the current report, the mechanisms of nucleoside and nucleoside-analog transport are reviewed.  Also, methods of exploiting prodrugs to improve the bioavailability characteristics of drugs are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQd-dHCCUUvbVg90H21EOLACvtfcHk0lhlb0Siy4JU4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVOqs74%253D&md5=c7849ac966da4e7445dec8fe36f0bded</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2899%2900026-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252899%252900026-5%26sid%3Dliteratum%253Aachs%26aulast%3DBalimane%26aufirst%3DP.%2BV.%26aulast%3DSinko%26aufirst%3DP.%2BJ.%26atitle%3DInvolvement%2520of%2520Multiple%2520Transporters%2520in%2520the%2520Oral%2520Absorption%2520of%2520Nucleoside%2520Analogues%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1999%26volume%3D39%26spage%3D183%26epage%3D209%26doi%3D10.1016%2FS0169-409X%2899%2900026-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Laar, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustum, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackland, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Groeningen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span> <span> </span><span class="NLM_article-title">Comparison of 5-Fluoro-2′-deoxyuridine with 5-Fluorouracil and Their Role in the Treatment of Colorectal Cancer</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(97)00366-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2FS0959-8049%2897%2900366-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=9640213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADyaK1cXivVSjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1998&pages=296-306&author=J.+A.+Van%0ALaarauthor=Y.+M.+Rustumauthor=S.+P.+Acklandauthor=C.+J.+Van+Groeningenauthor=G.+J.+Peters&title=Comparison+of+5-Fluoro-2%E2%80%B2-deoxyuridine+with+5-Fluorouracil+and+Their+Role+in+the+Treatment+of+Colorectal+Cancer&doi=10.1016%2FS0959-8049%2897%2900366-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer</span></div><div class="casAuthors">Van Laar, J. A. M.; Rustum, Y. M.; Ackland, S. P.; Van Groeningen, C. J.; Peters, G. J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">296-306</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Despite >30 yr of intensive studies on new drugs against advanced colorectal cancer, the fluoropyrimidines remain the drugs of choice for systemic treatment and for hepatic artery infusion (HAI).  This review, with 127 refs., describes new developments in advanced colorectal cancer chemotherapy, providing a rationale for more effective use of the fluoropyrimidines, with biochem. modulation, scheduling or by revealing biochem. mechanisms of action that correlate with antitumor activity.  In human colorectal cancer cell lines and various animal tumor model systems 5-fluoro-2'-deoxyuridine (FdUrd) is more effective than 5-fluorouracil (5-FU).  Comparably, FdUrd's modulation by leucovorin (LV) is more potent than 5-FU.  In animal studies intermittent high-bolus administration of FdUrd generates better antitumor activity, compared with equal toxic doses or any other schedule of 5-FU.  These effects are related to prolonged thymidylate synthase (TS) inhibition and the prevention of TS induction, rather than RNA incorporation.  Preclin. studies with modulators such as N-phosphonacetyl-L-aspartate (PALA), WR-2721, mitomycin C and Pt derivs. provide a rationale for clin. use in the future.  The 1st choice systemic chemotherapy of patients with advanced colorectal cancer remains 5-FU combined with LV.  Some improvement in therapeutic efficacy was achieved with locoregional HAI.  In randomized studies HAI FdUrd improves the quality of life and survival as compared with optimal systemic therapy.  Chronomodulation decreases toxicity, allowing dose intensification, while modulators such as LV or dexamethasone increase survival of patients treated with HAI FdUrd to 86% after 1 yr.  In conclusion, the clin. use of FdUrd was not fully explored.  Intermittent high-dose FdUrd, chronomodulation together using modulators or drugs focused on prolonged TS inhibition, should be studied in large randomized studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWL9P0hgeb1rVg90H21EOLACvtfcHk0lgHDEyV29-UBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivVSjur4%253D&md5=3c98629cf55c2f2c1f9802524844a087</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2897%2900366-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252897%252900366-3%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BLaar%26aufirst%3DJ.%2BA.%26aulast%3DRustum%26aufirst%3DY.%2BM.%26aulast%3DAckland%26aufirst%3DS.%2BP.%26aulast%3DVan%2BGroeningen%26aufirst%3DC.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26atitle%3DComparison%2520of%25205-Fluoro-2%25E2%2580%25B2-deoxyuridine%2520with%25205-Fluorouracil%2520and%2520Their%2520Role%2520in%2520the%2520Treatment%2520of%2520Colorectal%2520Cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1998%26volume%3D34%26spage%3D296%26epage%3D306%26doi%3D10.1016%2FS0959-8049%2897%2900366-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2′-Deoxyuridine for the Treatment of Hepatocellular Carcinoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3661</span>– <span class="NLM_lpage">3670</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC28XltFGhsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3661-3670&author=Y.+M.+Pengauthor=W.+Q.+Yuauthor=E.+T.+Liauthor=J.+F.+Kangauthor=Y.+F.+Wangauthor=Q.+H.+Yangauthor=B.+J.+Liuauthor=J.+M.+Zhangauthor=L.+Y.+Liauthor=J.+Wuauthor=J.+H.+Jiangauthor=Q.+D.+Wangauthor=J.+B.+Chang&title=Discovery+of+an+Orally+Active+and+Liver-Targeted+Prodrug+of+5-Fluoro-2%E2%80%B2-Deoxyuridine+for+the+Treatment+of+Hepatocellular+Carcinoma&doi=10.1021%2Facs.jmedchem.5b01807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma</span></div><div class="casAuthors">Peng, Youmei; Yu, Wenquan; Li, Ertong; Kang, Jinfeng; Wang, Yafeng; Yang, Qinghua; Liu, Bingjie; Zhang, Jingmin; Li, Longyu; Wu, Jie; Jiang, Jinhua; Wang, Qingduan; Chang, Junbiao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3661-3670</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report a series of novel O-(substituted benzyl) phosphoramidate prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of hepatocellular carcinoma.  Through structure optimization, the o-methylbenzyl analog ((S1)-iso-Pr 2-(((R)-(((2R,3S,5R)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)((2-methylbenzyl)oxy)phosphoryl)amino)propanoate (1t)) was identified as an orally bioavailable and liver-targeted lead compd.  This lead prodrug is well-tolerated at a dose up to 3 g/kg in Kuming mice via oral administration.  An efficacy study demonstrated that it possesses good inhibitory effect (61.67% and 72.50%, resp.) on tumor growth in a mouse xenograft model.  A metab. study in Sprague-Dawley rats suggested that (1t) can release the desired 5'-monophosphate in the liver with high liver-targeting index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohEoKlAna4cbVg90H21EOLACvtfcHk0lgHDEyV29-UBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltFGhsrg%253D&md5=5283aab20c58ab80d4795d3b47bdf932</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01807%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%2BM.%26aulast%3DYu%26aufirst%3DW.%2BQ.%26aulast%3DLi%26aufirst%3DE.%2BT.%26aulast%3DKang%26aufirst%3DJ.%2BF.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DYang%26aufirst%3DQ.%2BH.%26aulast%3DLiu%26aufirst%3DB.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DQ.%2BD.%26aulast%3DChang%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520an%2520Orally%2520Active%2520and%2520Liver-Targeted%2520Prodrug%2520of%25205-Fluoro-2%25E2%2580%25B2-Deoxyuridine%2520for%2520the%2520Treatment%2520of%2520Hepatocellular%2520Carcinoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3661%26epage%3D3670%26doi%3D10.1021%2Facs.jmedchem.5b01807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vivian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and In Vitro Evaluation of Bile Acid Prodrugs of Floxuridine to Target the Liver</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>475</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2014.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ijpharm.2014.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=25219859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCns7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=475&publication_year=2014&pages=597-604&author=D.+Vivianauthor=J.+E.+Polli&title=Synthesis+and+In+Vitro+Evaluation+of+Bile+Acid+Prodrugs+of+Floxuridine+to+Target+the+Liver&doi=10.1016%2Fj.ijpharm.2014.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver</span></div><div class="casAuthors">Vivian, Diana; Polli, James E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">475</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">597-604</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Floxuridine is often used to treat metastatic liver disease and is given as an infusion directly into the hepatic artery to increase the amt. of intact drug that reaches the liver.  The objective of this work was to design and synthesize prodrugs of floxuridine through conjugation to chenodeoxycholic acid (CDCA) to target the liver via the bile acid liver uptake transporter Na+/taurocholate cotransporting polypeptide (NTCP, SLC10A1).  Two isomeric prodrugs of floxuridine were synthesized: floxuridine 3'glutamic acid-CDCA and floxuridine 5'-glutamic acid-CDCA.  Both were potent inhibitors and substrates of NTCP.  Floxuridine 3'glutamic acid-CDCA showed Ki = 6.86 ± 1.37 μM, Km = 10.7 ± 2.1 μM, and passive permeability = 0.663 (±0.121) × 10-7 cm/s while floxuridine 5'-glutamic acid-CDCA showed Ki = 0.397 ± 0.038 μM, Km = 40.4 ± 15.2 μM, and passive permeability = 1.72 (±0.18) × 10-7 cm/s.  Floxuridine itself had a higher passively permeability of 7.54 (±0.45) × 10-7 cm/s in the same cell line, indicating that both prodrugs have the potential for lower non-specific effects than the drug alone.  Prodrugs were stable in rat plasma (t = 3 h), but quickly released in rat liver s9 fraction, suggesting future in vivo evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaO6MXv0q7rbVg90H21EOLACvtfcHk0lgHDEyV29-UBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCns7nK&md5=ed3310df016d70fda2ccd839797e6a24</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2014.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2014.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DVivian%26aufirst%3DD.%26aulast%3DPolli%26aufirst%3DJ.%2BE.%26atitle%3DSynthesis%2520and%2520In%2520Vitro%2520Evaluation%2520of%2520Bile%2520Acid%2520Prodrugs%2520of%2520Floxuridine%2520to%2520Target%2520the%2520Liver%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2014%26volume%3D475%26spage%3D597%26epage%3D604%26doi%3D10.1016%2Fj.ijpharm.2014.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Landowski, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vig, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. L.</span></span> <span> </span><span class="NLM_article-title">Targeted Delivery to PEPT1-overexpressing Cells: Acidic, Basic, and Secondary Floxuridine Amino Acid Ester Prodrugs</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-04-0290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1158%2F1535-7163.MCT-04-0290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=15827340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFegsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=659-667&author=C.+P.+Landowskiauthor=B.+S.+Vigauthor=X.+Q.+Songauthor=G.+L.+Amidon&title=Targeted+Delivery+to+PEPT1-overexpressing+Cells%3A+Acidic%2C+Basic%2C+and+Secondary+Floxuridine+Amino+Acid+Ester+Prodrugs&doi=10.1158%2F1535-7163.MCT-04-0290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs</span></div><div class="casAuthors">Landowski, Christopher P.; Vig, Balvinder S.; Song, Xueqin; Amidon, Gordon L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">659-667</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Floxuridine is a clin. proven anticancer agent in the treatment of metastatic colon carcinomas and hepatic metastases.  However, prodrug strategies may be necessary to improve its physiochem. properties and selectivity and to reduce undesirable toxicity effects.  Previous studies with amino acid ester prodrugs of nucleoside drugs targeted to the PEPT1 transporter coupled with recent findings of the functional expression of the PEPT1 oligopeptide transporter in pancreatic adenocarcinoma cell lines suggest the potential of PEPT1 as therapeutic targets for cancer treatment.  In this report, we show the feasibility of achieving enhanced transport and selective antiproliferative action of amino acid ester prodrugs of floxuridine in cell systems overexpressing PEPT1.  All prodrugs exhibited affinity for PEPT1 (IC50, 1.1-2.3 mmol/L).  However, only the prolyl and lysyl prodrugs exhibited enhanced uptake (2- to 8-fold) with HeLa/PEPT1 cells compared with HeLa cells, suggesting that the aspartyl prodrugs are PEPT1 inhibitors.  The selective growth inhibition of Madine-Darby canine kidney (MDCK)/PEPT1 cells over MDCK cells by the prodrugs was consistent with the extent of their PEPT1-mediated transport.  All ester prodrugs hydrolyzed to floxuridine fastest in Caco-2 cell and MDCK homogenates and slower in human plasma and were most chem. stable in pH 6.0 buffer.  Prolyl and lysyl prodrugs were relatively less stable compared with aspartyl prodrugs in buffers and in cell homogenates.  The results suggest that optimal design for targeted delivery would be possible by combining both stability and transport characteristics afforded by the promoiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDZQyYebUSk7Vg90H21EOLACvtfcHk0lj_yt3BHF1v0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFegsLk%253D&md5=8cce73d384941f9bdb547a635b4dd146</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-04-0290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-04-0290%26sid%3Dliteratum%253Aachs%26aulast%3DLandowski%26aufirst%3DC.%2BP.%26aulast%3DVig%26aufirst%3DB.%2BS.%26aulast%3DSong%26aufirst%3DX.%2BQ.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DTargeted%2520Delivery%2520to%2520PEPT1-overexpressing%2520Cells%253A%2520Acidic%252C%2520Basic%252C%2520and%2520Secondary%2520Floxuridine%2520Amino%2520Acid%2520Ester%2520Prodrugs%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26spage%3D659%26epage%3D667%26doi%3D10.1158%2F1535-7163.MCT-04-0290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsume, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfinger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. L.</span></span> <span> </span><span class="NLM_article-title">Enhanced Cancer Cell Growth Inhibition by Dipeptide Prodrugs of Floxuridine: Increased Transporter Affinity and Metabolic Stability</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1021/mp800008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp800008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFSkurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=717-727&author=Y.+Tsumeauthor=J.+M.+Hilfingerauthor=G.+L.+Amidon&title=Enhanced+Cancer+Cell+Growth+Inhibition+by+Dipeptide+Prodrugs+of+Floxuridine%3A+Increased+Transporter+Affinity+and+Metabolic+Stability&doi=10.1021%2Fmp800008c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Cancer Cell Growth Inhibition by Dipeptide Prodrugs of Floxuridine: Increased Transporter Affinity and Metabolic Stability</span></div><div class="casAuthors">Tsume, Yasuhiro; Hilfinger, John M.; Amidon, Gordon L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">717-727</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dipeptide monoester prodrugs of floxuridine were synthesized, and their chem. stability in buffers, resistance to glycosidic bond metab., affinity for PEPT1, enzymic activation and permeability in cancer cells were detd. and compared to those of mono amino acid monoester floxuridine prodrugs.  Prodrugs contg. glycyl moieties were the least stable in pH 7.4 buffer (t1/2 < 100 min).  The activation of all floxuridine prodrugs was 2- to 30-fold faster in cell homogenates than their hydrolysis in buffer, suggesting enzymic action.  The enzymic activation of dipeptide monoester prodrugs contg. arom. promoieties in cell homogenates was 5- to 20-fold slower than that of other dipeptide and most mono amino acid monoester prodrugs (t1/2 ∼ 40 to 100 min).  All prodrugs exhibited enhanced resistance to glycosidic bond metab. by thymidine phosphorylase compared to parent floxuridine.  In general, the 5'-O-dipeptide monoester floxuridine prodrugs exhibited higher affinity for PEPT1 than the corresponding 5'-O-mono amino acid ester prodrugs.  The permeability of dipeptide monoester prodrugs across Caco-2 and Capan-2 monolayers was 2- to 4-fold higher than the corresponding mono amino acid ester prodrug.  Cell proliferation assays in AsPC-1 and Capan-2 pancreatic ductal cell lines indicated that the dipeptide monoester prodrugs were equally as potent as mono amino acid prodrugs.  The transport and enzymic profiles of 5'-L-phenylalanyl-L-tyrosyl-floxuridine, 5'-L-phenylalanyl-L-glycyl-floxuridine, and 5'-L-isoleucyl-L-glycyl-floxuridine suggest their potential for increased oral uptake, delayed enzymic bioconversion and enhanced resistance to metab. to 5-fluorouracil, as well as enhanced uptake and cytotoxic activity in cancer cells, attributes that would facilitate prolonged systemic circulation for enhanced therapeutic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqALEnhYGvnZrVg90H21EOLACvtfcHk0lj_yt3BHF1v0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFSkurc%253D&md5=9646d4140b600e263fb95a76152e5631</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fmp800008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp800008c%26sid%3Dliteratum%253Aachs%26aulast%3DTsume%26aufirst%3DY.%26aulast%3DHilfinger%26aufirst%3DJ.%2BM.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DEnhanced%2520Cancer%2520Cell%2520Growth%2520Inhibition%2520by%2520Dipeptide%2520Prodrugs%2520of%2520Floxuridine%253A%2520Increased%2520Transporter%2520Affinity%2520and%2520Metabolic%2520Stability%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2008%26volume%3D5%26spage%3D717%26epage%3D727%26doi%3D10.1021%2Fmp800008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span> <span> </span><span class="NLM_article-title">PEPT1-mediated Prodrug Strategy for Oral Delivery of Peramivir</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2018.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2018.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=32104429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BB387mslWmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=555-565&author=Y.+B.+Sunauthor=W.+Ganauthor=M.+D.+Leiauthor=W.+Jiangauthor=M.+Chengauthor=J.+W.+Heauthor=Q.+Sunauthor=W.+Liuauthor=L.+J.+Huauthor=Y.+Jin&title=PEPT1-mediated+Prodrug+Strategy+for+Oral+Delivery+of+Peramivir&doi=10.1016%2Fj.ajps.2018.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">PEPT1-mediated prodrug strategy for oral delivery of peramivir</span></div><div class="casAuthors">Sun Yongbing; Gan Wei; Cheng Meng; Sun Qi; Liu Wan; Jin Yi; Lei Mingdao; Jiang Wei; He Junwei; Hu Lvjiang</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">555-565</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Peramivir was a novel and highly potent neuraminidase (NA) inhibitor for the treatment of influenza A and B.  However, it exhibited a very low oral bioavailability (only 3%) due to the high polarity (log P of -1.4) and the low membrane permeability across the intestine.  To utilize the PEPT1-mediated prodrug strategy to improve the oral absorption and develop the oral alternative, seven amino acid ester prodrugs and seven amino acid amide prodrugs have been synthesized.  The permeability of these prodrugs across Caco-2 cells were screened.  Peramivr-(CH2)2-l-Val and Peramivir-l-Ile were of the highest permeability in ester prodrugs and amide prodrugs, respectively, and then they were selected for further studies.  Glycylsarcosine (gly-sar) uptake by Caco-2 could be inbihited by Peramivir-(CH2)2-l-Val and Peramivir-l-Ile in a concentration-dependent manner, and the IC50 was 1.34 ± 0.31 mM and 1.78 ± 0.48 mM, respectively.  The direct uptake of Peramivir-(CH2)2-l-Val and Peramivir-l-Ile in MDCK-PEPT1 cells were significantly higher than in MDCK mock cells, and could be markedly inhibited by gly-sar.  The uptake of Peramivir-(CH2)2-l-Val and Peramivir-l-Ile (0.01 to 50 mM) in MDCK-hPEPT1 cells conformed to Michaelis-Menten Equation.  The oral bioavailability of peramivir was 65.3% and 37.3% after the oral administration of Peramivir-(CH2)2-l-Val and Peramivir-l-Ile to rats, respectively.  The oral absorption and bioactivation of Peramivir-(CH2)2-l-Val was rapid and extensive, and no Peramivir-(CH2)2-l-Val was found in plasma.  Because the amide bond was relatively stable, Peramivir-l-Ile could not be totally converted to the parent drug in vivo.  Peramivir-(CH2)2-l-Val with good oral profiles and rapid bioactivation might be a promising prodrug for the further clinic development.  The present study also corroborated the idea that the PEPT1-mediated prodrug approach has enormous promise for improving the oral absorption of poorly absorbed drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMUodMGTatQ7LfW6udTcc2ebvSbX4L57xW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslWmsA%253D%253D&md5=a932fa9988b1aec5f1c70e8b715e112a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2018.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2018.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%2BB.%26aulast%3DGan%26aufirst%3DW.%26aulast%3DLei%26aufirst%3DM.%2BD.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%2BW.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DL.%2BJ.%26aulast%3DJin%26aufirst%3DY.%26atitle%3DPEPT1-mediated%2520Prodrug%2520Strategy%2520for%2520Oral%2520Delivery%2520of%2520Peramivir%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2018%26volume%3D13%26spage%3D555%26epage%3D565%26doi%3D10.1016%2Fj.ajps.2018.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Voorde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liekens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murziani, P. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">The Cytostatic Activity of NUC-3073, a Phosphoramidate Prodrug of 5-Fluoro-2′-deoxyuridine, Is Independent of Activation by Thymidine Kinase and Insensitive to Degradation by Phosphorolytic Enzymes</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2011.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.bcp.2011.05.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=21658373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1ehsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=441-452&author=J.+Vande%0AVoordeauthor=S.+Liekensauthor=C.+McGuiganauthor=P.+G.+S.+Murzianiauthor=M.+Slusarczykauthor=J.+Balzarini&title=The+Cytostatic+Activity+of+NUC-3073%2C+a+Phosphoramidate+Prodrug+of+5-Fluoro-2%E2%80%B2-deoxyuridine%2C+Is+Independent+of+Activation+by+Thymidine+Kinase+and+Insensitive+to+Degradation+by+Phosphorolytic+Enzymes&doi=10.1016%2Fj.bcp.2011.05.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes</span></div><div class="casAuthors">Vande Voorde, Johan; Liekens, Sandra; McGuigan, Christopher; Murziani, Paola G. S.; Slusarczyk, Magdalena; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel phosphoramidate nucleotide prodrug of the anticancer nucleoside analog 5-fluoro-2'-deoxyuridine (5-FdUrd) was synthesized and evaluated for its cytostatic activity.  Whereas 5-FdUrd substantially lost its cytostatic potential in thymidine kinase (TK)-deficient murine leukemia L1210 and human lymphocyte CEM cell cultures, NUC-3073 markedly kept its antiproliferative activity in TK-deficient tumor cells, and thus is largely independent of intracellular TK activity to exert its cytostatic action.  NUC-3073 was found to inhibit thymidylate synthase (TS) in the TK-deficient and wild-type cell lines at drug concns. that correlated well with its cytostatic activity in these cells.  NUC-3073 does not seem to be susceptible to inactivation by catabolic enzymes such as thymidine phosphorylase (TP) and uridine phosphorylase (UP).  These findings are in line with our observations that 5-FdUrd, but not NUC-3073, substantially loses its cytostatic potential in the presence of TP-expressing mycoplasmas in the tumor cell cultures.  Therefore, we propose NUC-3073 as a novel 5-FdUrd phosphoramidate prodrug that (i) may circumvent potential resistance mechanisms of tumor cells (e.g. decreased TK activity) and (ii) is not degraded by catabolic enzymes such as TP which is often upregulated in tumor cells or expressed in mycoplasma-infected tumor tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0BkUUtRLZTrVg90H21EOLACvtfcHk0lgb-FjeOieP-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1ehsrw%253D&md5=50b53ced366a86c9180e178456b902d8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.05.024%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BVoorde%26aufirst%3DJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DMurziani%26aufirst%3DP.%2BG.%2BS.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DThe%2520Cytostatic%2520Activity%2520of%2520NUC-3073%252C%2520a%2520Phosphoramidate%2520Prodrug%2520of%25205-Fluoro-2%25E2%2580%25B2-deoxyuridine%252C%2520Is%2520Independent%2520of%2520Activation%2520by%2520Thymidine%2520Kinase%2520and%2520Insensitive%2520to%2520Degradation%2520by%2520Phosphorolytic%2520Enzymes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D441%26epage%3D452%26doi%3D10.1016%2Fj.bcp.2011.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murziani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonczy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande Voorde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liekens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Phosphoramidate Protides of Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage Over the Parent Nucleoside</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7247</span>– <span class="NLM_lpage">7258</span>, <span class="refDoi"> DOI: 10.1021/jm200815w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200815w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eru7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7247-7258&author=C.+McGuiganauthor=P.+Murzianiauthor=M.+Slusarczykauthor=B.+Gonczyauthor=J.+Vande+Voordeauthor=S.+Liekensauthor=J.+Balzarini&title=Phosphoramidate+Protides+of+Anticancer+Agent+FUDR+Successfully+Deliver+the+Preformed+Bioactive+Monophosphate+in+Cells+and+Confer+Advantage+Over+the+Parent+Nucleoside&doi=10.1021%2Fjm200815w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoramidate ProTides of the Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage over the Parent Nucleoside</span></div><div class="casAuthors">McGuigan, Christopher; Murziani, Paola; Slusarczyk, Magdalena; Gonczy, Blanka; Vande Voorde, Johan; Liekens, Sandra; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7247-7258</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The fluorinated pyrimidine family of nucleosides continues to represent major current chemotherapeutic agents for treating solid tumors.  We herein report their phosphate prodrugs, ProTides, as promising new derivs., which partially bypass the dependence of the current drugs on active transport and nucleoside kinase-mediated activation.  They are also resistant to metabolic deactivation by phosphorolytic enzymes.  We report 39 ProTides of the fluorinated pyrimidine FUDR with variation in the aryl, ester, and amino acid regions.  Notably, only certain ProTide motifs are successful in delivering the nucleoside monophosphate into intact cells.  We also find that the ProTides retain activity in mycoplasma infected cells, unlike FUDR.  Data suggest these compds. to be worthy of further progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppOiNKgrQqyLVg90H21EOLACvtfcHk0lgb-FjeOieP-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eru7zP&md5=dbc6dde916700391cbd0b13b5d0c116c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm200815w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200815w%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DMurziani%26aufirst%3DP.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DGonczy%26aufirst%3DB.%26aulast%3DVande%2BVoorde%26aufirst%3DJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DPhosphoramidate%2520Protides%2520of%2520Anticancer%2520Agent%2520FUDR%2520Successfully%2520Deliver%2520the%2520Preformed%2520Bioactive%2520Monophosphate%2520in%2520Cells%2520and%2520Confer%2520Advantage%2520Over%2520the%2520Parent%2520Nucleoside%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7247%26epage%3D7258%26doi%3D10.1021%2Fjm200815w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattan, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">The Protide Prodrug Technology: From the Concept to the Clinic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2211</span>– <span class="NLM_lpage">1126</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2211-1126&author=Y.+Mehellouauthor=H.+S.+Rattanauthor=J.+Balzarini&title=The+Protide+Prodrug+Technology%3A+From+the+Concept+to+the+Clinic&doi=10.1021%2Facs.jmedchem.7b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The ProTide Prodrug Technology: From the Concept to the Clinic</span></div><div class="casAuthors">Mehellou, Youcef; Rattan, Hardeep S.; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2211-2226</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ProTide technol. is a prodrug approach developed for the efficient intracellular delivery of nucleoside analog monophosphates and monophosphonates.  In this approach, the hydroxyls of the monophosphate or monophosphonate groups are masked by an arom. group and an amino acid ester moiety, which are enzymically cleaved-off inside cells to release the free nucleoside monophosphate and monophosphonate species.  Structurally, this represents the current end-point of an extensive medicinal chem. endeavor that spans almost three decades.  It started from the masking of nucleoside monophosphate and monophosphonate groups by simple alkyl groups and evolved into the sophisticated ProTide system as known today.  This technol. has been extensively employed in drug discovery, and it has already led to the discovery of two FDA-approved (antiviral) ProTides.  In this work, we will review the development of the ProTide technol., its application in drug discovery, and its role in the improvement of drug delivery and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeaJFaQn4HwrVg90H21EOLACvtfcHk0lgb-FjeOieP-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitL3P&md5=ab9f5805c3c9d2d80fbdd82a3ad86c73</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00734%26sid%3Dliteratum%253Aachs%26aulast%3DMehellou%26aufirst%3DY.%26aulast%3DRattan%26aufirst%3DH.%2BS.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DThe%2520Protide%2520Prodrug%2520Technology%253A%2520From%2520the%2520Concept%2520to%2520the%2520Clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2211%26epage%3D1126%26doi%3D10.1021%2Facs.jmedchem.7b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">The Hallmarks of Cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81683-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2FS0092-8674%2800%2981683-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10647931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=57-70&author=D.+Hanahanauthor=R.+A.+Weinberg&title=The+Hallmarks+of+Cancer&doi=10.1016%2FS0092-8674%2800%2981683-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The hallmarks of cancer</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review is given with many refs. on principles governing the transformation of normal human cells into malignant cancers.  The authors suggest that research over the past decades has revealed a small no. of mol., biochem., and cellular traits (acquired capabilities) shared by most and perhaps all types of cancer.  Topics included are the acquired capabilities self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis followed by genome instability as an enabling characteristic and alternative pathways to cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooXmGqKjM1C7Vg90H21EOLACvtfcHk0lgb-FjeOieP-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D&md5=1d23c4400dad34c7f32d4a0c41890349</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981683-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981683-9%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DThe%2520Hallmarks%2520of%2520Cancer%26jtitle%3DCell%26date%3D2000%26volume%3D100%26spage%3D57%26epage%3D70%26doi%3D10.1016%2FS0092-8674%2800%2981683-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of Cancer: the Next Generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+Cancer%3A+the+Next+Generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0li9c7mizihQ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520Cancer%253A%2520the%2520Next%2520Generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sloan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, S.</span></span> <span> </span><span class="NLM_article-title">Cloning and Functional Expression of a Human Na<sup>+</sup> and Cl<sup>–</sup>-dependent Neutral and Cationic Amino Acid Transporter B<sup>0+</sup></span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">23740</span>– <span class="NLM_lpage">23745</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.34.23740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1074%2Fjbc.274.34.23740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10446133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVOnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=23740-23745&author=J.+L.+Sloanauthor=S.+Mager&title=Cloning+and+Functional+Expression+of+a+Human+Na%2B+and+Cl%E2%80%93-dependent+Neutral+and+Cationic+Amino+Acid+Transporter+B0%2B&doi=10.1074%2Fjbc.274.34.23740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning and functional expression of a human Na+ and Cl--dependent neutral and cationic amino acid transporter B0+</span></div><div class="casAuthors">Sloan, Jennifer L.; Mager, Sela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">23740-23745</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A Na+-dependent neutral and cationic amino acid transport system (B0+) plays an important role in many cells and tissues; however, the mol. basis for this transport system is still unknown.  To identify new transporters, the expressed sequence tag database was queried, and cDNA fragments with sequence similarity to the Na+/Cl--dependent neurotransmitter transporter family were identified.  Based on these sequences, rapid amplification of cDNA ends of human mammary gland cDNA was used to obtain a cDNA of 4.5 kilobases (kb).  The open reading frame encodes a 642-amino acid protein named amino acid transporter B0+.  Human ATB0+ (hATB0+) is a novel member of the Na+/Cl--dependent neurotransmitter transporter family with the highest sequence similarity to the glycine and proline transporters.  Northern blot anal. identified transcripts of ∼4.5 kb and ∼2 kb in the lung.  Another tissue survey suggests expression in the trachea, salivary gland, mammary gland, stomach, and pituitary gland.  Electrophysiol. and radiolabeled amino acid uptake measurements were used to functionally characterize the transporter expressed in Xenopus oocytes.  HATB0+ was found to transport both neutral and cationic amino acids, with the highest affinity for hydrophobic amino acids and the lowest affinity for proline.  Amino acid transport was Na+ and Cl--dependent and was attenuated in the presence of 2-aminobicyclo-[2.2.1]-heptane-2-carboxylic acid, a system B0+ inhibitor.  These characteristics are consistent with system B0+ amino acid transport.  Thus, hATB0+ is the first cloned B0+ amino acid transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_aBj5nr5rZ7Vg90H21EOLACvtfcHk0li9c7mizihQ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVOnsL4%253D&md5=1cf8e4e71bacd02a793607d8d773d552</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.34.23740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.34.23740%26sid%3Dliteratum%253Aachs%26aulast%3DSloan%26aufirst%3DJ.%2BL.%26aulast%3DMager%26aufirst%3DS.%26atitle%3DCloning%2520and%2520Functional%2520Expression%2520of%2520a%2520Human%2520Na%252B%2520and%2520Cl%25E2%2580%2593-dependent%2520Neutral%2520and%2520Cationic%2520Amino%2520Acid%2520Transporter%2520B0%252B%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D23740%26epage%3D23745%26doi%3D10.1074%2Fjbc.274.34.23740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhutia, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">The Amino Acid Transporter SLC6A14 in Cancer and its Potential Use in Chemotherapy</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2014.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2014.04.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=293-303&author=Y.+D.+Bhutiaauthor=E.+Babuauthor=P.+D.+Prasadauthor=V.+Ganapathy&title=The+Amino+Acid+Transporter+SLC6A14+in+Cancer+and+its+Potential+Use+in+Chemotherapy&doi=10.1016%2Fj.ajps.2014.04.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2014.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2014.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DBhutia%26aufirst%3DY.%2BD.%26aulast%3DBabu%26aufirst%3DE.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DThe%2520Amino%2520Acid%2520Transporter%2520SLC6A14%2520in%2520Cancer%2520and%2520its%2520Potential%2520Use%2520in%2520Chemotherapy%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D9%26spage%3D293%26epage%3D303%26doi%3D10.1016%2Fj.ajps.2014.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karunakaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coothankandaswamy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elangovan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy-Thandavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnanaprakasam, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenlein, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thangaraju, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">SLC6A14 (ATB<sup>0,+</sup>) Protein, a Highly Concentrative and Broad Specific Amino Acid Transporter, Is a Novel and Effective Drug Target for Treatment of Estrogen Receptor-positive Breast Cancer</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">31830</span>– <span class="NLM_lpage">31838</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.229518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1074%2Fjbc.M111.229518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=21771784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaiurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=31830-31838&author=S.+Karunakaranauthor=S.+Ramachandranauthor=V.+Coothankandaswamyauthor=S.+Elangovanauthor=E.+Babuauthor=S.+Periyasamy-Thandavanauthor=A.+Guravauthor=J.+P.+Gnanaprakasamauthor=N.+Singhauthor=P.+V.+Schoenleinauthor=P.+D.+Prasadauthor=M.+Thangarajuauthor=V.+Ganapathy&title=SLC6A14+%28ATB0%2C%2B%29+Protein%2C+a+Highly+Concentrative+and+Broad+Specific+Amino+Acid+Transporter%2C+Is+a+Novel+and+Effective+Drug+Target+for+Treatment+of+Estrogen+Receptor-positive+Breast+Cancer&doi=10.1074%2Fjbc.M111.229518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer</span></div><div class="casAuthors">Karunakaran, Senthil; Ramachandran, Sabarish; Coothankandaswamy, Veena; Elangovan, Selvakumar; Babu, Ellappan; Periyasamy-Thandavan, Sudharsan; Gurav, Ashish; Gnanaprakasam, Jaya P.; Singh, Nagendra; Schoenlein, Patricia V.; Prasad, Puttur D.; Thangaraju, Muthusamy; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">31830-31838</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">SLC6A14, also known as ATB0,+, is an amino acid transporter with unique characteristics.  It transports 18 of the 20 proteinogenic amino acids.  However, this transporter is expressed only at low levels in normal tissues.  Here, we show that the transporter is up-regulated specifically in estrogen receptor (ER)-pos. breast cancer, demonstrable with primary human breast cancer tissues and human breast cancer cell lines.  SLC6A14 is an estrogen/ER target.  The transport features of SLC6A14 include concentrative transport of leucine (an activator of mTOR), glutamine (an essential amino acid for nucleotide biosynthesis and substrate for glutaminolysis), and arginine (an essential amino acid for tumor cells), suggesting that ER-pos. breast cancer cells up-regulate SLC6A14 to meet their increased demand for these amino acids.  Consequently, treatment of ER-pos. breast cancer cells in vitro with α-methyl-DL-tryptophan (α-MT), a selective blocker of SLC6A14, induces amino acid deprivation, inhibits mTOR, and activates autophagy.  Prolongation of the treatment with α-MT causes apoptosis.  Addn. of an autophagy inhibitor (3-methyladenine) during α-MT treatment also induces apoptosis.  These effects of α-MT are specific to ER-pos. breast cancer cells, which express the transporter.  The ability of α-MT to cause amino acid deprivation is significantly attenuated in MCF-7 cells, an ER-pos. breast cancer cell line, when SLC6A14 is silenced with shRNA.  In mouse xenograft studies, α-MT by itself is able to reduce the growth of the ER-pos. ZR-75-1 breast cancer cells.  These studies identify SLC6A14 as a novel and effective drug target for the treatment of ER-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfDE1psCVVsrVg90H21EOLACvtfcHk0li9c7mizihQ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaiurzO&md5=046c74001108f451cd741e46d2ab5ec8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.229518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.229518%26sid%3Dliteratum%253Aachs%26aulast%3DKarunakaran%26aufirst%3DS.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DCoothankandaswamy%26aufirst%3DV.%26aulast%3DElangovan%26aufirst%3DS.%26aulast%3DBabu%26aufirst%3DE.%26aulast%3DPeriyasamy-Thandavan%26aufirst%3DS.%26aulast%3DGurav%26aufirst%3DA.%26aulast%3DGnanaprakasam%26aufirst%3DJ.%2BP.%26aulast%3DSingh%26aufirst%3DN.%26aulast%3DSchoenlein%26aufirst%3DP.%2BV.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DThangaraju%26aufirst%3DM.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DSLC6A14%2520%2528ATB0%252C%252B%2529%2520Protein%252C%2520a%2520Highly%2520Concentrative%2520and%2520Broad%2520Specific%2520Amino%2520Acid%2520Transporter%252C%2520Is%2520a%2520Novel%2520and%2520Effective%2520Drug%2520Target%2520for%2520Treatment%2520of%2520Estrogen%2520Receptor-positive%2520Breast%2520Cancer%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D31830%26epage%3D31838%26doi%3D10.1074%2Fjbc.M111.229518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coothankandaswamy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutia, Y. D.</span></span> <span> </span><span class="NLM_article-title">Amino Acid Transporter SLC6A14 Is a Novel and Effective Drug Target for Pancreatic Cancer</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">3292</span>– <span class="NLM_lpage">3306</span>, <span class="refDoi"> DOI: 10.1111/bph.13616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1111%2Fbph.13616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=27747870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yqt7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=3292-3306&author=V.+Coothankandaswamyauthor=S.+Caoauthor=Y.+Xuauthor=P.+D.+Prasadauthor=P.+K.+Singhauthor=C.+P.+Reynoldsauthor=S.+Yangauthor=J.+Oguraauthor=V.+Ganapathyauthor=Y.+D.+Bhutia&title=Amino+Acid+Transporter+SLC6A14+Is+a+Novel+and+Effective+Drug+Target+for+Pancreatic+Cancer&doi=10.1111%2Fbph.13616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer</span></div><div class="casAuthors">Coothankandaswamy, V.; Cao, S.; Xu, Y.; Prasad, P. D.; Singh, P. K.; Reynolds, C. P.; Yang, S.; Ogura, J.; Ganapathy, V.; Bhutia, Y. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3292-3306</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Pancreatic cancer is a solid tumor that is often fatal.  Hence, there is an urgent need to identify new drug targets for this disease.  Highly proliferating cancer cells have an increased demand for nutrients and, therefore, need to up-regulate selective amino acid transporters.  Here, we investigated which amino acid transporters are up-regulated in pancreatic cancer and whether any of these transporters has potential as a drug target for this fatal disease.  Exptl. Approach : The expression of amino acid transporters in pancreatic cancer was analyzed using publicly available microarray datasets, and the findings with the transporter SLC6A14 were validated by mRNA and protein anal.  The potential of SLC6A14 as a drug target was evaluated using a pharmacol. blocker in vitro and in vivo.  Key Results : SLC6A14 was up-regulated several fold in patient-derived xenografts, primary tumor tissues and pancreatic cancer cells lines compared to normal pancreatic tissue or normal pancreatic epithelial cells.  The magnitude of the up-regulation of SLC6A14 was the highest among the amino acid transporters examd.  A pharmacol. blocker of SLC6A14, α-methyltryptophan, induced amino acid starvation in pancreatic cancer cells and reduced the growth and proliferation of these cells, both in vitro and in vivo.  Conclusion and Implications : The salient features of this study are that SLC6A14 is markedly up-regulated in pancreatic cancer and that pharmacol. blockade of this transporter interferes with amino acid nutrition and reduces growth and proliferation of pancreatic cancer cells.  These findings identify SLC6A14 as a novel druggable target for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTmV-u8hFgTbVg90H21EOLACvtfcHk0ljuZmjGc00YTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yqt7%252FF&md5=0c2587ccb3731b345948605a98499f0c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fbph.13616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13616%26sid%3Dliteratum%253Aachs%26aulast%3DCoothankandaswamy%26aufirst%3DV.%26aulast%3DCao%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DOgura%26aufirst%3DJ.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DBhutia%26aufirst%3DY.%2BD.%26atitle%3DAmino%2520Acid%2520Transporter%2520SLC6A14%2520Is%2520a%2520Novel%2520and%2520Effective%2520Drug%2520Target%2520for%2520Pancreatic%2520Cancer%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D3292%26epage%3D3306%26doi%3D10.1111%2Fbph.13616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyauchi, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martindale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdman, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podolsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">Upregulation of the Amino Acid Transporter ATB<sup>0,+</sup> (SLC6A14) in Colorectal Cancer and Metastasis in Humans</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1741</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.bbadis.2005.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.bbadis.2005.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=15905073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Witrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1741&publication_year=2005&pages=215-223&author=N.+Guptaauthor=S.+R.+Miyauchiauthor=G.+Martindaleauthor=A.+V.+Herdmanauthor=R.+Podolskyauthor=K.+Miyakeauthor=S.+Magerauthor=P.+D.+Prasadauthor=M.+E.+Ganapathyauthor=V.+Ganapathy&title=Upregulation+of+the+Amino+Acid+Transporter+ATB0%2C%2B+%28SLC6A14%29+in+Colorectal+Cancer+and+Metastasis+in+Humans&doi=10.1016%2Fj.bbadis.2005.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans</span></div><div class="casAuthors">Gupta, Naren; Miyauchi, Seiji; Martindale, Robert G.; Herdman, Anne V.; Podolsky, Robert; Miyake, Katsuya; Mager, Sela; Prasad, Puttur D.; Ganapathy, Malliga E.; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1741</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">215-223</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">ATB0,+ (SLC6A14) is a Na+/Cl--coupled arginine transporter expressed at low levels in normal colon.  Arginine is an essential amino acid for tumor cells.  Arginine is also the substrate for nitric oxide synthases (NOSs).  Since arginine and arginine-derived nitric oxide (NO) play a crit. role in cancer, the authors examd. the expression of ATB0,+ in colorectal cancer.  Paired normal and cancer tissues from colectomy specimens of 10 patients with colorectal cancer and from the liver tissue of one patient with hepatic metastasis from a colonic primary were used for the anal. of the levels of ATB0,+ mRNA, inducible NOS (iNOS) mRNA and the corresponding proteins.  Tissues samples from the colon, liver, and lymph nodes of an addnl. patient with metastatic colon cancer were analyzed for ATB0,+ protein alone.  The authors also examd. the levels of nitrotyrosylated proteins.  The ATB0,+ mRNA increased 22.9-fold in colorectal cancer compared to normal tissue and the increase was evident in each of the 10 cases examd.  INOS mRNA increased 5.2-fold in cancer specimens.  The changes in mRNA levels were assocd. with an increase in ATB0,+, iNOS, and nitrotyrosylated proteins.  The increased expression of ATB0,+ and iNOS was also demonstrated in liver and lymph node specimens with metastases from colonic primaries.  This study strongly suggests that the upregulation of ATB0,+ may have a pathogenic role in colorectal cancer.  Since ATB0,+ is a versatile transporter not only for arginine but also for several drugs including NOS inhibitors, these findings have significant clin. and therapeutic relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWMIx7-hMjxbVg90H21EOLACvtfcHk0ljuZmjGc00YTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Witrw%253D&md5=09dbdb32c102c4d63e973c3ab999f38c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2005.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2005.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DMiyauchi%26aufirst%3DS.%2BR.%26aulast%3DMartindale%26aufirst%3DG.%26aulast%3DHerdman%26aufirst%3DA.%2BV.%26aulast%3DPodolsky%26aufirst%3DR.%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DMager%26aufirst%3DS.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DGanapathy%26aufirst%3DM.%2BE.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DUpregulation%2520of%2520the%2520Amino%2520Acid%2520Transporter%2520ATB0%252C%252B%2520%2528SLC6A14%2529%2520in%2520Colorectal%2520Cancer%2520and%2520Metastasis%2520in%2520Humans%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2005%26volume%3D1741%26spage%3D215%26epage%3D223%26doi%3D10.1016%2Fj.bbadis.2005.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCracken, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edinger, A. L.</span></span> <span> </span><span class="NLM_article-title">Targeting Cancer Metabolism at the Plasma Membrane by Limiting Amino Acid Access Through SLC6A14</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>470</i></span>,  <span class="NLM_fpage">e17</span>– <span class="NLM_lpage">e19</span>, <span class="refDoi"> DOI: 10.1042/BJ20150721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1042%2FBJ20150721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=26341486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Wju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=470&publication_year=2015&pages=e17-e19&author=A.+N.+McCrackenauthor=A.+L.+Edinger&title=Targeting+Cancer+Metabolism+at+the+Plasma+Membrane+by+Limiting+Amino+Acid+Access+Through+SLC6A14&doi=10.1042%2FBJ20150721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer metabolism at the plasma membrane by limiting amino acid access through SLC6A14</span></div><div class="casAuthors">McCracken, Alison N.; Edinger, Aimee L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">470</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e17/1-e17/3</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Rapidly proliferating cancer cells increase flux through anabolic pathways to build the mass necessary to support cell division.  Imported amino acids and glucose lie at the apex of the anabolic pyramid.  Consistent with this, elevated expression of nutrient transporter proteins is characteristic of aggressive and highly malignant cancers.  Because tumor cells are more dependent than their normal neighbors on accelerated nutrient import, these up-regulated transporters could be excellent targets for selective anti-cancer therapies.  A study by Babu et al. in a recent issue of the Biochem. Journal definitively shows that SLC6A14 (where SLC is solute carrier) is one such cancer-specific amino acid transporter.  Although mice completely lacking SLC6A14 are viable and exhibit normal mammary gland development, these animals are highly resistant to mammary tumor initiation and progression driven by potent oncogenes.  Because SLC6A14 is essential for tumor growth yet dispensable for normal development and tissue maintenance, small mols. that block amino acid import through this transporter could be effective and selective anti-cancer agents, particularly as components of rational drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyXMKviI1wlrVg90H21EOLACvtfcHk0ljuZmjGc00YTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Wju7c%253D&md5=e66ee8dad413407423041e0d34a11d36</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1042%2FBJ20150721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20150721%26sid%3Dliteratum%253Aachs%26aulast%3DMcCracken%26aufirst%3DA.%2BN.%26aulast%3DEdinger%26aufirst%3DA.%2BL.%26atitle%3DTargeting%2520Cancer%2520Metabolism%2520at%2520the%2520Plasma%2520Membrane%2520by%2520Limiting%2520Amino%2520Acid%2520Access%2520Through%2520SLC6A14%26jtitle%3DBiochem.%2520J.%26date%3D2015%26volume%3D470%26spage%3De17%26epage%3De19%26doi%3D10.1042%2FBJ20150721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, M. J.</span></span> <span> </span><span class="NLM_article-title">The Expanding Role of Prodrugs in Contemporary Drug Design and Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1038%2Fnrd.2018.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=29700501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=559-587&author=J.+Rautioauthor=N.+A.+Meanwellauthor=L.+Diauthor=M.+J.+Hageman&title=The+Expanding+Role+of+Prodrugs+in+Contemporary+Drug+Design+and+Development&doi=10.1038%2Fnrd.2018.46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The expanding role of prodrugs in contemporary drug design and development</span></div><div class="casAuthors">Rautio, Jarkko; Meanwell, Nicholas A.; Di, Li; Hageman, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-587</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Prodrugs are mols. with little or no pharmacol. activity that are converted to the active parent drug in vivo by enzymic or chem. reactions or by a combination of the two.  Prodrugs have evolved from being serendipitously discovered or used as a salvage effort to being intentionally designed.  Such efforts can avoid drug development challenges that limit formulation options or result in unacceptable biopharmaceutical or pharmacokinetic performance, or poor targeting.  In the past 10 years, the US Food and Drug Administration has approved at least 30 prodrugs, which accounts for more than 12% of all approved small-mol. new chem. entities.  In this Review, we highlight prodrug design strategies for improved formulation and pharmacokinetic and targeting properties, with a focus on the most recently marketed prodrugs.  We also discuss preclin. and clin. challenges and considerations in prodrug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKsM1lriJObVg90H21EOLACvtfcHk0lj00jgHBGpFrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D&md5=9dea9fd2f30779f4ce182b822f2c9539</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.46%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DHageman%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520Expanding%2520Role%2520of%2520Prodrugs%2520in%2520Contemporary%2520Drug%2520Design%2520and%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D559%26epage%3D587%26doi%3D10.1038%2Fnrd.2018.46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haramura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyauchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, M. E.</span></span> <span> </span><span class="NLM_article-title">Transport of Amino Acid-based Prodrugs by the Na<sup>+</sup>- and Cl<sup>–</sup>-coupled Amino Acid Transporter ATB<sup>0,+</sup> and Expression of the Transporter in Tissues Amenable for Drug Delivery</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1138</span>– <span class="NLM_lpage">1147</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.057109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1124%2Fjpet.103.057109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=14617696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWnu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2004&pages=1138-1147&author=T.+Hatanakaauthor=M.+Haramuraauthor=Y.+J.+Feiauthor=S.+Miyauchiauthor=C.+C.+Bridgesauthor=P.+S.+Ganapathyauthor=S.+B.+Smithauthor=V.+Ganapathyauthor=M.+E.+Ganapathy&title=Transport+of+Amino+Acid-based+Prodrugs+by+the+Na%2B-+and+Cl%E2%80%93-coupled+Amino+Acid+Transporter+ATB0%2C%2B+and+Expression+of+the+Transporter+in+Tissues+Amenable+for+Drug+Delivery&doi=10.1124%2Fjpet.103.057109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of amino acid-based prodrugs by the Na+- and Cl--coupled amino acid transporter ATBo,+ and expression of the transporter in tissues amenable for drug delivery</span></div><div class="casAuthors">Hatanaka, Takahiro; Haramura, Masayuki; Fei, You-Jun; Miyauchi, Seiji; Bridges, Christy C.; Ganapathy, Preethi S.; Smith, Sylvia B.; Ganapathy, Vadivel; Ganapathy, Malliga E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1138-1147</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the potential of the Na+- and Cl--coupled amino acid transporter ATBo,+ as a delivery system for amino acid-based prodrugs.  Immunofluorescence anal. indicated that ATBo,+ is expressed abundantly on the luminal surface of cells lining the lumen of the large intestine and the airways of the lung and in various ocular tissues, including the conjunctival epithelium, the tissues easily amenable for drug delivery.  We screened a variety of β-carboxyl derivs. of aspartate and γ-carboxyl derivs. of glutamate as potential substrates for this transporter using heterologous expression systems.  In mammalian cells expressing the cloned ATBo,+, several of the aspartate and glutamate derivs. inhibited glycine transport via ATBo,+.  Direct evidence for ATBo,+-mediated transport of these derivs. was obtained in Xenopus laevis oocytes using electrophysiol. methods.  Exposure of oocytes, which express ATBo,+ heterologously, to aspartate β-benzyl ester as a model deriv. induced inward currents in a Na+- and Cl--dependent manner with a Na+/Cl-/aspartate β-benzyl ester stoichiometry of 2:1:1.  ATBo,+ transported not only the β-carboxyl derivs. of aspartate and the γ-carboxyl derivs. of glutamate but also valacyclovir, which is an α-carboxyl ester of acyclovir with valine.  The transport of valacyclovir via ATBo,+ was demonstrable in both heterologous expression systems.  This process was dependent on Na+ and Cl-.  The ability of ATBo,+ to transport valacyclovir was comparable with that of the peptide transporter PEPT1.  These findings suggest that ATBo,+ has significant potential as a delivery system for amino acid-based drugs and prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVWA6V9-1ZhbVg90H21EOLACvtfcHk0lj00jgHBGpFrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWnu74%253D&md5=a0a168267881b1049947465e555ce1a4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.057109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.057109%26sid%3Dliteratum%253Aachs%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DHaramura%26aufirst%3DM.%26aulast%3DFei%26aufirst%3DY.%2BJ.%26aulast%3DMiyauchi%26aufirst%3DS.%26aulast%3DBridges%26aufirst%3DC.%2BC.%26aulast%3DGanapathy%26aufirst%3DP.%2BS.%26aulast%3DSmith%26aufirst%3DS.%2BB.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DGanapathy%26aufirst%3DM.%2BE.%26atitle%3DTransport%2520of%2520Amino%2520Acid-based%2520Prodrugs%2520by%2520the%2520Na%252B-%2520and%2520Cl%25E2%2580%2593-coupled%2520Amino%2520Acid%2520Transporter%2520ATB0%252C%252B%2520and%2520Expression%2520of%2520the%2520Transporter%2520in%2520Tissues%2520Amenable%2520for%2520Drug%2520Delivery%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D308%26spage%3D1138%26epage%3D1147%26doi%3D10.1124%2Fjpet.103.057109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karunakaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umapathy, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thangaraju, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itagaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">Interaction of Tryptophan Derivatives with SLC6A14 (ATB<sup>0,+</sup>) Reveals the Potential of the Transporter As a Drug Target for Cancer Chemotherapy</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1042/BJ20080622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1042%2FBJ20080622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=18522536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVentrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2008&pages=343-355&author=S.+Karunakaranauthor=N.+S.+Umapathyauthor=M.+Thangarajuauthor=T.+Hatanakaauthor=S.+Itagakiauthor=D.+H.+Munnauthor=P.+D.+Prasadauthor=V.+Ganapathy&title=Interaction+of+Tryptophan+Derivatives+with+SLC6A14+%28ATB0%2C%2B%29+Reveals+the+Potential+of+the+Transporter+As+a+Drug+Target+for+Cancer+Chemotherapy&doi=10.1042%2FBJ20080622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy</span></div><div class="casAuthors">Karunakaran, Senthil; Umapathy, Nagavedi S.; Thangaraju, Muthusamy; Hatanaka, Takahiro; Itagaki, Shiro; Munn, David H.; Prasad, Puttur D.; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-355</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">ATB0,+ [SLC6A14 (solute carrier family 6 member 14)] is an Na+/Cl--coupled amino acid transporter whose expression is up-regulated in cancer.  1-Methyltryptophan is an inducer of immune surveillance against tumor cells through its ability to inhibit indoleamine dioxygenase.  In the present study, we investigated the role of ATB0,+ in the uptake of 1-methyltryptophan as a potential mechanism for entry of this putative anticancer drug into tumor cells.  These studies show that 1-methyltryptophan is a transportable substrate for ATB0,+.  The transport process is Na+/Cl--dependent with an Na+/Cl-/1-methyltryptophan stoichiometry of 2:1:1.  Evaluation of other derivs. of tryptophan has led to identification of α-methyltryptophan as a blocker, not a transportable substrate, for ATB0,+.  ATB0,+ can transport 18 of the 20 proteinogenic amino acids.  α-Methyltryptophan blocks the transport function of ATB0,+ with an IC50 value of ∼250 μM under conditions simulating normal plasma concns. of all these 18 amino acids.  These results suggest that α-methyltryptophan may induce amino acid deprivation in cells which depend on the transporter for their amino acid nutrition.  Screening of several mammary epithelial cell lines shows that ATB0,+ is expressed robustly in some cancer cell lines, but not in all; in contrast, non-malignant cell lines do not express the transporter.  Treatment of ATB0,+-pos. tumor cells with α-methyltryptophan leads to suppression of their colony-forming ability, whereas ATB0,+-neg. cell lines are not affected.  The blockade of ATB0,+ in these cells with α-methyltryptophan is assocd. with cell cycle arrest.  These studies reveal the potential of ATB0,+ as a drug target for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLorZa6TFSxLVg90H21EOLACvtfcHk0lhiksx6fQX1Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVentrbF&md5=0def80d64d2c5e879a1b1445adaba857</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1042%2FBJ20080622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20080622%26sid%3Dliteratum%253Aachs%26aulast%3DKarunakaran%26aufirst%3DS.%26aulast%3DUmapathy%26aufirst%3DN.%2BS.%26aulast%3DThangaraju%26aufirst%3DM.%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DItagaki%26aufirst%3DS.%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DInteraction%2520of%2520Tryptophan%2520Derivatives%2520with%2520SLC6A14%2520%2528ATB0%252C%252B%2529%2520Reveals%2520the%2520Potential%2520of%2520the%2520Transporter%2520As%2520a%2520Drug%2520Target%2520for%2520Cancer%2520Chemotherapy%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D414%26spage%3D343%26epage%3D355%26doi%3D10.1042%2FBJ20080622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kou, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">Transporter Occluded-state Conformation-induced Endocytosis: Amino Acid Transporter ATB<sup>0,+</sup>-mediated Tumor Targeting of Liposomes for Docetaxel Delivery for Hepatocarcinoma Therapy</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2016.10.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.jconrel.2016.10.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=27810556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGgtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=2016&pages=370-380&author=Q.+H.+Luoauthor=P.+Gongauthor=M.+C.+Sunauthor=L.+F.+Kouauthor=V.+Ganapathyauthor=Y.+K.+Jingauthor=Z.+G.+Heauthor=J.+Sun&title=Transporter+Occluded-state+Conformation-induced+Endocytosis%3A+Amino+Acid+Transporter+ATB0%2C%2B-mediated+Tumor+Targeting+of+Liposomes+for+Docetaxel+Delivery+for+Hepatocarcinoma+Therapy&doi=10.1016%2Fj.jconrel.2016.10.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB0,+-mediated tumor targeting of liposomes for docetaxel delivery for hepatocarcinoma therapy</span></div><div class="casAuthors">Luo, Qiuhua; Gong, Ping; Sun, Mengchi; Kou, Longfa; Ganapathy, Vadivel; Jing, Yongkui; He, Zhonggui; Sun, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">370-380</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rapidly proliferating tumor cells upregulate specific amino acid transporters, which hold great potential for tumor-selective drug delivery.  Published reports have focused primarily on blocking these transporters as a means of starving the tumor cells of amino acids, but their potential in drug delivery remains understudied.  In the present study, we developed liposomes functionalized with lysine and polyoxyethylene stearate conjugate (LPS) to interact with ATB0,+, an amino acid transporter overexpressed in hepatocarcinoma and the liver cancer cell line HepG2.  The LPS modified liposomes (LPS-Lips) were ∼ 100 nm in size and exhibited high drug encapsulation efficiency as 94.7%.  The uptake of LPS-Lips in HepG2 cells was dependent on Na+ and Cl-.  Mol. dynamic simulation showed that a sustained occluded state of the transporter upon binding to co-transported ions was formed and LPS-Lips triggered the cellular internalization of liposomes.  We loaded these LPS-Lips with docetaxel and evaluated the potential of ATB0,+-mediated endocytosis of the drug-loaded LPS-Lips in HepG2 cells in vitro and in syngeneic mouse transplants in vivo.  Compared with unmodified liposomes, which did not interact with ATB0,+, LPS-Lips exhibited the ability to deliver docetaxel more efficiently into tumor cells with consequent greater antitumor efficacy and less systemic toxicity.  These studies provide first evidences that ATB0,+ can be used as a novel and effective target for drug delivery system in tumor cells using chem. modified liposomes for loading with chemotherapeutics and targeting them for the transporter-mediated endocytosis.  As ATB0,+ is highly upregulated in several cancers, this approach holds potential for tumor-selective delivery of drugs to treat these cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6JsqyReB66LVg90H21EOLACvtfcHk0lhiksx6fQX1Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGgtbjI&md5=f23e1e62eb559cf595245ad5a92f4dda</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2016.10.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2016.10.031%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DQ.%2BH.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DM.%2BC.%26aulast%3DKou%26aufirst%3DL.%2BF.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DJing%26aufirst%3DY.%2BK.%26aulast%3DHe%26aufirst%3DZ.%2BG.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DTransporter%2520Occluded-state%2520Conformation-induced%2520Endocytosis%253A%2520Amino%2520Acid%2520Transporter%2520ATB0%252C%252B-mediated%2520Tumor%2520Targeting%2520of%2520Liposomes%2520for%2520Docetaxel%2520Delivery%2520for%2520Hepatocarcinoma%2520Therapy%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2016%26volume%3D243%26spage%3D370%26epage%3D380%26doi%3D10.1016%2Fj.jconrel.2016.10.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubatsch, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvidsson, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seebach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">β- or γ-Di<i>-</i> and Tripeptides as Potential Substrates for the Oligopeptide Transporter hPETP1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5238</span>– <span class="NLM_lpage">5242</span>, <span class="refDoi"> DOI: 10.1021/jm070148u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070148u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGqt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5238-5242&author=I.+Hubatschauthor=P.+I.+Arvidssonauthor=D.+Seebachauthor=K.+Luthmanauthor=P.+Artursson&title=%CE%B2-+or+%CE%B3-Di-+and+Tripeptides+as+Potential+Substrates+for+the+Oligopeptide+Transporter+hPETP1&doi=10.1021%2Fjm070148u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">β- and γ-Di- and Tripeptides as Potential Substrates for the Oligopeptide Transporter hPepT1</span></div><div class="casAuthors">Hubatsch, Ina; Arvidsson, Per I.; Seebach, Dieter; Luthman, Kristina; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5238-5242</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hPepT1-mediated transport properties of eleven synthesized β- and γ-peptides have been studied in Caco-2 cells.  The results show that several of the compds. interact with the peptide transporter, but only two β-dipeptides act as substrates and are transported across the cell monolayers.  These two are less-efficient substrates than α-peptides.  Larger derivs. than β-dipeptides do not act as hPepT1 substrates, but instead, they appear to be substrates for P-glycoprotein efflux.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK-gSaMwJFW7Vg90H21EOLACvtfcHk0lhiksx6fQX1Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGqt7jI&md5=0ef59d40eed7acaa1406708d28db6e8e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm070148u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070148u%26sid%3Dliteratum%253Aachs%26aulast%3DHubatsch%26aufirst%3DI.%26aulast%3DArvidsson%26aufirst%3DP.%2BI.%26aulast%3DSeebach%26aufirst%3DD.%26aulast%3DLuthman%26aufirst%3DK.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3D%25CE%25B2-%2520or%2520%25CE%25B3-Di-%2520and%2520Tripeptides%2520as%2520Potential%2520Substrates%2520for%2520the%2520Oligopeptide%2520Transporter%2520hPETP1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5238%26epage%3D5242%26doi%3D10.1021%2Fjm070148u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibach, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boron, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span> <span> </span><span class="NLM_article-title">Expression Cloning of a Mammalian Proton-coupled Oligopeptide Transporter</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/368563a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1038%2F368563a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=8139693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADyaK2cXksFCntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=1994&pages=563-566&author=Y.+J.+Feiauthor=Y.+Kanaiauthor=S.+Nussbergerauthor=V.+Ganapathyauthor=F.+H.+Leibachauthor=M.+F.+Romeroauthor=S.+K.+Singhauthor=W.+F.+Boronauthor=M.+A.+Hediger&title=Expression+Cloning+of+a+Mammalian+Proton-coupled+Oligopeptide+Transporter&doi=10.1038%2F368563a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Expression cloning of a mammalian proton-coupled oligopeptide transporter</span></div><div class="casAuthors">Fei, You Jun; Kanai, Yoshikatsu; Nussberger, Stephan; Ganapathy, Vadivel; Leibach, Frederick H.; Romero, Michael F.; Singh, Satish K.; Boron, Walter F.; Hediger, Matthias A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6471</span>),
    <span class="NLM_cas:pages">563-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">In mammals active transport of org. solutes across plasma membranes was thought to be primarily driven by the Na+ gradient.  Here the authors report the cloning and functional characterization of a H+-coupled transporter of oligopeptides and peptide-derived antibiotics from rabbit small intestine.  This new protein, named PepT1, displays an unusually broad substrate specificity.  PepT1-mediated uptake is electrogenic, independent of extracellular Na+, K+ and Cl-, and of membrane potential.  PepT1 mRNA was found in intestine, kidney and liver and in small amts. in brain.  In the intestine, the PepT1 pathway constitutes a major mechanism for absorption of the products of protein digestion.  To the authors' knowledge, the PepT1 primary structure is the first report for a proton-coupled org. solute transporter in vertebrates and represents an interesting evolutionary link between prokaryotic H+-coupled and vertebrate Na+-coupled transporters of org. solutes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtu0MdddqtV7Vg90H21EOLACvtfcHk0ljHMh5a9JLH0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFCntro%253D&md5=bc1a9a631a2d8159c61904a6aed89c96</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2F368563a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F368563a0%26sid%3Dliteratum%253Aachs%26aulast%3DFei%26aufirst%3DY.%2BJ.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DNussberger%26aufirst%3DS.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DLeibach%26aufirst%3DF.%2BH.%26aulast%3DRomero%26aufirst%3DM.%2BF.%26aulast%3DSingh%26aufirst%3DS.%2BK.%26aulast%3DBoron%26aufirst%3DW.%2BF.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26atitle%3DExpression%2520Cloning%2520of%2520a%2520Mammalian%2520Proton-coupled%2520Oligopeptide%2520Transporter%26jtitle%3DNature%26date%3D1994%26volume%3D368%26spage%3D563%26epage%3D566%26doi%3D10.1038%2F368563a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palazzolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paravicini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurenzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adobati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saporiti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianazza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Indiveri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thwaites, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberini, I.</span></span> <span> </span><span class="NLM_article-title">SLC6A14, a Pivotal Actor in Cancer Stage: When Function Meets Structure</span>. <i>SLAS. Discovery.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">938</span>, <span class="refDoi"> DOI: 10.1177/2472555219867317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1177%2F2472555219867317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=31373846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVars7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=928-938&author=L.+Palazzoloauthor=C.+Paraviciniauthor=T.+Laurenziauthor=S.+Adobatiauthor=S.+Saporitiauthor=U.+Guerriniauthor=E.+Gianazzaauthor=C.+Indiveriauthor=C.+M.+H.+Andersonauthor=D.+T.+Thwaitesauthor=I.+Eberini&title=SLC6A14%2C+a+Pivotal+Actor+in+Cancer+Stage%3A+When+Function+Meets+Structure&doi=10.1177%2F2472555219867317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">SLC6A14, a Pivotal Actor on Cancer Stage: When Function Meets Structure</span></div><div class="casAuthors">Palazzolo, Luca; Paravicini, Chiara; Laurenzi, Tommaso; Adobati, Sara; Saporiti, Simona; Guerrini, Uliano; Gianazza, Elisabetta; Indiveri, Cesare; Anderson, Catriona M. H.; Thwaites, David T.; Eberini, Ivano</div><div class="citationInfo"><span class="NLM_cas:title">SLAS Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">928-938</span>CODEN:
                <span class="NLM_cas:coden">SDLIBT</span>;
        ISSN:<span class="NLM_cas:issn">2472-5560</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">SLC6A14 (ATB0,+) is a sodium- and chloride-dependent neutral and dibasic amino acid transporter that regulates the distribution of amino acids across cell membranes.  The transporter is overexpressed in many human cancers characterized by an increased demand for amino acids; as such, it was recently acknowledged as a novel target for cancer therapy.  The knowledge on the mol. mechanism of SLC6A14 transport is still limited, but some elegant studies on related transporters report the involvement of the 12 transmembrane α-helixes in the transport mechanism, and describe structural rearrangements mediated by electrostatic interactions with some pivotal gating residues.  In the present work, we constructed a SLC6A14 model in outward-facing conformation via homol. modeling and used mol. dynamics simulations to predict amino acid residues crit. for substrate recognition and translocation.  We docked the proteinogenic amino acids and other known substrates in the SLC6A14 binding site to study both gating regions and the exposed residues involved in transport.  Interestingly, some of these residues correspond to those previously identified in other LeuT-fold transporters; however, we could also identify a novel relevant residue with such function.  For the first time, by combined approaches of mol. docking and mol. dynamics simulations, we highlight the potential role of these residues in neutral amino acid transport.  This novel information unravels new aspects of the human SLC6A14 structure-function relationship and may have important outcomes for cancer treatment through the design of novel inhibitors of SLC6A14-mediated transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd0MvXA-yZb7Vg90H21EOLACvtfcHk0ljHMh5a9JLH0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVars7fN&md5=fcec1e7824f4c93c5459ddba046cdf94</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1177%2F2472555219867317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2472555219867317%26sid%3Dliteratum%253Aachs%26aulast%3DPalazzolo%26aufirst%3DL.%26aulast%3DParavicini%26aufirst%3DC.%26aulast%3DLaurenzi%26aufirst%3DT.%26aulast%3DAdobati%26aufirst%3DS.%26aulast%3DSaporiti%26aufirst%3DS.%26aulast%3DGuerrini%26aufirst%3DU.%26aulast%3DGianazza%26aufirst%3DE.%26aulast%3DIndiveri%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DC.%2BM.%2BH.%26aulast%3DThwaites%26aufirst%3DD.%2BT.%26aulast%3DEberini%26aufirst%3DI.%26atitle%3DSLC6A14%252C%2520a%2520Pivotal%2520Actor%2520in%2520Cancer%2520Stage%253A%2520When%2520Function%2520Meets%2520Structure%26jtitle%3DSLAS.%2520Discovery.%26date%3D2019%26volume%3D24%26spage%3D928%26epage%3D938%26doi%3D10.1177%2F2472555219867317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">Translating Cancer Research into Targeted Therapeutics</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1038/nature09339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1038%2Fnature09339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=20882008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=543-549&author=J.+S.+De%0ABonoauthor=A.+Ashworth&title=Translating+Cancer+Research+into+Targeted+Therapeutics&doi=10.1038%2Fnature09339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Translating cancer research into targeted therapeutics</span></div><div class="casAuthors">de Bono, J. S.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">543-549</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The emphasis in cancer drug development has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs promising greater efficacy and less side effects.  Nevertheless, despite some successes drug development remains painfully slow.  Here, we highlight the issues involved and suggest ways in which this process can be improved and expedited.  We envision an increasing shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clin. trials.  The goal is the development of specific cancer medicines to treat the individual patient, with treatment selection being driven by a detailed understanding of the genetics and biol. of the patient and their cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNF4iuzr3HvbVg90H21EOLACvtfcHk0ljHMh5a9JLH0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajur7O&md5=1e65763ba1cddeef17e5b68e56a96452</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature09339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09339%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTranslating%2520Cancer%2520Research%2520into%2520Targeted%2520Therapeutics%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D543%26epage%3D549%26doi%3D10.1038%2Fnature09339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">A Novel Oral Prodrug-targeting Transporter MCT 1: 5-Fluorouracil-dicarboxylate Monoester Conjugates</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2019.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2019.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=32104489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BB387mslaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=631-639&author=Y.+X.+Sunauthor=D.+Y.+Zhaoauthor=G.+Wangauthor=Q.+K.+Jiangauthor=M.+R.+Guoauthor=Q.+M.+Kanauthor=Z.+G.+Heauthor=J.+Sun&title=A+Novel+Oral+Prodrug-targeting+Transporter+MCT+1%3A+5-Fluorouracil-dicarboxylate+Monoester+Conjugates&doi=10.1016%2Fj.ajps.2019.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A novel oral prodrug-targeting transporter MCT 1: 5-fluorouracil-dicarboxylate monoester conjugates</span></div><div class="casAuthors">Sun Yixin; Zhao Dongyang; Jiang Qikun; He Zhonggui; Sun Jin; Wang Gang; Guo Mengran; Kan Qiming</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">631-639</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Monocarboxylate transporter 1 (MCT1) is responsible for oral absorption of short-chain monocarboxylic acids from small intestine, hence, it's likely to serve as an ideal design target for the development of oral prodrugs.  However, potential application of MCT1 to facilitate the oral delivery is still unclear.  Irregular oral absorption, poor permeability and bioavailability greatly limit the oral delivery efficiency of 5-fluorouracil (5-FU).  Herein, we design three 5-FU-fatty acid conjugates targeting intestinal MCT1 with different lipophilic linkages.  Interestingly, due to high MCT1 affinity and good gastrointestinal stability, 5-FU-octanedioic acid monoester prodrug exhibited significant improvement in membrane permeability (13.1-fold) and oral bioavailability (4.1-fold) compared to 5-FU.  More surprisingly, stability experiment in intestinal homogenates showed that 5-FU prodrugs could be properly activated to release 5-FU within intestinal cells, which provides an ideal foundation for the improvement of oral bioavailability.  In summary, good gastrointestinal stability, high membrane permeability and appropriate intestinal cell bioactivation are the important factors for high-efficiency 5-FU oral prodrugs, and such work provides a good platform for the development of novel oral prodrugs targeting intestinal transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMSO2kE7krGOBfW6udTcc2eboPSuLUzaAE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslaisA%253D%253D&md5=4829bc8a1e1b53c1de36ca5d761942a0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2019.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2019.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%2BX.%26aulast%3DZhao%26aufirst%3DD.%2BY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DQ.%2BK.%26aulast%3DGuo%26aufirst%3DM.%2BR.%26aulast%3DKan%26aufirst%3DQ.%2BM.%26aulast%3DHe%26aufirst%3DZ.%2BG.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DA%2520Novel%2520Oral%2520Prodrug-targeting%2520Transporter%2520MCT%25201%253A%25205-Fluorouracil-dicarboxylate%2520Monoester%2520Conjugates%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D14%26spage%3D631%26epage%3D639%26doi%3D10.1016%2Fj.ajps.2019.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sikder, M. O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutia, Y. D.</span></span> <span> </span><span class="NLM_article-title">The Na<sup>+</sup>/Cl<sup>–</sup>-coupled Broad-specific, Amino Acid Transporter SLC6A14 (ATB<sup>0,+</sup>): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">12</span>, <span class="refDoi"> DOI: 10.1208/s12248-017-0164-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1208%2Fs12248-017-0164-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=12&author=M.+O.+F.+Sikderauthor=S.+Yangauthor=V.+Ganapathyauthor=Y.+D.+Bhutia&title=The+Na%2B%2FCl%E2%80%93-coupled+Broad-specific%2C+Amino+Acid+Transporter+SLC6A14+%28ATB0%2C%2B%29%3A+Emerging+Roles+in+Multiple+Diseases+and+Therapeutic+Potential+for+Treatment+and+Diagnosis&doi=10.1208%2Fs12248-017-0164-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1208%2Fs12248-017-0164-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-017-0164-7%26sid%3Dliteratum%253Aachs%26aulast%3DSikder%26aufirst%3DM.%2BO.%2BF.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DBhutia%26aufirst%3DY.%2BD.%26atitle%3DThe%2520Na%252B%252FCl%25E2%2580%2593-coupled%2520Broad-specific%252C%2520Amino%2520Acid%2520Transporter%2520SLC6A14%2520%2528ATB0%252C%252B%2529%253A%2520Emerging%2520Roles%2520in%2520Multiple%2520Diseases%2520and%2520Therapeutic%2520Potential%2520for%2520Treatment%2520and%2520Diagnosis%26jtitle%3DAAPS%2520J.%26date%3D2018%26volume%3D20%26spage%3D12%26doi%3D10.1208%2Fs12248-017-0164-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigmond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borch, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3743</span>– <span class="NLM_lpage">3746</span>, <span class="refDoi"> DOI: 10.1021/jm070269u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070269u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2sXns1Ohtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3743-3746&author=W.+D.+Wuauthor=J.+Sigmondauthor=G.+J.+Petersauthor=R.+F.+Borch&title=Synthesis+and+Biological+Activity+of+a+Gemcitabine+Phosphoramidate+Prodrug&doi=10.1021%2Fjm070269u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug</span></div><div class="casAuthors">Wu, Weidong; Sigmond, Jennifer; Peters, Godefridus J.; Borch, Richard F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3743-3746</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A gemcitabine (2',2'-difluorodeoxycytidine, dFdC) phosphoramidate prodrug I designed for the intracellular delivery of gemcitabine 5'-monophosphate was synthesized.  The prodrug was about an order of magnitude less active than gemcitabine against wild-type cells, and the nucleoside transport inhibitor dipyridamole reduced prodrug activity.  The prodrug was more active than gemcitabine against two deoxycytidine kinase-deficient cell lines.  The results suggest that the prodrug is a potent growth inhibitor that can bypass dCK deficiency at higher drug concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2DxPbwnYvf7Vg90H21EOLACvtfcHk0ljICEmBlVl77A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXns1Ohtr8%253D&md5=2243c529dc58ed393e05afffec285aba</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm070269u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070269u%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DW.%2BD.%26aulast%3DSigmond%26aufirst%3DJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DBorch%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520and%2520Biological%2520Activity%2520of%2520a%2520Gemcitabine%2520Phosphoramidate%2520Prodrug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3743%26epage%3D3746%26doi%3D10.1021%2Fjm070269u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marina, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, C. R.</span></span> <span> </span><span class="NLM_article-title">Nucleoside Transport in Normal and Neoplastic Cells</span>. <i>Adv. Enzyme Regul.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1016/0065-2571(93)90021-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2F0065-2571%2893%2990021-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=8356910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVenu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1993&pages=235-252&author=J.+A.+Beltauthor=N.+M.+Marinaauthor=D.+A.+Phelpsauthor=C.+R.+Crawford&title=Nucleoside+Transport+in+Normal+and+Neoplastic+Cells&doi=10.1016%2F0065-2571%2893%2990021-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside transport in normal and neoplastic cells</span></div><div class="casAuthors">Belt, Judith A.; Marina, Neyssa M.; Phelps, Doris A.; Crawford, Charles R.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Enzyme Regulation</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">235-52</span>CODEN:
                <span class="NLM_cas:coden">AEZRA2</span>;
        ISSN:<span class="NLM_cas:issn">0065-2571</span>.
    </div><div class="casAbstract">The nucleoside transport properties of a series of human tumor cell lines and 2 normal tissues that are highly susceptible to toxicity from antimetabolites, intestine and bone marrow, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJfeTxPTIuFrVg90H21EOLACvtfcHk0ljICEmBlVl77A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVenu7g%253D&md5=db7f2e949cfb406a1e343bc867891125</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2F0065-2571%2893%2990021-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0065-2571%252893%252990021-5%26sid%3Dliteratum%253Aachs%26aulast%3DBelt%26aufirst%3DJ.%2BA.%26aulast%3DMarina%26aufirst%3DN.%2BM.%26aulast%3DPhelps%26aufirst%3DD.%2BA.%26aulast%3DCrawford%26aufirst%3DC.%2BR.%26atitle%3DNucleoside%2520Transport%2520in%2520Normal%2520and%2520Neoplastic%2520Cells%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D1993%26volume%3D33%26spage%3D235%26epage%3D252%26doi%3D10.1016%2F0065-2571%2893%2990021-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puris, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gynther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttunen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petsalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttunen, K. M.</span></span> <span> </span><span class="NLM_article-title">L-type Amino Acid Transporter 1 Utilizing Prodrugs: How to Achieve Effective Brain Delivery and Low Systemic Exposure of Drugs</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2017.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.jconrel.2017.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=28662899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyqu7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=2017&pages=93-104&author=E.+Purisauthor=M.+Gyntherauthor=J.+Huttunenauthor=A.+Petsaloauthor=K.+M.+Huttunen&title=L-type+Amino+Acid+Transporter+1+Utilizing+Prodrugs%3A+How+to+Achieve+Effective+Brain+Delivery+and+Low+Systemic+Exposure+of+Drugs&doi=10.1016%2Fj.jconrel.2017.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs</span></div><div class="casAuthors">Puris, Elena; Gynther, Mikko; Huttunen, Johanna; Petsalo, Aleksanteri; Huttunen, Kristiina M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-104</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">L-type amino acid transporter 1 (LAT1) is selectively expressed in the blood-brain barrier (BBB) and brain parenchyma.  This transporter can facilitate brain delivery of neuroprotective agents and addnl. give opportunity to minimize systemic exposure.  Here, we investigated structure-pharmacokinetics relationship of five newly synthesized LAT1-utilizing prodrugs of the cyclooxygenase inhibitor, ketoprofen, in order to identify beneficial structural features of prodrugs to achieve both targeted brain delivery and low peripheral distribution of the parent drug.  Besides, we studied whether pharmacokinetics and bioconversion of LAT1-utilizing prodrugs in vivo can be predicted in early stage expts.  To achieve these goals, we compared the in vitro brain uptake mechanism of prodrugs, rate of BBB permeation of compds. using in situ perfusion technique, their systemic pharmacokinetics and release of parent drug in brain, plasma and liver of mice.  The results revealed that both excellent LAT1-binding ability and transporter utilization in vitro can be achieved by conjugating the parent drug to arom. amino acids such as phenylalanine in comparison to prodrugs with an aliph. promoiety.  The presence of an arom. promoiety directly conjugated in meta- or para-position to ketoprofen led to LAT1-utilizing prodrugs capable of delivering the parent drug into the brain with higher unbound brain to plasma ratio and reduced liver exposure than with ketoprofen itself.  In contrast, the prodrugs with aliph. promoieties and with an addnl. carbon attached between the parent drug and phenylalanine arom. ring did not enhance brain delivery of ketoprofen.  Furthermore, we have devised a screening strategy to pinpoint successful candidates at an early stage of development of LAT1-utilizing prodrugs.  The screening approach demonstrated that early stage expts. could not replace pharmacokinetic studies in vivo due to the lack of prediction of the intra-brain/systemic distribution of the prodrugs as well as the release of the parent drug.  Overall, this study provides essential knowledge required for improvement of targeted brain delivery and redn. of systemic exposure of drugs via the LAT1-mediated prodrug approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2t3GV2SIBeLVg90H21EOLACvtfcHk0ljICEmBlVl77A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyqu7vE&md5=d13112945f2c974b4bd1b7976bb224c5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2017.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2017.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DPuris%26aufirst%3DE.%26aulast%3DGynther%26aufirst%3DM.%26aulast%3DHuttunen%26aufirst%3DJ.%26aulast%3DPetsalo%26aufirst%3DA.%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26atitle%3DL-type%2520Amino%2520Acid%2520Transporter%25201%2520Utilizing%2520Prodrugs%253A%2520How%2520to%2520Achieve%2520Effective%2520Brain%2520Delivery%2520and%2520Low%2520Systemic%2520Exposure%2520of%2520Drugs%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2017%26volume%3D261%26spage%3D93%26epage%3D104%26doi%3D10.1016%2Fj.jconrel.2017.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umapathy, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, M. E.</span></span> <span> </span><span class="NLM_article-title">Transport of Amino Acid Esters and the Amino-acid-based Prodrug Valganciclovir by the Amino Acid Transporter ATB<sup>0,+</sup></span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1309</span>, <span class="refDoi"> DOI: 10.1023/B:PHAM.0000033019.49737.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1023%2FB%3APHAM.0000033019.49737.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=15290873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltF2gsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2004&pages=1303-1309&author=N.+S.+Umapathyauthor=V.+Ganapathyauthor=M.+E.+Ganapathy&title=Transport+of+Amino+Acid+Esters+and+the+Amino-acid-based+Prodrug+Valganciclovir+by+the+Amino+Acid+Transporter+ATB0%2C%2B&doi=10.1023%2FB%3APHAM.0000033019.49737.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB0,+</span></div><div class="casAuthors">Umapathy, Nagavedi S.; Ganapathy, Vadivel; Ganapathy, Malliga E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1303-1310</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">The purpose of this study was to analyze the transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the Na+/Cl--coupled amino acid transporter ATB0,+.  The interaction of amino acid esters and valganciclovir with the cloned rat ATB0,+ was evaluated in a mammalian cell expression system and in the Xenopus oocyte expression system.  In mammalian cells, expression of ATB0,+ induced glycine uptake.  This uptake was inhibited by valine and its Me, Bu, and benzyl esters.  The benzyl esters of other neutral amino acids were also effective inhibitors.  Valganciclovir, the valyl ester of ganciclovir, was also found to inhibit ATB0,+-mediated glycine uptake competitively.  Exposure of ATB0,+-expressing oocytes to glycine induced inward currents.  Exposure to different valyl esters (Me, Bu, and benzyl), benzyl esters of various neutral amino acids, and valganciclovir also induced inward currents in these oocytes.  The current induced by valganciclovir was saturable with a K0.5 value of 3.1 ± 0.7 mM and was obligatorily dependent on Na+ and Cl-.  The Na+:Cl-:valganciclovir stoichiometry was 2 or 3:1:1.  Amino acid esters and the amino-acid-based prodrug valganciclovir are transported by ATB0,+.  This shows that ATB0,+ can serve as an effective delivery system for amino acid-based prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_TkiK_izZLVg90H21EOLACvtfcHk0ljRnKUuxLexnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltF2gsLY%253D&md5=b2bcad9cd893c29abea3674b775cdd40</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1023%2FB%3APHAM.0000033019.49737.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253APHAM.0000033019.49737.28%26sid%3Dliteratum%253Aachs%26aulast%3DUmapathy%26aufirst%3DN.%2BS.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DGanapathy%26aufirst%3DM.%2BE.%26atitle%3DTransport%2520of%2520Amino%2520Acid%2520Esters%2520and%2520the%2520Amino-acid-based%2520Prodrug%2520Valganciclovir%2520by%2520the%2520Amino%2520Acid%2520Transporter%2520ATB0%252C%252B%26jtitle%3DPharm.%2520Res.%26date%3D2004%26volume%3D21%26spage%3D1303%26epage%3D1309%26doi%3D10.1023%2FB%3APHAM.0000033019.49737.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause-Heuer, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbutcheon-Singh, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich-Wright, J. R.</span></span> <span> </span><span class="NLM_article-title">Advances in Platinum Chemotherapeutics</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">7064</span>– <span class="NLM_lpage">7077</span>, <span class="refDoi"> DOI: 10.1002/chem.201000148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1002%2Fchem.201000148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=20533453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVertL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=7064-7077&author=B.+W.+Harperauthor=A.+M.+Krause-Heuerauthor=M.+P.+Grantauthor=M.+Manoharauthor=K.+B.+Garbutcheon-Singhauthor=J.+R.+Aldrich-Wright&title=Advances+in+Platinum+Chemotherapeutics&doi=10.1002%2Fchem.201000148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in Platinum Chemotherapeutics</span></div><div class="casAuthors">Harper, Benjamin W.; Krause-Heuer, Anwen M.; Grant, Maxine P.; Manohar, Madhura; Garbutcheon-Singh, K. Benjamin; Aldrich-Wright, Janice R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7064-7077</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The approved platinum(II)-based anticancer agents cisplatin, carboplatin and oxaliplatin are widely utilized in the clinic, although with numerous disadvantages.  With the aim of circumventing unwanted side-effects, a great deal of research is being conducted in the areas of cancer-specific targeting, drug administration and drug delivery.  The targeting of platinum complexes to cancerous tissues can be achieved by the attachment of small mols. with biol. significance.  In addn., the administration of platinum complexes in the form of platinum(IV) allows for intracellular redn. to release the active form of the drug, cisplatin.  Drug delivery includes such technologies as liposomes, dendrimers, polymers and nanotubes, with all showing promise for the delivery of platinum compds.  In this paper we highlight some of the recent advances in the field of platinum chemotherapeutics, with a focus on the technologies that attempt to utilize the cytotoxic nature of cisplatin, while improving drug targeting to reduce side-effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPVBEEXG7P0rVg90H21EOLACvtfcHk0ljRnKUuxLexnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVertL4%253D&md5=857b4f5a7a2c8fb4d2370f2369a13a1b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fchem.201000148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201000148%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DB.%2BW.%26aulast%3DKrause-Heuer%26aufirst%3DA.%2BM.%26aulast%3DGrant%26aufirst%3DM.%2BP.%26aulast%3DManohar%26aufirst%3DM.%26aulast%3DGarbutcheon-Singh%26aufirst%3DK.%2BB.%26aulast%3DAldrich-Wright%26aufirst%3DJ.%2BR.%26atitle%3DAdvances%2520in%2520Platinum%2520Chemotherapeutics%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2010%26volume%3D16%26spage%3D7064%26epage%3D7077%26doi%3D10.1002%2Fchem.201000148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raja, M. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amjad, M. W.</span></span> <span> </span><span class="NLM_article-title">Design, Mechanism, Delivery and Therapeutics of Canonical and Dicer-substrate siRNA</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2018.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2018.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=32104477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BB387mslajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=497-510&author=M.+A.+G.+Rajaauthor=H.+Katasauthor=M.+W.+Amjad&title=Design%2C+Mechanism%2C+Delivery+and+Therapeutics+of+Canonical+and+Dicer-substrate+siRNA&doi=10.1016%2Fj.ajps.2018.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA</span></div><div class="casAuthors">Raja Maria Abdul Ghafoor; Amjad Muhammad Wahab; Katas Haliza</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">497-510</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Upon the discovery of RNA interference (RNAi), canonical small interfering RNA (siRNA) has been recognized to trigger sequence-specific gene silencing.  Despite the benefits of siRNAs as potential new drugs, there are obstacles still to be overcome, including off-target effects and immune stimulation.  More recently, Dicer substrate siRNA (DsiRNA) has been introduced as an alternative to siRNA.  Similarly, it also is proving to be potent and target-specific, while rendering less immune stimulation.  DsiRNA is 25-30 nucleotides in length, and is further cleaved and processed by the Dicer enzyme.  As with siRNA, it is crucial to design and develop a stable, safe, and efficient system for the delivery of DsiRNA into the cytoplasm of targeted cells.  Several polymeric nanoparticle systems have been well established to load DsiRNA for in vitro and in vivo delivery, thereby overcoming a major hurdle in the therapeutic uses of DsiRNA.  The present review focuses on a comparison of siRNA and DsiRNA on the basis of their design, mechanism, in vitro and in vivo delivery, and therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMYNpW7w2tapOfW6udTcc2eYW8h6Sssr0Xrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslajsg%253D%253D&md5=d951de0be884acf4022e6eb0ddbe289e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2018.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2018.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DRaja%26aufirst%3DM.%2BA.%2BG.%26aulast%3DKatas%26aufirst%3DH.%26aulast%3DAmjad%26aufirst%3DM.%2BW.%26atitle%3DDesign%252C%2520Mechanism%252C%2520Delivery%2520and%2520Therapeutics%2520of%2520Canonical%2520and%2520Dicer-substrate%2520siRNA%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D14%26spage%3D497%26epage%3D510%26doi%3D10.1016%2Fj.ajps.2018.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span> <span> </span><span class="NLM_article-title">Redox-sensitive Micelles for Targeted Intracellular Delivery and Combination Chemotherapy of Paclitaxel and All-trans-retinoid Acid</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2018.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2018.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=32104480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BB387mslajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=531-541&author=L.+F.+Hanauthor=L.+J.+Huauthor=F.+L.+Liuauthor=X.+Wangauthor=X.+X.+Huangauthor=B.+W.+Liuauthor=F.+Fengauthor=W.+Y.+Liuauthor=W.+Qu&title=Redox-sensitive+Micelles+for+Targeted+Intracellular+Delivery+and+Combination+Chemotherapy+of+Paclitaxel+and+All-trans-retinoid+Acid&doi=10.1016%2Fj.ajps.2018.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Redox-sensitive micelles for targeted intracellular delivery and combination chemotherapy of paclitaxel and all-trans-retinoid acid</span></div><div class="casAuthors">Han Lingfei; Wang Xin; Liu Wenyuan; Hu Lejian; Liu Fulei; Huang Xiaoxian; Liu Bowen; Feng Feng; Qu Wei; Feng Feng; Liu Wenyuan</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">531-542</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The application of paclitaxel (PTX) in clinic has been restricted due to its poor solubility.  Several traditional nano-medicines have been developed to improve this defect, while they are still lack of tumor targeting ability and rapid drug release.  In this work, an amphiphilic polymeric micelle of hyaluronic acid (HA) - all-trans-retinoid acid (ATRA) with a disulfide bond, was developed successfully for the co-delivery of PTX and ATRA.  The combination chemotherapy of PTX and ATRA can strengthen the anti-tumor activity.  Along with self-assembling to micelles in water, the delivery system displayed satisfying drug loading capacities for both PTX (32.62% ± 1.39%) and ATRA, due to directly using ATRA as the hydrophobic group.  Rapid drug release properties of the PTX-loaded redox-sensitive micelles (HA-SS-ATRA) in vitro were confirmed under reducing condition containing GSH.  Besides, HA-CD44 mediated endocytosis promoted the uptake of HA-SS-ATRA micelles by B16F10 cells.  Due to these properties, cytotoxicity assay verified that PTX-loaded HA-SS-ATRA micelles showed concentration-dependent cytotoxicity and displayed obvious combination therapy of PTX and ATRA.  Importantly, HA-SS-ATRA micelles could remarkably prolong plasma circulation time after intravenously administration.  Therefore, redox-sensitive HA-SS-ATRA micelles could be utilized and explored as a promising drug delivery system for cancer combination chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMYkFb3mqPUYDfW6udTcc2ebfYb3nYNYAybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslajsQ%253D%253D&md5=56bef06c399cec9bfe676fc752588bbe</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2018.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2018.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DL.%2BF.%26aulast%3DHu%26aufirst%3DL.%2BJ.%26aulast%3DLiu%26aufirst%3DF.%2BL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DX.%2BX.%26aulast%3DLiu%26aufirst%3DB.%2BW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%2BY.%26aulast%3DQu%26aufirst%3DW.%26atitle%3DRedox-sensitive%2520Micelles%2520for%2520Targeted%2520Intracellular%2520Delivery%2520and%2520Combination%2520Chemotherapy%2520of%2520Paclitaxel%2520and%2520All-trans-retinoid%2520Acid%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D14%26spage%3D531%26epage%3D541%26doi%3D10.1016%2Fj.ajps.2018.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saneja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P. N.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Drug Delivery Strategies for Improved Therapeutic Efficacy of Gemcitabine</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2016.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ejps.2016.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=27531553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaktbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2016&pages=147-162&author=R.+D.+Dubeyauthor=A.+Sanejaauthor=P.+K.+Guptaauthor=P.+N.+Gupta&title=Recent+Advances+in+Drug+Delivery+Strategies+for+Improved+Therapeutic+Efficacy+of+Gemcitabine&doi=10.1016%2Fj.ejps.2016.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine</span></div><div class="casAuthors">Dubey, Ravindra Dhar; Saneja, Ankit; Gupta, Prasoon K.; Gupta, Prem N.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147-162</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gemcitabine (2',2'-difluoro-2'-deoxycytidine; dFdC) is an efficacious anticancer agent acting against a wide range of solid tumors, including pancreatic, non-small cell lung, bladder, breast, ovarian, thyroid and multiple myelomas.  However, short plasma half-life due to metab. by cytidine deaminase necessitates administration of high dose, which limits its medical applicability.  Further, due to its hydrophilic nature, it cannot traverse cell membranes by passive diffusion and, therefore, enters via nucleoside transporters that may lead to drug resistance.  To circumvent these limitations, macromol. prodrugs and nanocarrier-based formulations of Gemcitabine are gaining wide recognition.  The nanoformulations based approaches by virtue of their controlled release and targeted delivery have proved to improve bioavailability, increase therapeutic efficacy and reduce adverse effects of the drug.  Furthermore, the combination of Gemcitabine with other anticancer agents as well as siRNAs using nanocarriers has also been investigated in order to enhance its therapeutic potential.  This review deals with challenges and recent advances in the delivery of Gemcitabine with particular emphasis on macromol. prodrugs and nanomedicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfTB07iNJNgbVg90H21EOLACvtfcHk0lhLRvGeTWyHmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaktbbN&md5=7b1827c3f1391e9dbeb9f90d91411a27</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2016.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2016.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DDubey%26aufirst%3DR.%2BD.%26aulast%3DSaneja%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DP.%2BK.%26aulast%3DGupta%26aufirst%3DP.%2BN.%26atitle%3DRecent%2520Advances%2520in%2520Drug%2520Delivery%2520Strategies%2520for%2520Improved%2520Therapeutic%2520Efficacy%2520of%2520Gemcitabine%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D93%26spage%3D147%26epage%3D162%26doi%3D10.1016%2Fj.ejps.2016.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Lou</span>, <span class="hlFld-ContribAuthor ">Zijian  Lou</span>, <span class="hlFld-ContribAuthor ">Yuanzhen  Lin</span>, <span class="hlFld-ContribAuthor ">Hao  Shangguan</span>, <span class="hlFld-ContribAuthor ">Yujie  Lin</span>, <span class="hlFld-ContribAuthor ">Qiuhua  Luo</span>, <span class="hlFld-ContribAuthor ">Hailin  Zhang</span>, <span class="hlFld-ContribAuthor ">Guangyong  Lin</span>, <span class="hlFld-ContribAuthor ">Ruijie  Chen</span>, <span class="hlFld-ContribAuthor ">Longfa  Kou</span>, <span class="hlFld-ContribAuthor ">Shihui  Bao</span>. </span><span class="cited-content_cbyCitation_article-title">ATB0,+-targeted delivery of triptolide prodrugs for safer and more effective pancreatic cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>33 </em>, 127728. <a href="https://doi.org/10.1016/j.bmcl.2020.127728" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127728%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DATB0%25252C%25252B-targeted%252Bdelivery%252Bof%252Btriptolide%252Bprodrugs%252Bfor%252Bsafer%252Band%252Bmore%252Beffective%252Bpancreatic%252Bcancer%252Btherapy%26aulast%3DLou%26aufirst%3DDan%26date%3D2021%26volume%3D33%26spage%3D127728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Synthesis of <span class="smallcaps smallerCapital">l</span>-valine α-ester prodrugs of FUdR. (b) Synthesis of <span class="smallcaps smallerCapital">l</span>-aspartic acid β-ester or <span class="smallcaps smallerCapital">l</span>-glutamic acid γ-ester prodrugs of FUdR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibition of uptake of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (all 0.5 mM, pH 6.0) by <i>X. laevis</i> oocytes-ATB<sup>0,+</sup> was assessed in the presence of glycine (10 mM): *<i>P</i> < 0.05, significantly different from the absence of glycine. Data are presented as the mean ± SD, <i>n</i> = 4–5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Concentration-dependent uptake of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR in <i>X. laevis</i> oocytes-ATB<sup>0,+</sup> cells. <i>V</i> is the uptake rate (picomoles per milligram of protein per minute), and <i>S</i> is the prodrug concentration (micromolar).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Na<sup>+</sup> and Cl<sup>–</sup> activation kinetics for ATB<sup>0,+</sup>-mediated transport of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, and 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (all 1 mM) in the <i>X. laevis</i> oocytes-ATB<sup>0,+</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode with the chimera ATB<sup>0,+</sup> (with PDB entries <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4M48">4M48</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O8O">3O8O</a> as the template): (A) 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR; (B) 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR; (C) 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Thymidine phosphorylase activity against 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (A) and FUdR (B). 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (A) and FUdR (B) were incubated with a solution of thymidine phosphorylase (2 ng/mL) in phosphate buffer (pH 6.4) at 37 °C, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <i>In vivo</i> antitumor efficacy of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR and FUdR in tumor-bearing nude mice: (a) ZR-75–1; (b) PaCa-2; (c) MB-231. The control groups were free to the sucrose–water for drinking, and the treatment group was injected with FUdR or 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (90 mg/kg calculated as FUdR) for 20 successive days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/medium/jm0c00149_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Mean (±SD) plasma concentration–time profiles of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, FUdR and 5-FU in nude mouse xenograft model established with ZR-75-1 cells after 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (90 mg/kg calculated as FUdR) was intravenously injected. <i>n</i> = 5–6 at every time point: ◇, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR; ■, FUdR; ▲, 5-FU. (B) Mean (±SD) plasma concentration–time profiles of FUdR and 5-FU in nude mouse xenograft model established with ZR-75-1 cells after FUdR (90 mg/kg) was intravenously injected. <i>n</i> = 5–6 at every time point: ◇, FUdR; ■, 5-FU. (C) Mean (±SD) tumor concentration–time profiles of FUdR in nude mouse xenograft model established with ZR-75-1 cells after FUdR (90 mg/kg) and 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR (90 mg/kg calculated as FUdR) were injected to the mice, respectively. <i>n</i> = 5–6 at every time point: ◇, dosing of 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR; ■, dosing of FUdR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00149/20201001/images/large/jm0c00149_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00149&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 39 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparreboom, A.</span></span> <span> </span><span class="NLM_article-title">Role of Equilibrative Nucleoside Transporter 1 (ENT1) in the Disposition of Cytarabine in Mice</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e00534</span> <span class="refDoi"> DOI: 10.1002/prp2.534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1002%2Fprp2.534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=31832201" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&author=J.+T.+Andersonauthor=S.+Y.+Huauthor=Q.+Fuauthor=S.+D.+Bakerauthor=A.+Sparreboom&title=Role+of+Equilibrative+Nucleoside+Transporter+1+%28ENT1%29+in+the+Disposition+of+Cytarabine+in+Mice&doi=10.1002%2Fprp2.534"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fprp2.534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.534%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DJ.%2BT.%26aulast%3DHu%26aufirst%3DS.%2BY.%26aulast%3DFu%26aufirst%3DQ.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DSparreboom%26aufirst%3DA.%26atitle%3DRole%2520of%2520Equilibrative%2520Nucleoside%2520Transporter%25201%2520%2528ENT1%2529%2520in%2520the%2520Disposition%2520of%2520Cytarabine%2520in%2520Mice%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2019%26volume%3D7%26doi%3D10.1002%2Fprp2.534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Cancer Nanotechnology: Enhancing Tumor Cell Response to Chemotherapy for Hepatocellular Carcinoma Therapy</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2019.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2019.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=32104485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BB387mslajug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=581-594&author=Y.+B.+Sunauthor=W.+Maauthor=Y.+Y.+Yangauthor=M.+X.+Heauthor=A.+M.+Liauthor=L.+Baiauthor=B.+Yuauthor=Z.+Q.+Yu&title=Cancer+Nanotechnology%3A+Enhancing+Tumor+Cell+Response+to+Chemotherapy+for+Hepatocellular+Carcinoma+Therapy&doi=10.1016%2Fj.ajps.2019.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy</span></div><div class="casAuthors">Sun Yongbing; Ma Wen; Yang Yuanyuan; Yu Zhiqiang; He Mengxue; Li Aimin; Bai Lei; Yu Bin</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">581-594</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity.  In addition to sorafenib and lenvatinib for the treatment of HCC approved by FDA, various strategies including transarterial chemoembolization, radiotherapy, locoregional therapy and chemotherapy have been investigated in clinics.  Recently, cancer nanotechnology has got great attention for the treatment of various cancers including HCC.  Both passive and active targetings are progressing at a steady rate.  Herein, we describe the lessons learned from pathogenesis of HCC and the understanding of targeted and non-targeted nanoparticles used for the delivery of small molecules, monoclonal antibodies, miRNAs and peptides.  Exploring current efficacy is to enhance tumor cell response of chemotherapy.  It highlights the opportunities and challenges faced by nanotechnologies in contemporary hepatocellular carcinoma therapy, where personalized medicine is increasingly becoming the mainstay.  Overall objective of this review is to enhance our understanding in the design and development of nanotechnology for treatment of HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMcAKB7Fa-xrUfW6udTcc2eYZQ1vTOx7qgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslajug%253D%253D&md5=227a8b50f76971580bf9cea0798b72d6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2019.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2019.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%2BB.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%2BY.%26aulast%3DHe%26aufirst%3DM.%2BX.%26aulast%3DLi%26aufirst%3DA.%2BM.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DZ.%2BQ.%26atitle%3DCancer%2520Nanotechnology%253A%2520Enhancing%2520Tumor%2520Cell%2520Response%2520to%2520Chemotherapy%2520for%2520Hepatocellular%2520Carcinoma%2520Therapy%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D14%26spage%3D581%26epage%3D594%26doi%3D10.1016%2Fj.ajps.2019.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maag, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfredson, T.</span></span> <span> </span><span class="NLM_article-title">Prodrugs of Nucleoside Analogues for Improved Oral Absorption and Tissue Targeting</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1002/jps.21047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1002%2Fjps.21047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=17696166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FovVCgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2008&pages=1109-1133&author=F.+J.+Liauthor=H.+Maagauthor=T.+Alfredson&title=Prodrugs+of+Nucleoside+Analogues+for+Improved+Oral+Absorption+and+Tissue+Targeting&doi=10.1002%2Fjps.21047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting</span></div><div class="casAuthors">Li Fujun; Maag Hans; Alfredson Tom</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1109-34</span>
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    </div><div class="casAbstract">Nucleoside analogues are widely used for the treatment of antiviral infections and anticancer chemotherapy.  However, many nucleoside analogues suffer from poor oral bioavailability due to their high polarity and low intestinal permeability.  In order to improve oral absorption of these polar drugs, prodrugs have been employed to increase lipophilicity by chemical modification of the parent.  Alternatively, prodrugs targeting transporters present in the intestine have been exploited to facilitate the transport of the nucleoside analogues.  Valacyclovir and valganciclovir are two successful valine ester prodrugs transported by the PepT1 transporter.  Recently, research efforts have focused on design of prodrugs for tissue specific delivery to improve efficacy and safety.  This review presents advances of prodrug approaches for improved oral absorption of nucleoside analogues and recent developments in tissue targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-KOBK65zide2qxNLjzXe8fW6udTcc2eYZQ1vTOx7qgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FovVCgtQ%253D%253D&md5=ed6aeaf75134be8bc9ef23a89b673b80</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fjps.21047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21047%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%2BJ.%26aulast%3DMaag%26aufirst%3DH.%26aulast%3DAlfredson%26aufirst%3DT.%26atitle%3DProdrugs%2520of%2520Nucleoside%2520Analogues%2520for%2520Improved%2520Oral%2520Absorption%2520and%2520Tissue%2520Targeting%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D97%26spage%3D1109%26epage%3D1133%26doi%3D10.1002%2Fjps.21047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinko, P. J.</span></span> <span> </span><span class="NLM_article-title">Involvement of Multiple Transporters in the Oral Absorption of Nucleoside Analogues</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(99)00026-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2FS0169-409X%2899%2900026-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10837774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVOqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1999&pages=183-209&author=P.+V.+Balimaneauthor=P.+J.+Sinko&title=Involvement+of+Multiple+Transporters+in+the+Oral+Absorption+of+Nucleoside+Analogues&doi=10.1016%2FS0169-409X%2899%2900026-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of multiple transporters in the oral absorption of nucleoside analogues</span></div><div class="casAuthors">Balimane, P. V.; Sinko, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">183-209</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 95 refs.  Many nucleoside analogs such as azt, ddI, ddC, d4T, 3TC, acv and vacv are currently being used in the treatment of patients infected with HIV, suffering from AIDS, or AIDS-related opportunistic infections.  The transport of nucleoside analogs across the gastrointestinal tract is mediated by a no. of transporters that fall into three broad categories, i.e., Na+-dependent concentrative transporters, Na+-independent equilibrative transporters and H+/peptide transporters.  The first two transporter classes contain a large no. of subtypes that are based on the substrate specificity.  Recent studies have shown that most of the anti-HIV nucleoside analogs are transported by one or more of the nucleoside transporters.  Furthermore, certain analogs, such as acv, appear to be absorbed by non-carrier-mediated diffusion, whereas vacv is apparently transported by non-nucleoside transporters (e.g., the oligopeptide transporter, PepT1 and possibly others).  Thus, it is desirable to understand the precise nature of the absorption mechanism of these drugs to improve bioavailability and reduce the variability that is commonly obsd. in vivo in human patients.  A complete understanding of the complex interactions of nucleoside analogs with the various transporters will help in designing better delivery systems and strategies to improve efficacy.  In the current report, the mechanisms of nucleoside and nucleoside-analog transport are reviewed.  Also, methods of exploiting prodrugs to improve the bioavailability characteristics of drugs are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQd-dHCCUUvbVg90H21EOLACvtfcHk0liK0E8rjlwL8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVOqs74%253D&md5=c7849ac966da4e7445dec8fe36f0bded</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2899%2900026-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252899%252900026-5%26sid%3Dliteratum%253Aachs%26aulast%3DBalimane%26aufirst%3DP.%2BV.%26aulast%3DSinko%26aufirst%3DP.%2BJ.%26atitle%3DInvolvement%2520of%2520Multiple%2520Transporters%2520in%2520the%2520Oral%2520Absorption%2520of%2520Nucleoside%2520Analogues%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1999%26volume%3D39%26spage%3D183%26epage%3D209%26doi%3D10.1016%2FS0169-409X%2899%2900026-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Laar, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustum, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackland, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Groeningen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span> <span> </span><span class="NLM_article-title">Comparison of 5-Fluoro-2′-deoxyuridine with 5-Fluorouracil and Their Role in the Treatment of Colorectal Cancer</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(97)00366-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2FS0959-8049%2897%2900366-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=9640213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADyaK1cXivVSjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1998&pages=296-306&author=J.+A.+Van%0ALaarauthor=Y.+M.+Rustumauthor=S.+P.+Acklandauthor=C.+J.+Van+Groeningenauthor=G.+J.+Peters&title=Comparison+of+5-Fluoro-2%E2%80%B2-deoxyuridine+with+5-Fluorouracil+and+Their+Role+in+the+Treatment+of+Colorectal+Cancer&doi=10.1016%2FS0959-8049%2897%2900366-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer</span></div><div class="casAuthors">Van Laar, J. A. M.; Rustum, Y. M.; Ackland, S. P.; Van Groeningen, C. J.; Peters, G. J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">296-306</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Despite >30 yr of intensive studies on new drugs against advanced colorectal cancer, the fluoropyrimidines remain the drugs of choice for systemic treatment and for hepatic artery infusion (HAI).  This review, with 127 refs., describes new developments in advanced colorectal cancer chemotherapy, providing a rationale for more effective use of the fluoropyrimidines, with biochem. modulation, scheduling or by revealing biochem. mechanisms of action that correlate with antitumor activity.  In human colorectal cancer cell lines and various animal tumor model systems 5-fluoro-2'-deoxyuridine (FdUrd) is more effective than 5-fluorouracil (5-FU).  Comparably, FdUrd's modulation by leucovorin (LV) is more potent than 5-FU.  In animal studies intermittent high-bolus administration of FdUrd generates better antitumor activity, compared with equal toxic doses or any other schedule of 5-FU.  These effects are related to prolonged thymidylate synthase (TS) inhibition and the prevention of TS induction, rather than RNA incorporation.  Preclin. studies with modulators such as N-phosphonacetyl-L-aspartate (PALA), WR-2721, mitomycin C and Pt derivs. provide a rationale for clin. use in the future.  The 1st choice systemic chemotherapy of patients with advanced colorectal cancer remains 5-FU combined with LV.  Some improvement in therapeutic efficacy was achieved with locoregional HAI.  In randomized studies HAI FdUrd improves the quality of life and survival as compared with optimal systemic therapy.  Chronomodulation decreases toxicity, allowing dose intensification, while modulators such as LV or dexamethasone increase survival of patients treated with HAI FdUrd to 86% after 1 yr.  In conclusion, the clin. use of FdUrd was not fully explored.  Intermittent high-dose FdUrd, chronomodulation together using modulators or drugs focused on prolonged TS inhibition, should be studied in large randomized studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWL9P0hgeb1rVg90H21EOLACvtfcHk0liK0E8rjlwL8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivVSjur4%253D&md5=3c98629cf55c2f2c1f9802524844a087</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2897%2900366-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252897%252900366-3%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BLaar%26aufirst%3DJ.%2BA.%26aulast%3DRustum%26aufirst%3DY.%2BM.%26aulast%3DAckland%26aufirst%3DS.%2BP.%26aulast%3DVan%2BGroeningen%26aufirst%3DC.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26atitle%3DComparison%2520of%25205-Fluoro-2%25E2%2580%25B2-deoxyuridine%2520with%25205-Fluorouracil%2520and%2520Their%2520Role%2520in%2520the%2520Treatment%2520of%2520Colorectal%2520Cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1998%26volume%3D34%26spage%3D296%26epage%3D306%26doi%3D10.1016%2FS0959-8049%2897%2900366-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2′-Deoxyuridine for the Treatment of Hepatocellular Carcinoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3661</span>– <span class="NLM_lpage">3670</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC28XltFGhsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3661-3670&author=Y.+M.+Pengauthor=W.+Q.+Yuauthor=E.+T.+Liauthor=J.+F.+Kangauthor=Y.+F.+Wangauthor=Q.+H.+Yangauthor=B.+J.+Liuauthor=J.+M.+Zhangauthor=L.+Y.+Liauthor=J.+Wuauthor=J.+H.+Jiangauthor=Q.+D.+Wangauthor=J.+B.+Chang&title=Discovery+of+an+Orally+Active+and+Liver-Targeted+Prodrug+of+5-Fluoro-2%E2%80%B2-Deoxyuridine+for+the+Treatment+of+Hepatocellular+Carcinoma&doi=10.1021%2Facs.jmedchem.5b01807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma</span></div><div class="casAuthors">Peng, Youmei; Yu, Wenquan; Li, Ertong; Kang, Jinfeng; Wang, Yafeng; Yang, Qinghua; Liu, Bingjie; Zhang, Jingmin; Li, Longyu; Wu, Jie; Jiang, Jinhua; Wang, Qingduan; Chang, Junbiao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3661-3670</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report a series of novel O-(substituted benzyl) phosphoramidate prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of hepatocellular carcinoma.  Through structure optimization, the o-methylbenzyl analog ((S1)-iso-Pr 2-(((R)-(((2R,3S,5R)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)((2-methylbenzyl)oxy)phosphoryl)amino)propanoate (1t)) was identified as an orally bioavailable and liver-targeted lead compd.  This lead prodrug is well-tolerated at a dose up to 3 g/kg in Kuming mice via oral administration.  An efficacy study demonstrated that it possesses good inhibitory effect (61.67% and 72.50%, resp.) on tumor growth in a mouse xenograft model.  A metab. study in Sprague-Dawley rats suggested that (1t) can release the desired 5'-monophosphate in the liver with high liver-targeting index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohEoKlAna4cbVg90H21EOLACvtfcHk0liK0E8rjlwL8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltFGhsrg%253D&md5=5283aab20c58ab80d4795d3b47bdf932</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01807%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%2BM.%26aulast%3DYu%26aufirst%3DW.%2BQ.%26aulast%3DLi%26aufirst%3DE.%2BT.%26aulast%3DKang%26aufirst%3DJ.%2BF.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DYang%26aufirst%3DQ.%2BH.%26aulast%3DLiu%26aufirst%3DB.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DQ.%2BD.%26aulast%3DChang%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520an%2520Orally%2520Active%2520and%2520Liver-Targeted%2520Prodrug%2520of%25205-Fluoro-2%25E2%2580%25B2-Deoxyuridine%2520for%2520the%2520Treatment%2520of%2520Hepatocellular%2520Carcinoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3661%26epage%3D3670%26doi%3D10.1021%2Facs.jmedchem.5b01807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vivian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and In Vitro Evaluation of Bile Acid Prodrugs of Floxuridine to Target the Liver</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>475</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2014.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ijpharm.2014.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=25219859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCns7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=475&publication_year=2014&pages=597-604&author=D.+Vivianauthor=J.+E.+Polli&title=Synthesis+and+In+Vitro+Evaluation+of+Bile+Acid+Prodrugs+of+Floxuridine+to+Target+the+Liver&doi=10.1016%2Fj.ijpharm.2014.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver</span></div><div class="casAuthors">Vivian, Diana; Polli, James E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">475</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">597-604</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Floxuridine is often used to treat metastatic liver disease and is given as an infusion directly into the hepatic artery to increase the amt. of intact drug that reaches the liver.  The objective of this work was to design and synthesize prodrugs of floxuridine through conjugation to chenodeoxycholic acid (CDCA) to target the liver via the bile acid liver uptake transporter Na+/taurocholate cotransporting polypeptide (NTCP, SLC10A1).  Two isomeric prodrugs of floxuridine were synthesized: floxuridine 3'glutamic acid-CDCA and floxuridine 5'-glutamic acid-CDCA.  Both were potent inhibitors and substrates of NTCP.  Floxuridine 3'glutamic acid-CDCA showed Ki = 6.86 ± 1.37 μM, Km = 10.7 ± 2.1 μM, and passive permeability = 0.663 (±0.121) × 10-7 cm/s while floxuridine 5'-glutamic acid-CDCA showed Ki = 0.397 ± 0.038 μM, Km = 40.4 ± 15.2 μM, and passive permeability = 1.72 (±0.18) × 10-7 cm/s.  Floxuridine itself had a higher passively permeability of 7.54 (±0.45) × 10-7 cm/s in the same cell line, indicating that both prodrugs have the potential for lower non-specific effects than the drug alone.  Prodrugs were stable in rat plasma (t = 3 h), but quickly released in rat liver s9 fraction, suggesting future in vivo evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaO6MXv0q7rbVg90H21EOLACvtfcHk0ljAn-MMZjjo6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCns7nK&md5=ed3310df016d70fda2ccd839797e6a24</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2014.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2014.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DVivian%26aufirst%3DD.%26aulast%3DPolli%26aufirst%3DJ.%2BE.%26atitle%3DSynthesis%2520and%2520In%2520Vitro%2520Evaluation%2520of%2520Bile%2520Acid%2520Prodrugs%2520of%2520Floxuridine%2520to%2520Target%2520the%2520Liver%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2014%26volume%3D475%26spage%3D597%26epage%3D604%26doi%3D10.1016%2Fj.ijpharm.2014.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Landowski, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vig, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. L.</span></span> <span> </span><span class="NLM_article-title">Targeted Delivery to PEPT1-overexpressing Cells: Acidic, Basic, and Secondary Floxuridine Amino Acid Ester Prodrugs</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-04-0290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1158%2F1535-7163.MCT-04-0290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=15827340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFegsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=659-667&author=C.+P.+Landowskiauthor=B.+S.+Vigauthor=X.+Q.+Songauthor=G.+L.+Amidon&title=Targeted+Delivery+to+PEPT1-overexpressing+Cells%3A+Acidic%2C+Basic%2C+and+Secondary+Floxuridine+Amino+Acid+Ester+Prodrugs&doi=10.1158%2F1535-7163.MCT-04-0290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs</span></div><div class="casAuthors">Landowski, Christopher P.; Vig, Balvinder S.; Song, Xueqin; Amidon, Gordon L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">659-667</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Floxuridine is a clin. proven anticancer agent in the treatment of metastatic colon carcinomas and hepatic metastases.  However, prodrug strategies may be necessary to improve its physiochem. properties and selectivity and to reduce undesirable toxicity effects.  Previous studies with amino acid ester prodrugs of nucleoside drugs targeted to the PEPT1 transporter coupled with recent findings of the functional expression of the PEPT1 oligopeptide transporter in pancreatic adenocarcinoma cell lines suggest the potential of PEPT1 as therapeutic targets for cancer treatment.  In this report, we show the feasibility of achieving enhanced transport and selective antiproliferative action of amino acid ester prodrugs of floxuridine in cell systems overexpressing PEPT1.  All prodrugs exhibited affinity for PEPT1 (IC50, 1.1-2.3 mmol/L).  However, only the prolyl and lysyl prodrugs exhibited enhanced uptake (2- to 8-fold) with HeLa/PEPT1 cells compared with HeLa cells, suggesting that the aspartyl prodrugs are PEPT1 inhibitors.  The selective growth inhibition of Madine-Darby canine kidney (MDCK)/PEPT1 cells over MDCK cells by the prodrugs was consistent with the extent of their PEPT1-mediated transport.  All ester prodrugs hydrolyzed to floxuridine fastest in Caco-2 cell and MDCK homogenates and slower in human plasma and were most chem. stable in pH 6.0 buffer.  Prolyl and lysyl prodrugs were relatively less stable compared with aspartyl prodrugs in buffers and in cell homogenates.  The results suggest that optimal design for targeted delivery would be possible by combining both stability and transport characteristics afforded by the promoiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDZQyYebUSk7Vg90H21EOLACvtfcHk0ljAn-MMZjjo6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFegsLk%253D&md5=8cce73d384941f9bdb547a635b4dd146</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-04-0290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-04-0290%26sid%3Dliteratum%253Aachs%26aulast%3DLandowski%26aufirst%3DC.%2BP.%26aulast%3DVig%26aufirst%3DB.%2BS.%26aulast%3DSong%26aufirst%3DX.%2BQ.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DTargeted%2520Delivery%2520to%2520PEPT1-overexpressing%2520Cells%253A%2520Acidic%252C%2520Basic%252C%2520and%2520Secondary%2520Floxuridine%2520Amino%2520Acid%2520Ester%2520Prodrugs%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26spage%3D659%26epage%3D667%26doi%3D10.1158%2F1535-7163.MCT-04-0290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsume, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfinger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. L.</span></span> <span> </span><span class="NLM_article-title">Enhanced Cancer Cell Growth Inhibition by Dipeptide Prodrugs of Floxuridine: Increased Transporter Affinity and Metabolic Stability</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1021/mp800008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp800008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFSkurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=717-727&author=Y.+Tsumeauthor=J.+M.+Hilfingerauthor=G.+L.+Amidon&title=Enhanced+Cancer+Cell+Growth+Inhibition+by+Dipeptide+Prodrugs+of+Floxuridine%3A+Increased+Transporter+Affinity+and+Metabolic+Stability&doi=10.1021%2Fmp800008c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Cancer Cell Growth Inhibition by Dipeptide Prodrugs of Floxuridine: Increased Transporter Affinity and Metabolic Stability</span></div><div class="casAuthors">Tsume, Yasuhiro; Hilfinger, John M.; Amidon, Gordon L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">717-727</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dipeptide monoester prodrugs of floxuridine were synthesized, and their chem. stability in buffers, resistance to glycosidic bond metab., affinity for PEPT1, enzymic activation and permeability in cancer cells were detd. and compared to those of mono amino acid monoester floxuridine prodrugs.  Prodrugs contg. glycyl moieties were the least stable in pH 7.4 buffer (t1/2 < 100 min).  The activation of all floxuridine prodrugs was 2- to 30-fold faster in cell homogenates than their hydrolysis in buffer, suggesting enzymic action.  The enzymic activation of dipeptide monoester prodrugs contg. arom. promoieties in cell homogenates was 5- to 20-fold slower than that of other dipeptide and most mono amino acid monoester prodrugs (t1/2 ∼ 40 to 100 min).  All prodrugs exhibited enhanced resistance to glycosidic bond metab. by thymidine phosphorylase compared to parent floxuridine.  In general, the 5'-O-dipeptide monoester floxuridine prodrugs exhibited higher affinity for PEPT1 than the corresponding 5'-O-mono amino acid ester prodrugs.  The permeability of dipeptide monoester prodrugs across Caco-2 and Capan-2 monolayers was 2- to 4-fold higher than the corresponding mono amino acid ester prodrug.  Cell proliferation assays in AsPC-1 and Capan-2 pancreatic ductal cell lines indicated that the dipeptide monoester prodrugs were equally as potent as mono amino acid prodrugs.  The transport and enzymic profiles of 5'-L-phenylalanyl-L-tyrosyl-floxuridine, 5'-L-phenylalanyl-L-glycyl-floxuridine, and 5'-L-isoleucyl-L-glycyl-floxuridine suggest their potential for increased oral uptake, delayed enzymic bioconversion and enhanced resistance to metab. to 5-fluorouracil, as well as enhanced uptake and cytotoxic activity in cancer cells, attributes that would facilitate prolonged systemic circulation for enhanced therapeutic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqALEnhYGvnZrVg90H21EOLACvtfcHk0ljAn-MMZjjo6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFSkurc%253D&md5=9646d4140b600e263fb95a76152e5631</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fmp800008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp800008c%26sid%3Dliteratum%253Aachs%26aulast%3DTsume%26aufirst%3DY.%26aulast%3DHilfinger%26aufirst%3DJ.%2BM.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DEnhanced%2520Cancer%2520Cell%2520Growth%2520Inhibition%2520by%2520Dipeptide%2520Prodrugs%2520of%2520Floxuridine%253A%2520Increased%2520Transporter%2520Affinity%2520and%2520Metabolic%2520Stability%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2008%26volume%3D5%26spage%3D717%26epage%3D727%26doi%3D10.1021%2Fmp800008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span> <span> </span><span class="NLM_article-title">PEPT1-mediated Prodrug Strategy for Oral Delivery of Peramivir</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2018.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2018.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=32104429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BB387mslWmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=555-565&author=Y.+B.+Sunauthor=W.+Ganauthor=M.+D.+Leiauthor=W.+Jiangauthor=M.+Chengauthor=J.+W.+Heauthor=Q.+Sunauthor=W.+Liuauthor=L.+J.+Huauthor=Y.+Jin&title=PEPT1-mediated+Prodrug+Strategy+for+Oral+Delivery+of+Peramivir&doi=10.1016%2Fj.ajps.2018.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">PEPT1-mediated prodrug strategy for oral delivery of peramivir</span></div><div class="casAuthors">Sun Yongbing; Gan Wei; Cheng Meng; Sun Qi; Liu Wan; Jin Yi; Lei Mingdao; Jiang Wei; He Junwei; Hu Lvjiang</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">555-565</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Peramivir was a novel and highly potent neuraminidase (NA) inhibitor for the treatment of influenza A and B.  However, it exhibited a very low oral bioavailability (only 3%) due to the high polarity (log P of -1.4) and the low membrane permeability across the intestine.  To utilize the PEPT1-mediated prodrug strategy to improve the oral absorption and develop the oral alternative, seven amino acid ester prodrugs and seven amino acid amide prodrugs have been synthesized.  The permeability of these prodrugs across Caco-2 cells were screened.  Peramivr-(CH2)2-l-Val and Peramivir-l-Ile were of the highest permeability in ester prodrugs and amide prodrugs, respectively, and then they were selected for further studies.  Glycylsarcosine (gly-sar) uptake by Caco-2 could be inbihited by Peramivir-(CH2)2-l-Val and Peramivir-l-Ile in a concentration-dependent manner, and the IC50 was 1.34 ± 0.31 mM and 1.78 ± 0.48 mM, respectively.  The direct uptake of Peramivir-(CH2)2-l-Val and Peramivir-l-Ile in MDCK-PEPT1 cells were significantly higher than in MDCK mock cells, and could be markedly inhibited by gly-sar.  The uptake of Peramivir-(CH2)2-l-Val and Peramivir-l-Ile (0.01 to 50 mM) in MDCK-hPEPT1 cells conformed to Michaelis-Menten Equation.  The oral bioavailability of peramivir was 65.3% and 37.3% after the oral administration of Peramivir-(CH2)2-l-Val and Peramivir-l-Ile to rats, respectively.  The oral absorption and bioactivation of Peramivir-(CH2)2-l-Val was rapid and extensive, and no Peramivir-(CH2)2-l-Val was found in plasma.  Because the amide bond was relatively stable, Peramivir-l-Ile could not be totally converted to the parent drug in vivo.  Peramivir-(CH2)2-l-Val with good oral profiles and rapid bioactivation might be a promising prodrug for the further clinic development.  The present study also corroborated the idea that the PEPT1-mediated prodrug approach has enormous promise for improving the oral absorption of poorly absorbed drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMUodMGTatQ7LfW6udTcc2eZVggQHvc8HWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslWmsA%253D%253D&md5=a932fa9988b1aec5f1c70e8b715e112a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2018.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2018.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%2BB.%26aulast%3DGan%26aufirst%3DW.%26aulast%3DLei%26aufirst%3DM.%2BD.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%2BW.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DL.%2BJ.%26aulast%3DJin%26aufirst%3DY.%26atitle%3DPEPT1-mediated%2520Prodrug%2520Strategy%2520for%2520Oral%2520Delivery%2520of%2520Peramivir%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2018%26volume%3D13%26spage%3D555%26epage%3D565%26doi%3D10.1016%2Fj.ajps.2018.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Voorde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liekens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murziani, P. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">The Cytostatic Activity of NUC-3073, a Phosphoramidate Prodrug of 5-Fluoro-2′-deoxyuridine, Is Independent of Activation by Thymidine Kinase and Insensitive to Degradation by Phosphorolytic Enzymes</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2011.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.bcp.2011.05.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=21658373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1ehsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=441-452&author=J.+Vande%0AVoordeauthor=S.+Liekensauthor=C.+McGuiganauthor=P.+G.+S.+Murzianiauthor=M.+Slusarczykauthor=J.+Balzarini&title=The+Cytostatic+Activity+of+NUC-3073%2C+a+Phosphoramidate+Prodrug+of+5-Fluoro-2%E2%80%B2-deoxyuridine%2C+Is+Independent+of+Activation+by+Thymidine+Kinase+and+Insensitive+to+Degradation+by+Phosphorolytic+Enzymes&doi=10.1016%2Fj.bcp.2011.05.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes</span></div><div class="casAuthors">Vande Voorde, Johan; Liekens, Sandra; McGuigan, Christopher; Murziani, Paola G. S.; Slusarczyk, Magdalena; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel phosphoramidate nucleotide prodrug of the anticancer nucleoside analog 5-fluoro-2'-deoxyuridine (5-FdUrd) was synthesized and evaluated for its cytostatic activity.  Whereas 5-FdUrd substantially lost its cytostatic potential in thymidine kinase (TK)-deficient murine leukemia L1210 and human lymphocyte CEM cell cultures, NUC-3073 markedly kept its antiproliferative activity in TK-deficient tumor cells, and thus is largely independent of intracellular TK activity to exert its cytostatic action.  NUC-3073 was found to inhibit thymidylate synthase (TS) in the TK-deficient and wild-type cell lines at drug concns. that correlated well with its cytostatic activity in these cells.  NUC-3073 does not seem to be susceptible to inactivation by catabolic enzymes such as thymidine phosphorylase (TP) and uridine phosphorylase (UP).  These findings are in line with our observations that 5-FdUrd, but not NUC-3073, substantially loses its cytostatic potential in the presence of TP-expressing mycoplasmas in the tumor cell cultures.  Therefore, we propose NUC-3073 as a novel 5-FdUrd phosphoramidate prodrug that (i) may circumvent potential resistance mechanisms of tumor cells (e.g. decreased TK activity) and (ii) is not degraded by catabolic enzymes such as TP which is often upregulated in tumor cells or expressed in mycoplasma-infected tumor tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0BkUUtRLZTrVg90H21EOLACvtfcHk0lgsmhR5P907UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1ehsrw%253D&md5=50b53ced366a86c9180e178456b902d8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.05.024%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BVoorde%26aufirst%3DJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DMurziani%26aufirst%3DP.%2BG.%2BS.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DThe%2520Cytostatic%2520Activity%2520of%2520NUC-3073%252C%2520a%2520Phosphoramidate%2520Prodrug%2520of%25205-Fluoro-2%25E2%2580%25B2-deoxyuridine%252C%2520Is%2520Independent%2520of%2520Activation%2520by%2520Thymidine%2520Kinase%2520and%2520Insensitive%2520to%2520Degradation%2520by%2520Phosphorolytic%2520Enzymes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D441%26epage%3D452%26doi%3D10.1016%2Fj.bcp.2011.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murziani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonczy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande Voorde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liekens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Phosphoramidate Protides of Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage Over the Parent Nucleoside</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7247</span>– <span class="NLM_lpage">7258</span>, <span class="refDoi"> DOI: 10.1021/jm200815w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200815w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eru7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7247-7258&author=C.+McGuiganauthor=P.+Murzianiauthor=M.+Slusarczykauthor=B.+Gonczyauthor=J.+Vande+Voordeauthor=S.+Liekensauthor=J.+Balzarini&title=Phosphoramidate+Protides+of+Anticancer+Agent+FUDR+Successfully+Deliver+the+Preformed+Bioactive+Monophosphate+in+Cells+and+Confer+Advantage+Over+the+Parent+Nucleoside&doi=10.1021%2Fjm200815w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoramidate ProTides of the Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage over the Parent Nucleoside</span></div><div class="casAuthors">McGuigan, Christopher; Murziani, Paola; Slusarczyk, Magdalena; Gonczy, Blanka; Vande Voorde, Johan; Liekens, Sandra; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7247-7258</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The fluorinated pyrimidine family of nucleosides continues to represent major current chemotherapeutic agents for treating solid tumors.  We herein report their phosphate prodrugs, ProTides, as promising new derivs., which partially bypass the dependence of the current drugs on active transport and nucleoside kinase-mediated activation.  They are also resistant to metabolic deactivation by phosphorolytic enzymes.  We report 39 ProTides of the fluorinated pyrimidine FUDR with variation in the aryl, ester, and amino acid regions.  Notably, only certain ProTide motifs are successful in delivering the nucleoside monophosphate into intact cells.  We also find that the ProTides retain activity in mycoplasma infected cells, unlike FUDR.  Data suggest these compds. to be worthy of further progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppOiNKgrQqyLVg90H21EOLACvtfcHk0lgsmhR5P907UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eru7zP&md5=dbc6dde916700391cbd0b13b5d0c116c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm200815w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200815w%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DMurziani%26aufirst%3DP.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DGonczy%26aufirst%3DB.%26aulast%3DVande%2BVoorde%26aufirst%3DJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DPhosphoramidate%2520Protides%2520of%2520Anticancer%2520Agent%2520FUDR%2520Successfully%2520Deliver%2520the%2520Preformed%2520Bioactive%2520Monophosphate%2520in%2520Cells%2520and%2520Confer%2520Advantage%2520Over%2520the%2520Parent%2520Nucleoside%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7247%26epage%3D7258%26doi%3D10.1021%2Fjm200815w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattan, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">The Protide Prodrug Technology: From the Concept to the Clinic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2211</span>– <span class="NLM_lpage">1126</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2211-1126&author=Y.+Mehellouauthor=H.+S.+Rattanauthor=J.+Balzarini&title=The+Protide+Prodrug+Technology%3A+From+the+Concept+to+the+Clinic&doi=10.1021%2Facs.jmedchem.7b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The ProTide Prodrug Technology: From the Concept to the Clinic</span></div><div class="casAuthors">Mehellou, Youcef; Rattan, Hardeep S.; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2211-2226</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ProTide technol. is a prodrug approach developed for the efficient intracellular delivery of nucleoside analog monophosphates and monophosphonates.  In this approach, the hydroxyls of the monophosphate or monophosphonate groups are masked by an arom. group and an amino acid ester moiety, which are enzymically cleaved-off inside cells to release the free nucleoside monophosphate and monophosphonate species.  Structurally, this represents the current end-point of an extensive medicinal chem. endeavor that spans almost three decades.  It started from the masking of nucleoside monophosphate and monophosphonate groups by simple alkyl groups and evolved into the sophisticated ProTide system as known today.  This technol. has been extensively employed in drug discovery, and it has already led to the discovery of two FDA-approved (antiviral) ProTides.  In this work, we will review the development of the ProTide technol., its application in drug discovery, and its role in the improvement of drug delivery and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeaJFaQn4HwrVg90H21EOLACvtfcHk0lgH26EsRh5cnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitL3P&md5=ab9f5805c3c9d2d80fbdd82a3ad86c73</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00734%26sid%3Dliteratum%253Aachs%26aulast%3DMehellou%26aufirst%3DY.%26aulast%3DRattan%26aufirst%3DH.%2BS.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DThe%2520Protide%2520Prodrug%2520Technology%253A%2520From%2520the%2520Concept%2520to%2520the%2520Clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2211%26epage%3D1126%26doi%3D10.1021%2Facs.jmedchem.7b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">The Hallmarks of Cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81683-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2FS0092-8674%2800%2981683-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10647931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=57-70&author=D.+Hanahanauthor=R.+A.+Weinberg&title=The+Hallmarks+of+Cancer&doi=10.1016%2FS0092-8674%2800%2981683-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The hallmarks of cancer</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review is given with many refs. on principles governing the transformation of normal human cells into malignant cancers.  The authors suggest that research over the past decades has revealed a small no. of mol., biochem., and cellular traits (acquired capabilities) shared by most and perhaps all types of cancer.  Topics included are the acquired capabilities self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis followed by genome instability as an enabling characteristic and alternative pathways to cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooXmGqKjM1C7Vg90H21EOLACvtfcHk0lgH26EsRh5cnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D&md5=1d23c4400dad34c7f32d4a0c41890349</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981683-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981683-9%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DThe%2520Hallmarks%2520of%2520Cancer%26jtitle%3DCell%26date%3D2000%26volume%3D100%26spage%3D57%26epage%3D70%26doi%3D10.1016%2FS0092-8674%2800%2981683-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of Cancer: the Next Generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+Cancer%3A+the+Next+Generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lgH26EsRh5cnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520Cancer%253A%2520the%2520Next%2520Generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sloan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, S.</span></span> <span> </span><span class="NLM_article-title">Cloning and Functional Expression of a Human Na<sup>+</sup> and Cl<sup>–</sup>-dependent Neutral and Cationic Amino Acid Transporter B<sup>0+</sup></span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">23740</span>– <span class="NLM_lpage">23745</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.34.23740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1074%2Fjbc.274.34.23740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10446133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVOnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=23740-23745&author=J.+L.+Sloanauthor=S.+Mager&title=Cloning+and+Functional+Expression+of+a+Human+Na%2B+and+Cl%E2%80%93-dependent+Neutral+and+Cationic+Amino+Acid+Transporter+B0%2B&doi=10.1074%2Fjbc.274.34.23740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning and functional expression of a human Na+ and Cl--dependent neutral and cationic amino acid transporter B0+</span></div><div class="casAuthors">Sloan, Jennifer L.; Mager, Sela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">23740-23745</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A Na+-dependent neutral and cationic amino acid transport system (B0+) plays an important role in many cells and tissues; however, the mol. basis for this transport system is still unknown.  To identify new transporters, the expressed sequence tag database was queried, and cDNA fragments with sequence similarity to the Na+/Cl--dependent neurotransmitter transporter family were identified.  Based on these sequences, rapid amplification of cDNA ends of human mammary gland cDNA was used to obtain a cDNA of 4.5 kilobases (kb).  The open reading frame encodes a 642-amino acid protein named amino acid transporter B0+.  Human ATB0+ (hATB0+) is a novel member of the Na+/Cl--dependent neurotransmitter transporter family with the highest sequence similarity to the glycine and proline transporters.  Northern blot anal. identified transcripts of ∼4.5 kb and ∼2 kb in the lung.  Another tissue survey suggests expression in the trachea, salivary gland, mammary gland, stomach, and pituitary gland.  Electrophysiol. and radiolabeled amino acid uptake measurements were used to functionally characterize the transporter expressed in Xenopus oocytes.  HATB0+ was found to transport both neutral and cationic amino acids, with the highest affinity for hydrophobic amino acids and the lowest affinity for proline.  Amino acid transport was Na+ and Cl--dependent and was attenuated in the presence of 2-aminobicyclo-[2.2.1]-heptane-2-carboxylic acid, a system B0+ inhibitor.  These characteristics are consistent with system B0+ amino acid transport.  Thus, hATB0+ is the first cloned B0+ amino acid transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_aBj5nr5rZ7Vg90H21EOLACvtfcHk0lgH26EsRh5cnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVOnsL4%253D&md5=1cf8e4e71bacd02a793607d8d773d552</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.34.23740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.34.23740%26sid%3Dliteratum%253Aachs%26aulast%3DSloan%26aufirst%3DJ.%2BL.%26aulast%3DMager%26aufirst%3DS.%26atitle%3DCloning%2520and%2520Functional%2520Expression%2520of%2520a%2520Human%2520Na%252B%2520and%2520Cl%25E2%2580%2593-dependent%2520Neutral%2520and%2520Cationic%2520Amino%2520Acid%2520Transporter%2520B0%252B%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D23740%26epage%3D23745%26doi%3D10.1074%2Fjbc.274.34.23740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhutia, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">The Amino Acid Transporter SLC6A14 in Cancer and its Potential Use in Chemotherapy</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2014.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2014.04.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=293-303&author=Y.+D.+Bhutiaauthor=E.+Babuauthor=P.+D.+Prasadauthor=V.+Ganapathy&title=The+Amino+Acid+Transporter+SLC6A14+in+Cancer+and+its+Potential+Use+in+Chemotherapy&doi=10.1016%2Fj.ajps.2014.04.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2014.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2014.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DBhutia%26aufirst%3DY.%2BD.%26aulast%3DBabu%26aufirst%3DE.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DThe%2520Amino%2520Acid%2520Transporter%2520SLC6A14%2520in%2520Cancer%2520and%2520its%2520Potential%2520Use%2520in%2520Chemotherapy%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D9%26spage%3D293%26epage%3D303%26doi%3D10.1016%2Fj.ajps.2014.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karunakaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coothankandaswamy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elangovan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy-Thandavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnanaprakasam, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenlein, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thangaraju, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">SLC6A14 (ATB<sup>0,+</sup>) Protein, a Highly Concentrative and Broad Specific Amino Acid Transporter, Is a Novel and Effective Drug Target for Treatment of Estrogen Receptor-positive Breast Cancer</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">31830</span>– <span class="NLM_lpage">31838</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.229518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1074%2Fjbc.M111.229518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=21771784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaiurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=31830-31838&author=S.+Karunakaranauthor=S.+Ramachandranauthor=V.+Coothankandaswamyauthor=S.+Elangovanauthor=E.+Babuauthor=S.+Periyasamy-Thandavanauthor=A.+Guravauthor=J.+P.+Gnanaprakasamauthor=N.+Singhauthor=P.+V.+Schoenleinauthor=P.+D.+Prasadauthor=M.+Thangarajuauthor=V.+Ganapathy&title=SLC6A14+%28ATB0%2C%2B%29+Protein%2C+a+Highly+Concentrative+and+Broad+Specific+Amino+Acid+Transporter%2C+Is+a+Novel+and+Effective+Drug+Target+for+Treatment+of+Estrogen+Receptor-positive+Breast+Cancer&doi=10.1074%2Fjbc.M111.229518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer</span></div><div class="casAuthors">Karunakaran, Senthil; Ramachandran, Sabarish; Coothankandaswamy, Veena; Elangovan, Selvakumar; Babu, Ellappan; Periyasamy-Thandavan, Sudharsan; Gurav, Ashish; Gnanaprakasam, Jaya P.; Singh, Nagendra; Schoenlein, Patricia V.; Prasad, Puttur D.; Thangaraju, Muthusamy; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">31830-31838</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">SLC6A14, also known as ATB0,+, is an amino acid transporter with unique characteristics.  It transports 18 of the 20 proteinogenic amino acids.  However, this transporter is expressed only at low levels in normal tissues.  Here, we show that the transporter is up-regulated specifically in estrogen receptor (ER)-pos. breast cancer, demonstrable with primary human breast cancer tissues and human breast cancer cell lines.  SLC6A14 is an estrogen/ER target.  The transport features of SLC6A14 include concentrative transport of leucine (an activator of mTOR), glutamine (an essential amino acid for nucleotide biosynthesis and substrate for glutaminolysis), and arginine (an essential amino acid for tumor cells), suggesting that ER-pos. breast cancer cells up-regulate SLC6A14 to meet their increased demand for these amino acids.  Consequently, treatment of ER-pos. breast cancer cells in vitro with α-methyl-DL-tryptophan (α-MT), a selective blocker of SLC6A14, induces amino acid deprivation, inhibits mTOR, and activates autophagy.  Prolongation of the treatment with α-MT causes apoptosis.  Addn. of an autophagy inhibitor (3-methyladenine) during α-MT treatment also induces apoptosis.  These effects of α-MT are specific to ER-pos. breast cancer cells, which express the transporter.  The ability of α-MT to cause amino acid deprivation is significantly attenuated in MCF-7 cells, an ER-pos. breast cancer cell line, when SLC6A14 is silenced with shRNA.  In mouse xenograft studies, α-MT by itself is able to reduce the growth of the ER-pos. ZR-75-1 breast cancer cells.  These studies identify SLC6A14 as a novel and effective drug target for the treatment of ER-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfDE1psCVVsrVg90H21EOLACvtfcHk0lhm12oKTFUJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaiurzO&md5=046c74001108f451cd741e46d2ab5ec8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.229518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.229518%26sid%3Dliteratum%253Aachs%26aulast%3DKarunakaran%26aufirst%3DS.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DCoothankandaswamy%26aufirst%3DV.%26aulast%3DElangovan%26aufirst%3DS.%26aulast%3DBabu%26aufirst%3DE.%26aulast%3DPeriyasamy-Thandavan%26aufirst%3DS.%26aulast%3DGurav%26aufirst%3DA.%26aulast%3DGnanaprakasam%26aufirst%3DJ.%2BP.%26aulast%3DSingh%26aufirst%3DN.%26aulast%3DSchoenlein%26aufirst%3DP.%2BV.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DThangaraju%26aufirst%3DM.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DSLC6A14%2520%2528ATB0%252C%252B%2529%2520Protein%252C%2520a%2520Highly%2520Concentrative%2520and%2520Broad%2520Specific%2520Amino%2520Acid%2520Transporter%252C%2520Is%2520a%2520Novel%2520and%2520Effective%2520Drug%2520Target%2520for%2520Treatment%2520of%2520Estrogen%2520Receptor-positive%2520Breast%2520Cancer%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D31830%26epage%3D31838%26doi%3D10.1074%2Fjbc.M111.229518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coothankandaswamy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutia, Y. D.</span></span> <span> </span><span class="NLM_article-title">Amino Acid Transporter SLC6A14 Is a Novel and Effective Drug Target for Pancreatic Cancer</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">3292</span>– <span class="NLM_lpage">3306</span>, <span class="refDoi"> DOI: 10.1111/bph.13616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1111%2Fbph.13616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=27747870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yqt7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=3292-3306&author=V.+Coothankandaswamyauthor=S.+Caoauthor=Y.+Xuauthor=P.+D.+Prasadauthor=P.+K.+Singhauthor=C.+P.+Reynoldsauthor=S.+Yangauthor=J.+Oguraauthor=V.+Ganapathyauthor=Y.+D.+Bhutia&title=Amino+Acid+Transporter+SLC6A14+Is+a+Novel+and+Effective+Drug+Target+for+Pancreatic+Cancer&doi=10.1111%2Fbph.13616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer</span></div><div class="casAuthors">Coothankandaswamy, V.; Cao, S.; Xu, Y.; Prasad, P. D.; Singh, P. K.; Reynolds, C. P.; Yang, S.; Ogura, J.; Ganapathy, V.; Bhutia, Y. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3292-3306</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Pancreatic cancer is a solid tumor that is often fatal.  Hence, there is an urgent need to identify new drug targets for this disease.  Highly proliferating cancer cells have an increased demand for nutrients and, therefore, need to up-regulate selective amino acid transporters.  Here, we investigated which amino acid transporters are up-regulated in pancreatic cancer and whether any of these transporters has potential as a drug target for this fatal disease.  Exptl. Approach : The expression of amino acid transporters in pancreatic cancer was analyzed using publicly available microarray datasets, and the findings with the transporter SLC6A14 were validated by mRNA and protein anal.  The potential of SLC6A14 as a drug target was evaluated using a pharmacol. blocker in vitro and in vivo.  Key Results : SLC6A14 was up-regulated several fold in patient-derived xenografts, primary tumor tissues and pancreatic cancer cells lines compared to normal pancreatic tissue or normal pancreatic epithelial cells.  The magnitude of the up-regulation of SLC6A14 was the highest among the amino acid transporters examd.  A pharmacol. blocker of SLC6A14, α-methyltryptophan, induced amino acid starvation in pancreatic cancer cells and reduced the growth and proliferation of these cells, both in vitro and in vivo.  Conclusion and Implications : The salient features of this study are that SLC6A14 is markedly up-regulated in pancreatic cancer and that pharmacol. blockade of this transporter interferes with amino acid nutrition and reduces growth and proliferation of pancreatic cancer cells.  These findings identify SLC6A14 as a novel druggable target for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTmV-u8hFgTbVg90H21EOLACvtfcHk0lhm12oKTFUJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yqt7%252FF&md5=0c2587ccb3731b345948605a98499f0c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fbph.13616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13616%26sid%3Dliteratum%253Aachs%26aulast%3DCoothankandaswamy%26aufirst%3DV.%26aulast%3DCao%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DOgura%26aufirst%3DJ.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DBhutia%26aufirst%3DY.%2BD.%26atitle%3DAmino%2520Acid%2520Transporter%2520SLC6A14%2520Is%2520a%2520Novel%2520and%2520Effective%2520Drug%2520Target%2520for%2520Pancreatic%2520Cancer%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D3292%26epage%3D3306%26doi%3D10.1111%2Fbph.13616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyauchi, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martindale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdman, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podolsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">Upregulation of the Amino Acid Transporter ATB<sup>0,+</sup> (SLC6A14) in Colorectal Cancer and Metastasis in Humans</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1741</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.bbadis.2005.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.bbadis.2005.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=15905073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Witrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1741&publication_year=2005&pages=215-223&author=N.+Guptaauthor=S.+R.+Miyauchiauthor=G.+Martindaleauthor=A.+V.+Herdmanauthor=R.+Podolskyauthor=K.+Miyakeauthor=S.+Magerauthor=P.+D.+Prasadauthor=M.+E.+Ganapathyauthor=V.+Ganapathy&title=Upregulation+of+the+Amino+Acid+Transporter+ATB0%2C%2B+%28SLC6A14%29+in+Colorectal+Cancer+and+Metastasis+in+Humans&doi=10.1016%2Fj.bbadis.2005.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans</span></div><div class="casAuthors">Gupta, Naren; Miyauchi, Seiji; Martindale, Robert G.; Herdman, Anne V.; Podolsky, Robert; Miyake, Katsuya; Mager, Sela; Prasad, Puttur D.; Ganapathy, Malliga E.; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1741</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">215-223</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">ATB0,+ (SLC6A14) is a Na+/Cl--coupled arginine transporter expressed at low levels in normal colon.  Arginine is an essential amino acid for tumor cells.  Arginine is also the substrate for nitric oxide synthases (NOSs).  Since arginine and arginine-derived nitric oxide (NO) play a crit. role in cancer, the authors examd. the expression of ATB0,+ in colorectal cancer.  Paired normal and cancer tissues from colectomy specimens of 10 patients with colorectal cancer and from the liver tissue of one patient with hepatic metastasis from a colonic primary were used for the anal. of the levels of ATB0,+ mRNA, inducible NOS (iNOS) mRNA and the corresponding proteins.  Tissues samples from the colon, liver, and lymph nodes of an addnl. patient with metastatic colon cancer were analyzed for ATB0,+ protein alone.  The authors also examd. the levels of nitrotyrosylated proteins.  The ATB0,+ mRNA increased 22.9-fold in colorectal cancer compared to normal tissue and the increase was evident in each of the 10 cases examd.  INOS mRNA increased 5.2-fold in cancer specimens.  The changes in mRNA levels were assocd. with an increase in ATB0,+, iNOS, and nitrotyrosylated proteins.  The increased expression of ATB0,+ and iNOS was also demonstrated in liver and lymph node specimens with metastases from colonic primaries.  This study strongly suggests that the upregulation of ATB0,+ may have a pathogenic role in colorectal cancer.  Since ATB0,+ is a versatile transporter not only for arginine but also for several drugs including NOS inhibitors, these findings have significant clin. and therapeutic relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWMIx7-hMjxbVg90H21EOLACvtfcHk0lhm12oKTFUJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Witrw%253D&md5=09dbdb32c102c4d63e973c3ab999f38c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2005.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2005.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DMiyauchi%26aufirst%3DS.%2BR.%26aulast%3DMartindale%26aufirst%3DG.%26aulast%3DHerdman%26aufirst%3DA.%2BV.%26aulast%3DPodolsky%26aufirst%3DR.%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DMager%26aufirst%3DS.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DGanapathy%26aufirst%3DM.%2BE.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DUpregulation%2520of%2520the%2520Amino%2520Acid%2520Transporter%2520ATB0%252C%252B%2520%2528SLC6A14%2529%2520in%2520Colorectal%2520Cancer%2520and%2520Metastasis%2520in%2520Humans%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2005%26volume%3D1741%26spage%3D215%26epage%3D223%26doi%3D10.1016%2Fj.bbadis.2005.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCracken, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edinger, A. L.</span></span> <span> </span><span class="NLM_article-title">Targeting Cancer Metabolism at the Plasma Membrane by Limiting Amino Acid Access Through SLC6A14</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>470</i></span>,  <span class="NLM_fpage">e17</span>– <span class="NLM_lpage">e19</span>, <span class="refDoi"> DOI: 10.1042/BJ20150721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1042%2FBJ20150721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=26341486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Wju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=470&publication_year=2015&pages=e17-e19&author=A.+N.+McCrackenauthor=A.+L.+Edinger&title=Targeting+Cancer+Metabolism+at+the+Plasma+Membrane+by+Limiting+Amino+Acid+Access+Through+SLC6A14&doi=10.1042%2FBJ20150721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer metabolism at the plasma membrane by limiting amino acid access through SLC6A14</span></div><div class="casAuthors">McCracken, Alison N.; Edinger, Aimee L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">470</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e17/1-e17/3</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Rapidly proliferating cancer cells increase flux through anabolic pathways to build the mass necessary to support cell division.  Imported amino acids and glucose lie at the apex of the anabolic pyramid.  Consistent with this, elevated expression of nutrient transporter proteins is characteristic of aggressive and highly malignant cancers.  Because tumor cells are more dependent than their normal neighbors on accelerated nutrient import, these up-regulated transporters could be excellent targets for selective anti-cancer therapies.  A study by Babu et al. in a recent issue of the Biochem. Journal definitively shows that SLC6A14 (where SLC is solute carrier) is one such cancer-specific amino acid transporter.  Although mice completely lacking SLC6A14 are viable and exhibit normal mammary gland development, these animals are highly resistant to mammary tumor initiation and progression driven by potent oncogenes.  Because SLC6A14 is essential for tumor growth yet dispensable for normal development and tissue maintenance, small mols. that block amino acid import through this transporter could be effective and selective anti-cancer agents, particularly as components of rational drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyXMKviI1wlrVg90H21EOLACvtfcHk0lgsPfJi59dmsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Wju7c%253D&md5=e66ee8dad413407423041e0d34a11d36</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1042%2FBJ20150721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20150721%26sid%3Dliteratum%253Aachs%26aulast%3DMcCracken%26aufirst%3DA.%2BN.%26aulast%3DEdinger%26aufirst%3DA.%2BL.%26atitle%3DTargeting%2520Cancer%2520Metabolism%2520at%2520the%2520Plasma%2520Membrane%2520by%2520Limiting%2520Amino%2520Acid%2520Access%2520Through%2520SLC6A14%26jtitle%3DBiochem.%2520J.%26date%3D2015%26volume%3D470%26spage%3De17%26epage%3De19%26doi%3D10.1042%2FBJ20150721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, M. J.</span></span> <span> </span><span class="NLM_article-title">The Expanding Role of Prodrugs in Contemporary Drug Design and Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1038%2Fnrd.2018.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=29700501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=559-587&author=J.+Rautioauthor=N.+A.+Meanwellauthor=L.+Diauthor=M.+J.+Hageman&title=The+Expanding+Role+of+Prodrugs+in+Contemporary+Drug+Design+and+Development&doi=10.1038%2Fnrd.2018.46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The expanding role of prodrugs in contemporary drug design and development</span></div><div class="casAuthors">Rautio, Jarkko; Meanwell, Nicholas A.; Di, Li; Hageman, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-587</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Prodrugs are mols. with little or no pharmacol. activity that are converted to the active parent drug in vivo by enzymic or chem. reactions or by a combination of the two.  Prodrugs have evolved from being serendipitously discovered or used as a salvage effort to being intentionally designed.  Such efforts can avoid drug development challenges that limit formulation options or result in unacceptable biopharmaceutical or pharmacokinetic performance, or poor targeting.  In the past 10 years, the US Food and Drug Administration has approved at least 30 prodrugs, which accounts for more than 12% of all approved small-mol. new chem. entities.  In this Review, we highlight prodrug design strategies for improved formulation and pharmacokinetic and targeting properties, with a focus on the most recently marketed prodrugs.  We also discuss preclin. and clin. challenges and considerations in prodrug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKsM1lriJObVg90H21EOLACvtfcHk0lgsPfJi59dmsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D&md5=9dea9fd2f30779f4ce182b822f2c9539</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.46%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DHageman%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520Expanding%2520Role%2520of%2520Prodrugs%2520in%2520Contemporary%2520Drug%2520Design%2520and%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D559%26epage%3D587%26doi%3D10.1038%2Fnrd.2018.46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haramura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyauchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, M. E.</span></span> <span> </span><span class="NLM_article-title">Transport of Amino Acid-based Prodrugs by the Na<sup>+</sup>- and Cl<sup>–</sup>-coupled Amino Acid Transporter ATB<sup>0,+</sup> and Expression of the Transporter in Tissues Amenable for Drug Delivery</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1138</span>– <span class="NLM_lpage">1147</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.057109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1124%2Fjpet.103.057109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=14617696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWnu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2004&pages=1138-1147&author=T.+Hatanakaauthor=M.+Haramuraauthor=Y.+J.+Feiauthor=S.+Miyauchiauthor=C.+C.+Bridgesauthor=P.+S.+Ganapathyauthor=S.+B.+Smithauthor=V.+Ganapathyauthor=M.+E.+Ganapathy&title=Transport+of+Amino+Acid-based+Prodrugs+by+the+Na%2B-+and+Cl%E2%80%93-coupled+Amino+Acid+Transporter+ATB0%2C%2B+and+Expression+of+the+Transporter+in+Tissues+Amenable+for+Drug+Delivery&doi=10.1124%2Fjpet.103.057109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of amino acid-based prodrugs by the Na+- and Cl--coupled amino acid transporter ATBo,+ and expression of the transporter in tissues amenable for drug delivery</span></div><div class="casAuthors">Hatanaka, Takahiro; Haramura, Masayuki; Fei, You-Jun; Miyauchi, Seiji; Bridges, Christy C.; Ganapathy, Preethi S.; Smith, Sylvia B.; Ganapathy, Vadivel; Ganapathy, Malliga E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1138-1147</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the potential of the Na+- and Cl--coupled amino acid transporter ATBo,+ as a delivery system for amino acid-based prodrugs.  Immunofluorescence anal. indicated that ATBo,+ is expressed abundantly on the luminal surface of cells lining the lumen of the large intestine and the airways of the lung and in various ocular tissues, including the conjunctival epithelium, the tissues easily amenable for drug delivery.  We screened a variety of β-carboxyl derivs. of aspartate and γ-carboxyl derivs. of glutamate as potential substrates for this transporter using heterologous expression systems.  In mammalian cells expressing the cloned ATBo,+, several of the aspartate and glutamate derivs. inhibited glycine transport via ATBo,+.  Direct evidence for ATBo,+-mediated transport of these derivs. was obtained in Xenopus laevis oocytes using electrophysiol. methods.  Exposure of oocytes, which express ATBo,+ heterologously, to aspartate β-benzyl ester as a model deriv. induced inward currents in a Na+- and Cl--dependent manner with a Na+/Cl-/aspartate β-benzyl ester stoichiometry of 2:1:1.  ATBo,+ transported not only the β-carboxyl derivs. of aspartate and the γ-carboxyl derivs. of glutamate but also valacyclovir, which is an α-carboxyl ester of acyclovir with valine.  The transport of valacyclovir via ATBo,+ was demonstrable in both heterologous expression systems.  This process was dependent on Na+ and Cl-.  The ability of ATBo,+ to transport valacyclovir was comparable with that of the peptide transporter PEPT1.  These findings suggest that ATBo,+ has significant potential as a delivery system for amino acid-based drugs and prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVWA6V9-1ZhbVg90H21EOLACvtfcHk0lgsPfJi59dmsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWnu74%253D&md5=a0a168267881b1049947465e555ce1a4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.057109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.057109%26sid%3Dliteratum%253Aachs%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DHaramura%26aufirst%3DM.%26aulast%3DFei%26aufirst%3DY.%2BJ.%26aulast%3DMiyauchi%26aufirst%3DS.%26aulast%3DBridges%26aufirst%3DC.%2BC.%26aulast%3DGanapathy%26aufirst%3DP.%2BS.%26aulast%3DSmith%26aufirst%3DS.%2BB.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DGanapathy%26aufirst%3DM.%2BE.%26atitle%3DTransport%2520of%2520Amino%2520Acid-based%2520Prodrugs%2520by%2520the%2520Na%252B-%2520and%2520Cl%25E2%2580%2593-coupled%2520Amino%2520Acid%2520Transporter%2520ATB0%252C%252B%2520and%2520Expression%2520of%2520the%2520Transporter%2520in%2520Tissues%2520Amenable%2520for%2520Drug%2520Delivery%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D308%26spage%3D1138%26epage%3D1147%26doi%3D10.1124%2Fjpet.103.057109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karunakaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umapathy, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thangaraju, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itagaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">Interaction of Tryptophan Derivatives with SLC6A14 (ATB<sup>0,+</sup>) Reveals the Potential of the Transporter As a Drug Target for Cancer Chemotherapy</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1042/BJ20080622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1042%2FBJ20080622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=18522536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVentrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2008&pages=343-355&author=S.+Karunakaranauthor=N.+S.+Umapathyauthor=M.+Thangarajuauthor=T.+Hatanakaauthor=S.+Itagakiauthor=D.+H.+Munnauthor=P.+D.+Prasadauthor=V.+Ganapathy&title=Interaction+of+Tryptophan+Derivatives+with+SLC6A14+%28ATB0%2C%2B%29+Reveals+the+Potential+of+the+Transporter+As+a+Drug+Target+for+Cancer+Chemotherapy&doi=10.1042%2FBJ20080622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy</span></div><div class="casAuthors">Karunakaran, Senthil; Umapathy, Nagavedi S.; Thangaraju, Muthusamy; Hatanaka, Takahiro; Itagaki, Shiro; Munn, David H.; Prasad, Puttur D.; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-355</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">ATB0,+ [SLC6A14 (solute carrier family 6 member 14)] is an Na+/Cl--coupled amino acid transporter whose expression is up-regulated in cancer.  1-Methyltryptophan is an inducer of immune surveillance against tumor cells through its ability to inhibit indoleamine dioxygenase.  In the present study, we investigated the role of ATB0,+ in the uptake of 1-methyltryptophan as a potential mechanism for entry of this putative anticancer drug into tumor cells.  These studies show that 1-methyltryptophan is a transportable substrate for ATB0,+.  The transport process is Na+/Cl--dependent with an Na+/Cl-/1-methyltryptophan stoichiometry of 2:1:1.  Evaluation of other derivs. of tryptophan has led to identification of α-methyltryptophan as a blocker, not a transportable substrate, for ATB0,+.  ATB0,+ can transport 18 of the 20 proteinogenic amino acids.  α-Methyltryptophan blocks the transport function of ATB0,+ with an IC50 value of ∼250 μM under conditions simulating normal plasma concns. of all these 18 amino acids.  These results suggest that α-methyltryptophan may induce amino acid deprivation in cells which depend on the transporter for their amino acid nutrition.  Screening of several mammary epithelial cell lines shows that ATB0,+ is expressed robustly in some cancer cell lines, but not in all; in contrast, non-malignant cell lines do not express the transporter.  Treatment of ATB0,+-pos. tumor cells with α-methyltryptophan leads to suppression of their colony-forming ability, whereas ATB0,+-neg. cell lines are not affected.  The blockade of ATB0,+ in these cells with α-methyltryptophan is assocd. with cell cycle arrest.  These studies reveal the potential of ATB0,+ as a drug target for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLorZa6TFSxLVg90H21EOLACvtfcHk0ljC9Fm9x6EYWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVentrbF&md5=0def80d64d2c5e879a1b1445adaba857</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1042%2FBJ20080622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20080622%26sid%3Dliteratum%253Aachs%26aulast%3DKarunakaran%26aufirst%3DS.%26aulast%3DUmapathy%26aufirst%3DN.%2BS.%26aulast%3DThangaraju%26aufirst%3DM.%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DItagaki%26aufirst%3DS.%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DInteraction%2520of%2520Tryptophan%2520Derivatives%2520with%2520SLC6A14%2520%2528ATB0%252C%252B%2529%2520Reveals%2520the%2520Potential%2520of%2520the%2520Transporter%2520As%2520a%2520Drug%2520Target%2520for%2520Cancer%2520Chemotherapy%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D414%26spage%3D343%26epage%3D355%26doi%3D10.1042%2FBJ20080622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kou, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">Transporter Occluded-state Conformation-induced Endocytosis: Amino Acid Transporter ATB<sup>0,+</sup>-mediated Tumor Targeting of Liposomes for Docetaxel Delivery for Hepatocarcinoma Therapy</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2016.10.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.jconrel.2016.10.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=27810556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGgtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=2016&pages=370-380&author=Q.+H.+Luoauthor=P.+Gongauthor=M.+C.+Sunauthor=L.+F.+Kouauthor=V.+Ganapathyauthor=Y.+K.+Jingauthor=Z.+G.+Heauthor=J.+Sun&title=Transporter+Occluded-state+Conformation-induced+Endocytosis%3A+Amino+Acid+Transporter+ATB0%2C%2B-mediated+Tumor+Targeting+of+Liposomes+for+Docetaxel+Delivery+for+Hepatocarcinoma+Therapy&doi=10.1016%2Fj.jconrel.2016.10.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB0,+-mediated tumor targeting of liposomes for docetaxel delivery for hepatocarcinoma therapy</span></div><div class="casAuthors">Luo, Qiuhua; Gong, Ping; Sun, Mengchi; Kou, Longfa; Ganapathy, Vadivel; Jing, Yongkui; He, Zhonggui; Sun, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">370-380</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rapidly proliferating tumor cells upregulate specific amino acid transporters, which hold great potential for tumor-selective drug delivery.  Published reports have focused primarily on blocking these transporters as a means of starving the tumor cells of amino acids, but their potential in drug delivery remains understudied.  In the present study, we developed liposomes functionalized with lysine and polyoxyethylene stearate conjugate (LPS) to interact with ATB0,+, an amino acid transporter overexpressed in hepatocarcinoma and the liver cancer cell line HepG2.  The LPS modified liposomes (LPS-Lips) were ∼ 100 nm in size and exhibited high drug encapsulation efficiency as 94.7%.  The uptake of LPS-Lips in HepG2 cells was dependent on Na+ and Cl-.  Mol. dynamic simulation showed that a sustained occluded state of the transporter upon binding to co-transported ions was formed and LPS-Lips triggered the cellular internalization of liposomes.  We loaded these LPS-Lips with docetaxel and evaluated the potential of ATB0,+-mediated endocytosis of the drug-loaded LPS-Lips in HepG2 cells in vitro and in syngeneic mouse transplants in vivo.  Compared with unmodified liposomes, which did not interact with ATB0,+, LPS-Lips exhibited the ability to deliver docetaxel more efficiently into tumor cells with consequent greater antitumor efficacy and less systemic toxicity.  These studies provide first evidences that ATB0,+ can be used as a novel and effective target for drug delivery system in tumor cells using chem. modified liposomes for loading with chemotherapeutics and targeting them for the transporter-mediated endocytosis.  As ATB0,+ is highly upregulated in several cancers, this approach holds potential for tumor-selective delivery of drugs to treat these cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6JsqyReB66LVg90H21EOLACvtfcHk0ljC9Fm9x6EYWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGgtbjI&md5=f23e1e62eb559cf595245ad5a92f4dda</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2016.10.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2016.10.031%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DQ.%2BH.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DM.%2BC.%26aulast%3DKou%26aufirst%3DL.%2BF.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DJing%26aufirst%3DY.%2BK.%26aulast%3DHe%26aufirst%3DZ.%2BG.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DTransporter%2520Occluded-state%2520Conformation-induced%2520Endocytosis%253A%2520Amino%2520Acid%2520Transporter%2520ATB0%252C%252B-mediated%2520Tumor%2520Targeting%2520of%2520Liposomes%2520for%2520Docetaxel%2520Delivery%2520for%2520Hepatocarcinoma%2520Therapy%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2016%26volume%3D243%26spage%3D370%26epage%3D380%26doi%3D10.1016%2Fj.jconrel.2016.10.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubatsch, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvidsson, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seebach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">β- or γ-Di<i>-</i> and Tripeptides as Potential Substrates for the Oligopeptide Transporter hPETP1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5238</span>– <span class="NLM_lpage">5242</span>, <span class="refDoi"> DOI: 10.1021/jm070148u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070148u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGqt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5238-5242&author=I.+Hubatschauthor=P.+I.+Arvidssonauthor=D.+Seebachauthor=K.+Luthmanauthor=P.+Artursson&title=%CE%B2-+or+%CE%B3-Di-+and+Tripeptides+as+Potential+Substrates+for+the+Oligopeptide+Transporter+hPETP1&doi=10.1021%2Fjm070148u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">β- and γ-Di- and Tripeptides as Potential Substrates for the Oligopeptide Transporter hPepT1</span></div><div class="casAuthors">Hubatsch, Ina; Arvidsson, Per I.; Seebach, Dieter; Luthman, Kristina; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5238-5242</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hPepT1-mediated transport properties of eleven synthesized β- and γ-peptides have been studied in Caco-2 cells.  The results show that several of the compds. interact with the peptide transporter, but only two β-dipeptides act as substrates and are transported across the cell monolayers.  These two are less-efficient substrates than α-peptides.  Larger derivs. than β-dipeptides do not act as hPepT1 substrates, but instead, they appear to be substrates for P-glycoprotein efflux.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK-gSaMwJFW7Vg90H21EOLACvtfcHk0ljC9Fm9x6EYWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGqt7jI&md5=0ef59d40eed7acaa1406708d28db6e8e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm070148u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070148u%26sid%3Dliteratum%253Aachs%26aulast%3DHubatsch%26aufirst%3DI.%26aulast%3DArvidsson%26aufirst%3DP.%2BI.%26aulast%3DSeebach%26aufirst%3DD.%26aulast%3DLuthman%26aufirst%3DK.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3D%25CE%25B2-%2520or%2520%25CE%25B3-Di-%2520and%2520Tripeptides%2520as%2520Potential%2520Substrates%2520for%2520the%2520Oligopeptide%2520Transporter%2520hPETP1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5238%26epage%3D5242%26doi%3D10.1021%2Fjm070148u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibach, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boron, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span> <span> </span><span class="NLM_article-title">Expression Cloning of a Mammalian Proton-coupled Oligopeptide Transporter</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/368563a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1038%2F368563a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=8139693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADyaK2cXksFCntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=1994&pages=563-566&author=Y.+J.+Feiauthor=Y.+Kanaiauthor=S.+Nussbergerauthor=V.+Ganapathyauthor=F.+H.+Leibachauthor=M.+F.+Romeroauthor=S.+K.+Singhauthor=W.+F.+Boronauthor=M.+A.+Hediger&title=Expression+Cloning+of+a+Mammalian+Proton-coupled+Oligopeptide+Transporter&doi=10.1038%2F368563a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Expression cloning of a mammalian proton-coupled oligopeptide transporter</span></div><div class="casAuthors">Fei, You Jun; Kanai, Yoshikatsu; Nussberger, Stephan; Ganapathy, Vadivel; Leibach, Frederick H.; Romero, Michael F.; Singh, Satish K.; Boron, Walter F.; Hediger, Matthias A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6471</span>),
    <span class="NLM_cas:pages">563-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">In mammals active transport of org. solutes across plasma membranes was thought to be primarily driven by the Na+ gradient.  Here the authors report the cloning and functional characterization of a H+-coupled transporter of oligopeptides and peptide-derived antibiotics from rabbit small intestine.  This new protein, named PepT1, displays an unusually broad substrate specificity.  PepT1-mediated uptake is electrogenic, independent of extracellular Na+, K+ and Cl-, and of membrane potential.  PepT1 mRNA was found in intestine, kidney and liver and in small amts. in brain.  In the intestine, the PepT1 pathway constitutes a major mechanism for absorption of the products of protein digestion.  To the authors' knowledge, the PepT1 primary structure is the first report for a proton-coupled org. solute transporter in vertebrates and represents an interesting evolutionary link between prokaryotic H+-coupled and vertebrate Na+-coupled transporters of org. solutes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtu0MdddqtV7Vg90H21EOLACvtfcHk0lgwlt2RlJHWyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFCntro%253D&md5=bc1a9a631a2d8159c61904a6aed89c96</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2F368563a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F368563a0%26sid%3Dliteratum%253Aachs%26aulast%3DFei%26aufirst%3DY.%2BJ.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DNussberger%26aufirst%3DS.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DLeibach%26aufirst%3DF.%2BH.%26aulast%3DRomero%26aufirst%3DM.%2BF.%26aulast%3DSingh%26aufirst%3DS.%2BK.%26aulast%3DBoron%26aufirst%3DW.%2BF.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26atitle%3DExpression%2520Cloning%2520of%2520a%2520Mammalian%2520Proton-coupled%2520Oligopeptide%2520Transporter%26jtitle%3DNature%26date%3D1994%26volume%3D368%26spage%3D563%26epage%3D566%26doi%3D10.1038%2F368563a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palazzolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paravicini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurenzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adobati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saporiti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianazza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Indiveri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thwaites, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberini, I.</span></span> <span> </span><span class="NLM_article-title">SLC6A14, a Pivotal Actor in Cancer Stage: When Function Meets Structure</span>. <i>SLAS. Discovery.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">938</span>, <span class="refDoi"> DOI: 10.1177/2472555219867317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1177%2F2472555219867317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=31373846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVars7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=928-938&author=L.+Palazzoloauthor=C.+Paraviciniauthor=T.+Laurenziauthor=S.+Adobatiauthor=S.+Saporitiauthor=U.+Guerriniauthor=E.+Gianazzaauthor=C.+Indiveriauthor=C.+M.+H.+Andersonauthor=D.+T.+Thwaitesauthor=I.+Eberini&title=SLC6A14%2C+a+Pivotal+Actor+in+Cancer+Stage%3A+When+Function+Meets+Structure&doi=10.1177%2F2472555219867317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">SLC6A14, a Pivotal Actor on Cancer Stage: When Function Meets Structure</span></div><div class="casAuthors">Palazzolo, Luca; Paravicini, Chiara; Laurenzi, Tommaso; Adobati, Sara; Saporiti, Simona; Guerrini, Uliano; Gianazza, Elisabetta; Indiveri, Cesare; Anderson, Catriona M. H.; Thwaites, David T.; Eberini, Ivano</div><div class="citationInfo"><span class="NLM_cas:title">SLAS Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">928-938</span>CODEN:
                <span class="NLM_cas:coden">SDLIBT</span>;
        ISSN:<span class="NLM_cas:issn">2472-5560</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">SLC6A14 (ATB0,+) is a sodium- and chloride-dependent neutral and dibasic amino acid transporter that regulates the distribution of amino acids across cell membranes.  The transporter is overexpressed in many human cancers characterized by an increased demand for amino acids; as such, it was recently acknowledged as a novel target for cancer therapy.  The knowledge on the mol. mechanism of SLC6A14 transport is still limited, but some elegant studies on related transporters report the involvement of the 12 transmembrane α-helixes in the transport mechanism, and describe structural rearrangements mediated by electrostatic interactions with some pivotal gating residues.  In the present work, we constructed a SLC6A14 model in outward-facing conformation via homol. modeling and used mol. dynamics simulations to predict amino acid residues crit. for substrate recognition and translocation.  We docked the proteinogenic amino acids and other known substrates in the SLC6A14 binding site to study both gating regions and the exposed residues involved in transport.  Interestingly, some of these residues correspond to those previously identified in other LeuT-fold transporters; however, we could also identify a novel relevant residue with such function.  For the first time, by combined approaches of mol. docking and mol. dynamics simulations, we highlight the potential role of these residues in neutral amino acid transport.  This novel information unravels new aspects of the human SLC6A14 structure-function relationship and may have important outcomes for cancer treatment through the design of novel inhibitors of SLC6A14-mediated transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd0MvXA-yZb7Vg90H21EOLACvtfcHk0lgwlt2RlJHWyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVars7fN&md5=fcec1e7824f4c93c5459ddba046cdf94</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1177%2F2472555219867317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2472555219867317%26sid%3Dliteratum%253Aachs%26aulast%3DPalazzolo%26aufirst%3DL.%26aulast%3DParavicini%26aufirst%3DC.%26aulast%3DLaurenzi%26aufirst%3DT.%26aulast%3DAdobati%26aufirst%3DS.%26aulast%3DSaporiti%26aufirst%3DS.%26aulast%3DGuerrini%26aufirst%3DU.%26aulast%3DGianazza%26aufirst%3DE.%26aulast%3DIndiveri%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DC.%2BM.%2BH.%26aulast%3DThwaites%26aufirst%3DD.%2BT.%26aulast%3DEberini%26aufirst%3DI.%26atitle%3DSLC6A14%252C%2520a%2520Pivotal%2520Actor%2520in%2520Cancer%2520Stage%253A%2520When%2520Function%2520Meets%2520Structure%26jtitle%3DSLAS.%2520Discovery.%26date%3D2019%26volume%3D24%26spage%3D928%26epage%3D938%26doi%3D10.1177%2F2472555219867317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">Translating Cancer Research into Targeted Therapeutics</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1038/nature09339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1038%2Fnature09339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=20882008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=543-549&author=J.+S.+De%0ABonoauthor=A.+Ashworth&title=Translating+Cancer+Research+into+Targeted+Therapeutics&doi=10.1038%2Fnature09339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Translating cancer research into targeted therapeutics</span></div><div class="casAuthors">de Bono, J. S.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">543-549</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The emphasis in cancer drug development has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs promising greater efficacy and less side effects.  Nevertheless, despite some successes drug development remains painfully slow.  Here, we highlight the issues involved and suggest ways in which this process can be improved and expedited.  We envision an increasing shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clin. trials.  The goal is the development of specific cancer medicines to treat the individual patient, with treatment selection being driven by a detailed understanding of the genetics and biol. of the patient and their cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNF4iuzr3HvbVg90H21EOLACvtfcHk0lgwlt2RlJHWyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajur7O&md5=1e65763ba1cddeef17e5b68e56a96452</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature09339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09339%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTranslating%2520Cancer%2520Research%2520into%2520Targeted%2520Therapeutics%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D543%26epage%3D549%26doi%3D10.1038%2Fnature09339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">A Novel Oral Prodrug-targeting Transporter MCT 1: 5-Fluorouracil-dicarboxylate Monoester Conjugates</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2019.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2019.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=32104489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BB387mslaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=631-639&author=Y.+X.+Sunauthor=D.+Y.+Zhaoauthor=G.+Wangauthor=Q.+K.+Jiangauthor=M.+R.+Guoauthor=Q.+M.+Kanauthor=Z.+G.+Heauthor=J.+Sun&title=A+Novel+Oral+Prodrug-targeting+Transporter+MCT+1%3A+5-Fluorouracil-dicarboxylate+Monoester+Conjugates&doi=10.1016%2Fj.ajps.2019.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A novel oral prodrug-targeting transporter MCT 1: 5-fluorouracil-dicarboxylate monoester conjugates</span></div><div class="casAuthors">Sun Yixin; Zhao Dongyang; Jiang Qikun; He Zhonggui; Sun Jin; Wang Gang; Guo Mengran; Kan Qiming</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">631-639</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Monocarboxylate transporter 1 (MCT1) is responsible for oral absorption of short-chain monocarboxylic acids from small intestine, hence, it's likely to serve as an ideal design target for the development of oral prodrugs.  However, potential application of MCT1 to facilitate the oral delivery is still unclear.  Irregular oral absorption, poor permeability and bioavailability greatly limit the oral delivery efficiency of 5-fluorouracil (5-FU).  Herein, we design three 5-FU-fatty acid conjugates targeting intestinal MCT1 with different lipophilic linkages.  Interestingly, due to high MCT1 affinity and good gastrointestinal stability, 5-FU-octanedioic acid monoester prodrug exhibited significant improvement in membrane permeability (13.1-fold) and oral bioavailability (4.1-fold) compared to 5-FU.  More surprisingly, stability experiment in intestinal homogenates showed that 5-FU prodrugs could be properly activated to release 5-FU within intestinal cells, which provides an ideal foundation for the improvement of oral bioavailability.  In summary, good gastrointestinal stability, high membrane permeability and appropriate intestinal cell bioactivation are the important factors for high-efficiency 5-FU oral prodrugs, and such work provides a good platform for the development of novel oral prodrugs targeting intestinal transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMSO2kE7krGOBfW6udTcc2eZS1tl7uziDo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslaisA%253D%253D&md5=4829bc8a1e1b53c1de36ca5d761942a0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2019.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2019.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%2BX.%26aulast%3DZhao%26aufirst%3DD.%2BY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DQ.%2BK.%26aulast%3DGuo%26aufirst%3DM.%2BR.%26aulast%3DKan%26aufirst%3DQ.%2BM.%26aulast%3DHe%26aufirst%3DZ.%2BG.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DA%2520Novel%2520Oral%2520Prodrug-targeting%2520Transporter%2520MCT%25201%253A%25205-Fluorouracil-dicarboxylate%2520Monoester%2520Conjugates%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D14%26spage%3D631%26epage%3D639%26doi%3D10.1016%2Fj.ajps.2019.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sikder, M. O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutia, Y. D.</span></span> <span> </span><span class="NLM_article-title">The Na<sup>+</sup>/Cl<sup>–</sup>-coupled Broad-specific, Amino Acid Transporter SLC6A14 (ATB<sup>0,+</sup>): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">12</span>, <span class="refDoi"> DOI: 10.1208/s12248-017-0164-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1208%2Fs12248-017-0164-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=12&author=M.+O.+F.+Sikderauthor=S.+Yangauthor=V.+Ganapathyauthor=Y.+D.+Bhutia&title=The+Na%2B%2FCl%E2%80%93-coupled+Broad-specific%2C+Amino+Acid+Transporter+SLC6A14+%28ATB0%2C%2B%29%3A+Emerging+Roles+in+Multiple+Diseases+and+Therapeutic+Potential+for+Treatment+and+Diagnosis&doi=10.1208%2Fs12248-017-0164-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1208%2Fs12248-017-0164-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-017-0164-7%26sid%3Dliteratum%253Aachs%26aulast%3DSikder%26aufirst%3DM.%2BO.%2BF.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DBhutia%26aufirst%3DY.%2BD.%26atitle%3DThe%2520Na%252B%252FCl%25E2%2580%2593-coupled%2520Broad-specific%252C%2520Amino%2520Acid%2520Transporter%2520SLC6A14%2520%2528ATB0%252C%252B%2529%253A%2520Emerging%2520Roles%2520in%2520Multiple%2520Diseases%2520and%2520Therapeutic%2520Potential%2520for%2520Treatment%2520and%2520Diagnosis%26jtitle%3DAAPS%2520J.%26date%3D2018%26volume%3D20%26spage%3D12%26doi%3D10.1208%2Fs12248-017-0164-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigmond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borch, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3743</span>– <span class="NLM_lpage">3746</span>, <span class="refDoi"> DOI: 10.1021/jm070269u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070269u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2sXns1Ohtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3743-3746&author=W.+D.+Wuauthor=J.+Sigmondauthor=G.+J.+Petersauthor=R.+F.+Borch&title=Synthesis+and+Biological+Activity+of+a+Gemcitabine+Phosphoramidate+Prodrug&doi=10.1021%2Fjm070269u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug</span></div><div class="casAuthors">Wu, Weidong; Sigmond, Jennifer; Peters, Godefridus J.; Borch, Richard F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3743-3746</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A gemcitabine (2',2'-difluorodeoxycytidine, dFdC) phosphoramidate prodrug I designed for the intracellular delivery of gemcitabine 5'-monophosphate was synthesized.  The prodrug was about an order of magnitude less active than gemcitabine against wild-type cells, and the nucleoside transport inhibitor dipyridamole reduced prodrug activity.  The prodrug was more active than gemcitabine against two deoxycytidine kinase-deficient cell lines.  The results suggest that the prodrug is a potent growth inhibitor that can bypass dCK deficiency at higher drug concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2DxPbwnYvf7Vg90H21EOLACvtfcHk0lhrUH0ZByyY8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXns1Ohtr8%253D&md5=2243c529dc58ed393e05afffec285aba</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm070269u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070269u%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DW.%2BD.%26aulast%3DSigmond%26aufirst%3DJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DBorch%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520and%2520Biological%2520Activity%2520of%2520a%2520Gemcitabine%2520Phosphoramidate%2520Prodrug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3743%26epage%3D3746%26doi%3D10.1021%2Fjm070269u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marina, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, C. R.</span></span> <span> </span><span class="NLM_article-title">Nucleoside Transport in Normal and Neoplastic Cells</span>. <i>Adv. Enzyme Regul.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1016/0065-2571(93)90021-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2F0065-2571%2893%2990021-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=8356910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVenu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1993&pages=235-252&author=J.+A.+Beltauthor=N.+M.+Marinaauthor=D.+A.+Phelpsauthor=C.+R.+Crawford&title=Nucleoside+Transport+in+Normal+and+Neoplastic+Cells&doi=10.1016%2F0065-2571%2893%2990021-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside transport in normal and neoplastic cells</span></div><div class="casAuthors">Belt, Judith A.; Marina, Neyssa M.; Phelps, Doris A.; Crawford, Charles R.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Enzyme Regulation</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">235-52</span>CODEN:
                <span class="NLM_cas:coden">AEZRA2</span>;
        ISSN:<span class="NLM_cas:issn">0065-2571</span>.
    </div><div class="casAbstract">The nucleoside transport properties of a series of human tumor cell lines and 2 normal tissues that are highly susceptible to toxicity from antimetabolites, intestine and bone marrow, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJfeTxPTIuFrVg90H21EOLACvtfcHk0lgoJZX25HRAIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVenu7g%253D&md5=db7f2e949cfb406a1e343bc867891125</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2F0065-2571%2893%2990021-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0065-2571%252893%252990021-5%26sid%3Dliteratum%253Aachs%26aulast%3DBelt%26aufirst%3DJ.%2BA.%26aulast%3DMarina%26aufirst%3DN.%2BM.%26aulast%3DPhelps%26aufirst%3DD.%2BA.%26aulast%3DCrawford%26aufirst%3DC.%2BR.%26atitle%3DNucleoside%2520Transport%2520in%2520Normal%2520and%2520Neoplastic%2520Cells%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D1993%26volume%3D33%26spage%3D235%26epage%3D252%26doi%3D10.1016%2F0065-2571%2893%2990021-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puris, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gynther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttunen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petsalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttunen, K. M.</span></span> <span> </span><span class="NLM_article-title">L-type Amino Acid Transporter 1 Utilizing Prodrugs: How to Achieve Effective Brain Delivery and Low Systemic Exposure of Drugs</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2017.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.jconrel.2017.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=28662899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyqu7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=2017&pages=93-104&author=E.+Purisauthor=M.+Gyntherauthor=J.+Huttunenauthor=A.+Petsaloauthor=K.+M.+Huttunen&title=L-type+Amino+Acid+Transporter+1+Utilizing+Prodrugs%3A+How+to+Achieve+Effective+Brain+Delivery+and+Low+Systemic+Exposure+of+Drugs&doi=10.1016%2Fj.jconrel.2017.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs</span></div><div class="casAuthors">Puris, Elena; Gynther, Mikko; Huttunen, Johanna; Petsalo, Aleksanteri; Huttunen, Kristiina M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-104</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">L-type amino acid transporter 1 (LAT1) is selectively expressed in the blood-brain barrier (BBB) and brain parenchyma.  This transporter can facilitate brain delivery of neuroprotective agents and addnl. give opportunity to minimize systemic exposure.  Here, we investigated structure-pharmacokinetics relationship of five newly synthesized LAT1-utilizing prodrugs of the cyclooxygenase inhibitor, ketoprofen, in order to identify beneficial structural features of prodrugs to achieve both targeted brain delivery and low peripheral distribution of the parent drug.  Besides, we studied whether pharmacokinetics and bioconversion of LAT1-utilizing prodrugs in vivo can be predicted in early stage expts.  To achieve these goals, we compared the in vitro brain uptake mechanism of prodrugs, rate of BBB permeation of compds. using in situ perfusion technique, their systemic pharmacokinetics and release of parent drug in brain, plasma and liver of mice.  The results revealed that both excellent LAT1-binding ability and transporter utilization in vitro can be achieved by conjugating the parent drug to arom. amino acids such as phenylalanine in comparison to prodrugs with an aliph. promoiety.  The presence of an arom. promoiety directly conjugated in meta- or para-position to ketoprofen led to LAT1-utilizing prodrugs capable of delivering the parent drug into the brain with higher unbound brain to plasma ratio and reduced liver exposure than with ketoprofen itself.  In contrast, the prodrugs with aliph. promoieties and with an addnl. carbon attached between the parent drug and phenylalanine arom. ring did not enhance brain delivery of ketoprofen.  Furthermore, we have devised a screening strategy to pinpoint successful candidates at an early stage of development of LAT1-utilizing prodrugs.  The screening approach demonstrated that early stage expts. could not replace pharmacokinetic studies in vivo due to the lack of prediction of the intra-brain/systemic distribution of the prodrugs as well as the release of the parent drug.  Overall, this study provides essential knowledge required for improvement of targeted brain delivery and redn. of systemic exposure of drugs via the LAT1-mediated prodrug approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2t3GV2SIBeLVg90H21EOLACvtfcHk0lgoJZX25HRAIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyqu7vE&md5=d13112945f2c974b4bd1b7976bb224c5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2017.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2017.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DPuris%26aufirst%3DE.%26aulast%3DGynther%26aufirst%3DM.%26aulast%3DHuttunen%26aufirst%3DJ.%26aulast%3DPetsalo%26aufirst%3DA.%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26atitle%3DL-type%2520Amino%2520Acid%2520Transporter%25201%2520Utilizing%2520Prodrugs%253A%2520How%2520to%2520Achieve%2520Effective%2520Brain%2520Delivery%2520and%2520Low%2520Systemic%2520Exposure%2520of%2520Drugs%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2017%26volume%3D261%26spage%3D93%26epage%3D104%26doi%3D10.1016%2Fj.jconrel.2017.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umapathy, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, M. E.</span></span> <span> </span><span class="NLM_article-title">Transport of Amino Acid Esters and the Amino-acid-based Prodrug Valganciclovir by the Amino Acid Transporter ATB<sup>0,+</sup></span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1309</span>, <span class="refDoi"> DOI: 10.1023/B:PHAM.0000033019.49737.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1023%2FB%3APHAM.0000033019.49737.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=15290873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltF2gsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2004&pages=1303-1309&author=N.+S.+Umapathyauthor=V.+Ganapathyauthor=M.+E.+Ganapathy&title=Transport+of+Amino+Acid+Esters+and+the+Amino-acid-based+Prodrug+Valganciclovir+by+the+Amino+Acid+Transporter+ATB0%2C%2B&doi=10.1023%2FB%3APHAM.0000033019.49737.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB0,+</span></div><div class="casAuthors">Umapathy, Nagavedi S.; Ganapathy, Vadivel; Ganapathy, Malliga E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1303-1310</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">The purpose of this study was to analyze the transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the Na+/Cl--coupled amino acid transporter ATB0,+.  The interaction of amino acid esters and valganciclovir with the cloned rat ATB0,+ was evaluated in a mammalian cell expression system and in the Xenopus oocyte expression system.  In mammalian cells, expression of ATB0,+ induced glycine uptake.  This uptake was inhibited by valine and its Me, Bu, and benzyl esters.  The benzyl esters of other neutral amino acids were also effective inhibitors.  Valganciclovir, the valyl ester of ganciclovir, was also found to inhibit ATB0,+-mediated glycine uptake competitively.  Exposure of ATB0,+-expressing oocytes to glycine induced inward currents.  Exposure to different valyl esters (Me, Bu, and benzyl), benzyl esters of various neutral amino acids, and valganciclovir also induced inward currents in these oocytes.  The current induced by valganciclovir was saturable with a K0.5 value of 3.1 ± 0.7 mM and was obligatorily dependent on Na+ and Cl-.  The Na+:Cl-:valganciclovir stoichiometry was 2 or 3:1:1.  Amino acid esters and the amino-acid-based prodrug valganciclovir are transported by ATB0,+.  This shows that ATB0,+ can serve as an effective delivery system for amino acid-based prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_TkiK_izZLVg90H21EOLACvtfcHk0lgoJZX25HRAIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltF2gsLY%253D&md5=b2bcad9cd893c29abea3674b775cdd40</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1023%2FB%3APHAM.0000033019.49737.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253APHAM.0000033019.49737.28%26sid%3Dliteratum%253Aachs%26aulast%3DUmapathy%26aufirst%3DN.%2BS.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DGanapathy%26aufirst%3DM.%2BE.%26atitle%3DTransport%2520of%2520Amino%2520Acid%2520Esters%2520and%2520the%2520Amino-acid-based%2520Prodrug%2520Valganciclovir%2520by%2520the%2520Amino%2520Acid%2520Transporter%2520ATB0%252C%252B%26jtitle%3DPharm.%2520Res.%26date%3D2004%26volume%3D21%26spage%3D1303%26epage%3D1309%26doi%3D10.1023%2FB%3APHAM.0000033019.49737.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause-Heuer, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbutcheon-Singh, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich-Wright, J. R.</span></span> <span> </span><span class="NLM_article-title">Advances in Platinum Chemotherapeutics</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">7064</span>– <span class="NLM_lpage">7077</span>, <span class="refDoi"> DOI: 10.1002/chem.201000148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1002%2Fchem.201000148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=20533453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVertL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=7064-7077&author=B.+W.+Harperauthor=A.+M.+Krause-Heuerauthor=M.+P.+Grantauthor=M.+Manoharauthor=K.+B.+Garbutcheon-Singhauthor=J.+R.+Aldrich-Wright&title=Advances+in+Platinum+Chemotherapeutics&doi=10.1002%2Fchem.201000148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in Platinum Chemotherapeutics</span></div><div class="casAuthors">Harper, Benjamin W.; Krause-Heuer, Anwen M.; Grant, Maxine P.; Manohar, Madhura; Garbutcheon-Singh, K. Benjamin; Aldrich-Wright, Janice R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7064-7077</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The approved platinum(II)-based anticancer agents cisplatin, carboplatin and oxaliplatin are widely utilized in the clinic, although with numerous disadvantages.  With the aim of circumventing unwanted side-effects, a great deal of research is being conducted in the areas of cancer-specific targeting, drug administration and drug delivery.  The targeting of platinum complexes to cancerous tissues can be achieved by the attachment of small mols. with biol. significance.  In addn., the administration of platinum complexes in the form of platinum(IV) allows for intracellular redn. to release the active form of the drug, cisplatin.  Drug delivery includes such technologies as liposomes, dendrimers, polymers and nanotubes, with all showing promise for the delivery of platinum compds.  In this paper we highlight some of the recent advances in the field of platinum chemotherapeutics, with a focus on the technologies that attempt to utilize the cytotoxic nature of cisplatin, while improving drug targeting to reduce side-effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPVBEEXG7P0rVg90H21EOLACvtfcHk0lgiDV2BsmH91w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVertL4%253D&md5=857b4f5a7a2c8fb4d2370f2369a13a1b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fchem.201000148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201000148%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DB.%2BW.%26aulast%3DKrause-Heuer%26aufirst%3DA.%2BM.%26aulast%3DGrant%26aufirst%3DM.%2BP.%26aulast%3DManohar%26aufirst%3DM.%26aulast%3DGarbutcheon-Singh%26aufirst%3DK.%2BB.%26aulast%3DAldrich-Wright%26aufirst%3DJ.%2BR.%26atitle%3DAdvances%2520in%2520Platinum%2520Chemotherapeutics%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2010%26volume%3D16%26spage%3D7064%26epage%3D7077%26doi%3D10.1002%2Fchem.201000148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raja, M. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amjad, M. W.</span></span> <span> </span><span class="NLM_article-title">Design, Mechanism, Delivery and Therapeutics of Canonical and Dicer-substrate siRNA</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2018.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2018.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=32104477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BB387mslajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=497-510&author=M.+A.+G.+Rajaauthor=H.+Katasauthor=M.+W.+Amjad&title=Design%2C+Mechanism%2C+Delivery+and+Therapeutics+of+Canonical+and+Dicer-substrate+siRNA&doi=10.1016%2Fj.ajps.2018.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA</span></div><div class="casAuthors">Raja Maria Abdul Ghafoor; Amjad Muhammad Wahab; Katas Haliza</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">497-510</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Upon the discovery of RNA interference (RNAi), canonical small interfering RNA (siRNA) has been recognized to trigger sequence-specific gene silencing.  Despite the benefits of siRNAs as potential new drugs, there are obstacles still to be overcome, including off-target effects and immune stimulation.  More recently, Dicer substrate siRNA (DsiRNA) has been introduced as an alternative to siRNA.  Similarly, it also is proving to be potent and target-specific, while rendering less immune stimulation.  DsiRNA is 25-30 nucleotides in length, and is further cleaved and processed by the Dicer enzyme.  As with siRNA, it is crucial to design and develop a stable, safe, and efficient system for the delivery of DsiRNA into the cytoplasm of targeted cells.  Several polymeric nanoparticle systems have been well established to load DsiRNA for in vitro and in vivo delivery, thereby overcoming a major hurdle in the therapeutic uses of DsiRNA.  The present review focuses on a comparison of siRNA and DsiRNA on the basis of their design, mechanism, in vitro and in vivo delivery, and therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMYNpW7w2tapOfW6udTcc2eYXMo8ukAeuuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslajsg%253D%253D&md5=d951de0be884acf4022e6eb0ddbe289e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2018.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2018.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DRaja%26aufirst%3DM.%2BA.%2BG.%26aulast%3DKatas%26aufirst%3DH.%26aulast%3DAmjad%26aufirst%3DM.%2BW.%26atitle%3DDesign%252C%2520Mechanism%252C%2520Delivery%2520and%2520Therapeutics%2520of%2520Canonical%2520and%2520Dicer-substrate%2520siRNA%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D14%26spage%3D497%26epage%3D510%26doi%3D10.1016%2Fj.ajps.2018.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span> <span> </span><span class="NLM_article-title">Redox-sensitive Micelles for Targeted Intracellular Delivery and Combination Chemotherapy of Paclitaxel and All-trans-retinoid Acid</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2018.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ajps.2018.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=32104480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A280%3ADC%252BB387mslajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=531-541&author=L.+F.+Hanauthor=L.+J.+Huauthor=F.+L.+Liuauthor=X.+Wangauthor=X.+X.+Huangauthor=B.+W.+Liuauthor=F.+Fengauthor=W.+Y.+Liuauthor=W.+Qu&title=Redox-sensitive+Micelles+for+Targeted+Intracellular+Delivery+and+Combination+Chemotherapy+of+Paclitaxel+and+All-trans-retinoid+Acid&doi=10.1016%2Fj.ajps.2018.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Redox-sensitive micelles for targeted intracellular delivery and combination chemotherapy of paclitaxel and all-trans-retinoid acid</span></div><div class="casAuthors">Han Lingfei; Wang Xin; Liu Wenyuan; Hu Lejian; Liu Fulei; Huang Xiaoxian; Liu Bowen; Feng Feng; Qu Wei; Feng Feng; Liu Wenyuan</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">531-542</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The application of paclitaxel (PTX) in clinic has been restricted due to its poor solubility.  Several traditional nano-medicines have been developed to improve this defect, while they are still lack of tumor targeting ability and rapid drug release.  In this work, an amphiphilic polymeric micelle of hyaluronic acid (HA) - all-trans-retinoid acid (ATRA) with a disulfide bond, was developed successfully for the co-delivery of PTX and ATRA.  The combination chemotherapy of PTX and ATRA can strengthen the anti-tumor activity.  Along with self-assembling to micelles in water, the delivery system displayed satisfying drug loading capacities for both PTX (32.62% ± 1.39%) and ATRA, due to directly using ATRA as the hydrophobic group.  Rapid drug release properties of the PTX-loaded redox-sensitive micelles (HA-SS-ATRA) in vitro were confirmed under reducing condition containing GSH.  Besides, HA-CD44 mediated endocytosis promoted the uptake of HA-SS-ATRA micelles by B16F10 cells.  Due to these properties, cytotoxicity assay verified that PTX-loaded HA-SS-ATRA micelles showed concentration-dependent cytotoxicity and displayed obvious combination therapy of PTX and ATRA.  Importantly, HA-SS-ATRA micelles could remarkably prolong plasma circulation time after intravenously administration.  Therefore, redox-sensitive HA-SS-ATRA micelles could be utilized and explored as a promising drug delivery system for cancer combination chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMYkFb3mqPUYDfW6udTcc2eYXMo8ukAeuuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslajsQ%253D%253D&md5=56bef06c399cec9bfe676fc752588bbe</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2018.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2018.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DL.%2BF.%26aulast%3DHu%26aufirst%3DL.%2BJ.%26aulast%3DLiu%26aufirst%3DF.%2BL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DX.%2BX.%26aulast%3DLiu%26aufirst%3DB.%2BW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%2BY.%26aulast%3DQu%26aufirst%3DW.%26atitle%3DRedox-sensitive%2520Micelles%2520for%2520Targeted%2520Intracellular%2520Delivery%2520and%2520Combination%2520Chemotherapy%2520of%2520Paclitaxel%2520and%2520All-trans-retinoid%2520Acid%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D14%26spage%3D531%26epage%3D541%26doi%3D10.1016%2Fj.ajps.2018.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saneja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P. N.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Drug Delivery Strategies for Improved Therapeutic Efficacy of Gemcitabine</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2016.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=10.1016%2Fj.ejps.2016.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=27531553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaktbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2016&pages=147-162&author=R.+D.+Dubeyauthor=A.+Sanejaauthor=P.+K.+Guptaauthor=P.+N.+Gupta&title=Recent+Advances+in+Drug+Delivery+Strategies+for+Improved+Therapeutic+Efficacy+of+Gemcitabine&doi=10.1016%2Fj.ejps.2016.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine</span></div><div class="casAuthors">Dubey, Ravindra Dhar; Saneja, Ankit; Gupta, Prasoon K.; Gupta, Prem N.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147-162</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gemcitabine (2',2'-difluoro-2'-deoxycytidine; dFdC) is an efficacious anticancer agent acting against a wide range of solid tumors, including pancreatic, non-small cell lung, bladder, breast, ovarian, thyroid and multiple myelomas.  However, short plasma half-life due to metab. by cytidine deaminase necessitates administration of high dose, which limits its medical applicability.  Further, due to its hydrophilic nature, it cannot traverse cell membranes by passive diffusion and, therefore, enters via nucleoside transporters that may lead to drug resistance.  To circumvent these limitations, macromol. prodrugs and nanocarrier-based formulations of Gemcitabine are gaining wide recognition.  The nanoformulations based approaches by virtue of their controlled release and targeted delivery have proved to improve bioavailability, increase therapeutic efficacy and reduce adverse effects of the drug.  Furthermore, the combination of Gemcitabine with other anticancer agents as well as siRNAs using nanocarriers has also been investigated in order to enhance its therapeutic potential.  This review deals with challenges and recent advances in the delivery of Gemcitabine with particular emphasis on macromol. prodrugs and nanomedicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfTB07iNJNgbVg90H21EOLACvtfcHk0lgiDV2BsmH91w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaktbbN&md5=7b1827c3f1391e9dbeb9f90d91411a27</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2016.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2016.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DDubey%26aufirst%3DR.%2BD.%26aulast%3DSaneja%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DP.%2BK.%26aulast%3DGupta%26aufirst%3DP.%2BN.%26atitle%3DRecent%2520Advances%2520in%2520Drug%2520Delivery%2520Strategies%2520for%2520Improved%2520Therapeutic%2520Efficacy%2520of%2520Gemcitabine%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D93%26spage%3D147%26epage%3D162%26doi%3D10.1016%2Fj.ejps.2016.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4M48" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4M48','PDB','4M48'); return false;">PDB: 4M48</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O8O" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O8O','PDB','3O8O'); return false;">PDB: 3O8O</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i47"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00149">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_12734"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00149?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00149</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>), and HPLC of 5′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 3′-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 3′,5′-di-α-<span class="smallcaps smallerCapital">l</span>-Val-FUdR, 5′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, 3′-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, 3′,5′-di-β-<span class="smallcaps smallerCapital">l</span>-Asp-FUdR, 5′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR, 3′-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR, and 3′,5′-di-γ-<span class="smallcaps smallerCapital">l</span>-Glu-FUdR (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_002.csv">CSV</a>)</p></li><li><p class="inline">Coordinates of homology models for ATB<sup>0,+</sup> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_001.pdf">jm0c00149_si_001.pdf (2.21 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_002.csv">jm0c00149_si_002.csv (1.35 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_003.pdb">jm0c00149_si_003.pdb (365.87 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00149&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-19%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00149" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00149" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992df4ebc5d1fb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
